Heterocyclic Compounds, Fused-Ring

Multiple ring heterocyclic compounds containing two or more rings that share two atoms and one bond in common.
DrugDrug NameDrug Indication
DB00115Cyanocobalamin **Nasal spray** The cyanocobalamin nasal spray is indicated for the maintenance of vitamin B12 concentrations after normalization with intramuscular vitamin B12 therapy in patients with deficiency of this vitamin who have no nervous system involvement [FDA label]. Note: CaloMist [FDA label], the nasal spray form, has not been evaluated for the treatment of newly diagnosed vitamin B12 deficiency. **Injection forms (subcutaneous, intramuscular)** These forms are indicated for vitamin B12 deficiencies due to various causes, with or without neurologic manifestations [F3736]. Vitamin B12 deficiency is frequently caused by malabsorption, which is often associated with the following conditions [L5545]: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of the pancreas or bowel Folic acid deficiency **Oral forms** Vitamin B12 supplements are widely available and indicated in patients who require supplementation for various reasons. Dose requirements for vitamin B12 which are higher than normal (caused by pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be achieved with oral supplementation [L5545]. Oral products of vitamin B12 are not recommended in patients with malabsorption, as these forms are primarily absorbed in the gastrointestinal tract [F3739].
DB00116Tetrahydrofolic acidFor nutritional supplementation, also for treating dietary shortage or imbalance.
DB00118AdemetionineS-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
DB00131Adenosine phosphateFor nutritional supplementation, also for treating dietary shortage or imbalance
DB00140RiboflavinFor the treatment of ariboflavinosis (vitamin B2 deficiency).
DB00157NADHSome evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease.
DB00158Folic acidFolic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.
DB00163Vitamin EVitamin E supplementation is indicated for treatment of vitamin E deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet[A176104,L3063].
DB00171ATPFor nutritional supplementation, also for treating dietary shortage or imbalance
DB00173AdenineFor nutritional supplementation, also for treating dietary shortage or imbalance
DB00178RamiprilFor the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
DB00186LorazepamLorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
DB00194VidarabineFor treatment of chickenpox - varicella, herpes zoster and herpes simplex
DB00197TroglitazoneFor the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
DB00200HydroxocobalaminFor treatment of pernicious anemia and the prevention and treatment of vitamin B12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets. Also for the treatment of known or suspected cyanide poisoning.
DB00201CaffeineFor management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.
DB00203SildenafilSildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications: (1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and (2) treatment of pulmonary hypertension, where: a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850]; b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].
DB00206ReserpineFoe the treatment of hypertension
DB00208TiclopidineUsed in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
DB00213Pantoprazole **Pantoprazole Injection**: **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis** Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label] **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome** Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label] **Pantoprazole delayed-release oral suspension**: **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)** Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202] **Maintenance of healing of erosive esophagitis** Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202] **Pathological hypersecretory conditions including Zollinger-Ellison syndrome** Indicated for the long-term treatment of the above conditions.[F3202]
DB00215CitalopramFor the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].
DB00216EletriptanFor the acute treatment of migraine with or without aura in adults.
DB00218MoxifloxacinFor the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
DB00220NelfinavirUsed in combination with other antiviral drugs in the treatment of HIV in both adults and children.
DB00229CefotiamFor treatment of severe infections caused by susceptible bacteria.
DB00231TemazepamTemazepam is specifically indicated only for the short-term management of insomnia [FDA Label], [L5539]. Furthermore, such management is generally predominantly associated with the symptomatic relief of transient and short-term insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings [F3718]. In particular, the official prescribing information for temazepam typically specifies that the instructions issued for dispensed prescriptions of the medication should indicate specifically that patients are only expected to use the therapy for short periods of time - usually 7-10 days in general [FDA Label, F3718]. Subsequently, treatment with temazepam should usually not exceed 7 to 10 consecutive days and nor should it be prescribed in quantities exceeding a one-month supply [F3718]. Some regional prescribing information also notes that temazepam may be used for premedication prior to minor surgery or other related procedures [L5539].
DB00232MethyclothiazideFor use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
DB00242CladribineFor the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
DB00247MethysergideFor the treatment of vascular headache
DB00248CabergolineFor the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
DB00261AnagrelideFor the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00267CefmenoximeUsed to treat female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria.
DB00268RopiniroleFor the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome [FDA label].
DB00274CefmetazoleFor the treatment of infections caused by susceptible organisms.
DB00276AmsacrineFor treatment of acute myeloid leukaemia.
DB00277TheophyllineFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
DB00293RaltitrexedFor the treatment of malignant neoplasm of colon and rectum
DB00295MorphineMorphine is used for the management of chronic moderate-to-severe pain.[A176050] Opioids, including morphine, can manage pain effectively when used for a short amount of time. The use of opioids for longer periods needs to be monitored as they can develop a physical dependence, addiction disorder and drug abuse.[L5728]
DB00299PenciclovirUsed to treat recurrent cold sores on the lips and face from various herpesvirus invections.
DB00300Tenofovir disoproxilTenofovir is indicated in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older [FDA label]. This drug is also a component of multiple products used for the management of HIV-1 infection [F3418], [F3421]. Safety and effectiveness of tenofovir disoproxil in pediatric patients younger than 2 years of age has not been established to this date [FDA label].
DB00301FlucloxacillinUsed to treat bacterial infection by susceptible microorganisms.
DB00303ErtapenemFor the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis, (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia, (3) community acquired pneumonia due to Streptococcus pneumoniae (penicillin susceptible isolates only) including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis, (4) complicated urinary tract infections including pyelonephritis due to Escherichia coli, including cases with concurrent bacteremia, or Klebsiella pneumoniae, (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia.
DB00305MitomycinFor treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
DB00309VindesineFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
DB00310ChlorthalidoneChlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
DB00311EthoxzolamideFor use in the treatment of duodenal ulcers, as a diuretic, and in the treatment of glaucoma, and may also be useful in the treatment of seizures associated with epilepsy.
DB00315ZolmitriptanFor the acute treatment of adult migraine with or without auras.
DB00317GefitinibFor the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
DB00318CodeineCodeine sulfate is a form of this drug that is commonly used. It is available in tablet form [FDA label] and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate [FDA label]. The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above [L5521], [L5524].
DB00319PiperacillinFor the treatment of polymicrobial infections.
DB00320DihydroergotamineFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
DB00327HydromorphoneHydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain. Due to its addictive potential and overdose risk, hydromorphone is only prescribed when other first-line treatments have failed.[A176468] The WHO has proposed a three-step ladder for the management of pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as hydromorphone along with the existing regimen for cases of severe pain.[A176471] Off-label, hydromorphone can be administered for the suppression of refractory cough.[A176468]
DB00328IndomethacinOral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778] Intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[F4600]
DB00334OlanzapineOlanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label] As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014] Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label] Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936] Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]
DB00338OmeprazoleOmeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes: • Treatment of active duodenal ulcer in adults • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults • Treatment of active benign gastric ulcer in adults • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older • Pathologic hypersecretory conditions in adults
DB00340MetixeneUsed for the symptomatic treatment of parkinsonism.
DB00343Diltiazem**Oral** Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[label] Indicated for use to improve exercise tolerance in patients with chronic stable angina.[label] Indicated for the management of variant angina (Prinzmetal's angina).[L6298] **Intravenous** Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292] Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292] **Off-label** Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]
DB00346AlfuzosinFor the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
DB00349ClobazamFor treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
DB00352TioguanineFor remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
DB00353MethylergometrineFor the prevention and control of excessive bleeding following vaginal childbirth
DB00355AztreonamFor the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.
DB00356ChlorzoxazoneFor the relief of discomfort associated with acute painful musculoskeletal conditions.
DB00358MefloquineFor the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
DB00360SapropterinFor the treatment of tetrahydrobiopterin (BH4) deficiency.
DB00361Vinorelbine Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998]. Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011]. For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011]. For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011]. For the treatment of recurrent ovarian cancer [L2011]. For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011]. For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].
DB00363ClozapineFor use in patients with treatment-resistant schizophrenia.
DB00365GrepafloxacinFor treatment of adults with mild to moderate infections caused by susceptible strains of Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
DB00370MirtazapineThis drug is indicated for the treatment of major depressive disorder and its associated symptoms.[FDA label] Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.[A177811,A177946]
DB00372ThiethylperazineFor the treatment or relief of nausea and vomiting.
DB00377PalonosetronFor the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
DB00382TacrineFor the palliative treatment of mild to moderate dementia of the Alzheimer's type.
DB00384TriamtereneTriamterene is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.[Label] Triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked.[L6169] Triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazides.[T28]
DB00392ProfenamineFor use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine.
DB00400GriseofulvinFor the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.
DB00404AlprazolamAlprazolam is indicated for the management of anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.[Label] Alprazolam may also be prescribed off label for insomnia, premenstrual syndrome, and depression.[A177973]
DB00408LoxapineFor the management of the manifestations of psychotic disorders such as schizophrenia
DB00413PramipexoleThis drug is indicated for the symptomatic treatment of Parkinson’s disease [FDA label]. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) [FDA label].
DB00415AmpicillinFor treatment of infection (Respiratory, GI, UTI and meningitis) due to E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella, nonpenicillinase-producing N. gononhoeae, H. influenzae, staphylococci, streptococci including streptoc
DB00416Metocurine IodideFor use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
DB00417PhenoxymethylpenicillinIndicated for the treatment of mild to moderately severe infections due to penicillin G­-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response.[label] Phenoxymethylpenicillin may be used for the treatment of: - mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas caused by Streptococcus without bacteremia - mild to moderately severe infections of the respiratory tract caused by Pneumococcus - mild infections of the skin and soft tissues caused by penicillin G-sensitive Staphylococcus - mild to moderately severe infections of the oropharynx caused by Fusospirochetosis, including Vincent’s gingivitis and pharyngitis, usually respond to oral penicillin therapy **Off-label** Indicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract.[label]
DB00420PromazineUsed as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
DB00422MethylphenidateMethylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
DB00426FamciclovirFor the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
DB00430CefpiramideFor treatment of severe infections caused by susceptible bacteria such as P. aeruginosa.
DB00433ProchlorperazineIndicated for the symptomatic treatment of severe nausea and vomiting.[label] Indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.[label,L6634] Off-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.[L6637]
DB00436BendroflumethiazideFor the treatment of high blood pressure and management of edema related to heart failure.
DB00437AllopurinolAllopurinol is indicated in [FDA label]: 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
DB00438CeftazidimeFor the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
DB00442EntecavirFor the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
DB00447LoracarbefUsed to treat upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis and tonsillitis, skin absceses, urinary tract infections and pyelonephritis caused by E. coli, S. pyogenes, S. aureus, S. saprphyticus, S. penumoniae, H. influenzae and M. catarrhalis.
DB00448LansoprazoleLansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]
DB00450DroperidolDroperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
DB00456CefalotinUsed to prevent infection during surgery and to treat many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract.
DB00457PrazosinThis drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents [FDA label]. Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD)[A176630].
DB00458ImipramineFor the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label]. May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
DB00460VerteporfinFor the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
DB00465KetorolacKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. [A176131] It is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids. [L6526] Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. [L6520] Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days).[L6526] A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.[A176131]
DB00467EnoxacinFor the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae, (2) uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus, and (3) complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae.
DB00468QuinineFor the treatment of malaria and leg cramps
DB00471MontelukastMontelukast is indicated for: (a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304]; (b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and (c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307]. Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331] Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328] Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]
DB00475ChlordiazepoxideFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
DB00477ChlorpromazineFor the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
DB00480LenalidomideLenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
DB00484Brimonidine**Opthalmic** Indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [label] as monotherapy or combination product with [brinzolamide]. **Topical** Indicated for the treatment of persistent (non-transient) facial erythema of rosacea in adults 18 years of age or older.[L6535]
DB00485DicloxacillinUsed to treat infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
DB00487PefloxacinFor the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract.
DB00493CefotaximeUsed to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
DB00496DarifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
DB00497OxycodoneOxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
DB00504LevallorphanFor the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids.
DB00508TriflupromazineUsed mainly in the management of psychoses. Also used to control nausea and vomiting.
DB00514DextromethorphanFor treatment and relief of dry cough.
DB00518AlbendazoleFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
DB00519TrandolaprilFor the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
DB00521CarteololFor the treatment of intraocular hypertension and chronic open-angle glaucoma
DB00524MetolazoneFor the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
DB00527CinchocaineFor production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
DB00530ErlotinibErlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label]. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label]. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label]
DB00535CefdinirCefdinir is indicated to treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (CA) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.[L7330,A180739] The organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinir.[L7330] Various beta-lactamase producing organisms may be treated, as indicated in certain sections below. **Respiratory** Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis Community-acquired pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis **Ear, nose, and throat** Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae (penicillin-susceptible only) Tonsillitis caused by Streptococcus pyogenes Pharyngitis caused by Streptococcus pyogenes Acute maxillary sinusitis caused by Haemophilus pneumoniae and Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis **Skin and skin structure infections** Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes
DB00537CiprofloxacinCiprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478] A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493] A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475] A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]
DB00541VincristineTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
DB00542BenazeprilBenazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].
DB00543AmoxapineFor the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
DB00546AdinazolamFor the treatment of anxiety and status epilepticus.
DB00553MethoxsalenFor the treatment of psoriasis and vitiligo
DB00562BenzthiazideFor the treatment of high blood pressure and management of edema.
DB00563MethotrexateMethotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]
DB00564CarbamazepineCarbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
DB00565CisatracuriumFor inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.
DB00567CephalexinCephalexin is indicated for the treatment of certain infections caused by susceptible bacteria.[Label,L6550,L6553] These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.[Label,L6550,L6553]
DB00570VinblastineFor treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
DB00577ValaciclovirValacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for [FDA label]: **Adults** • Cold Sores (Herpes Labialis) • Genital Herpes • Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode) • Suppression of genital herpes lesions in immunocompetent or HIV-infected patients • Reduction of viral transmission • Herpes Zoster **Pediatric Patients** • Cold Sores (Herpes Labialis) • Chickenpox **Limitations of use** [FDA label] The efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.
DB00578CarbenicillinFor the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.
DB00579MazindolUsed in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
DB00589LisurideFor the management of Parkinson's Disease
DB00590DoxazosinDoxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]
DB00606CyclothiazideCyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
DB00607NafcillinIndicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
DB00608ChloroquineFor the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
DB00611ButorphanolFor the relief of moderate to severe pain.
DB00613AmodiaquineFor treatment of acute malarial attacks in non-immune subjects.
DB00615RifabutinFor the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
DB00623FluphenazineFor management of manifestations of psychotic disorders.
DB00625EfavirenzFor use in combination treatment of HIV infection (AIDS)
DB00628Clorazepic acidFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
DB00631ClofarabineFor the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
DB00637AstemizoleAstemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
DB00640AdenosineUsed as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
DB00642PemetrexedUsed in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
DB00643MebendazoleFor the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
DB00650LeucovorinFor the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
DB00651DyphyllineFor relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
DB00652PentazocineFor the relief of moderate to severe pain.
DB00669SumatriptanA combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
DB00670PirenzepineFor the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.
DB00671CefiximeFor use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).
DB00674GalantamineFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
DB00679ThioridazineFor the treatment of schizophrenia and generalized anxiety disorder.
DB00680MoricizineUsed to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.
DB00682Warfarin**Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
DB00683Midazolam**Intravenous** Indicated for promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia.[F2434] **Intramuscular** Indicated for the treatment of status epilepticus in adults.[FDA label] **Nasal** Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.[L6559]
DB00685TrovafloxacinFor treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by Neisseria gonorrhoeae as well as non gonoccocal urethritis and cervicitis due to Chlamydia trachomatis.
DB00689CephaloglycinFor treatment of severe infections caused by susceptible bacteria.
DB00690FlurazepamFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
DB00691MoexiprilFor the treatment of hypertension.
DB00693FluoresceinFor diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
DB00696ErgotamineFor use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
DB00699NicergolineFor the treatment of senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration.
DB00704NaltrexoneUsed as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
DB00705DelavirdineFor the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
DB00707Porfimer sodiumIndicated in the treatment of esophageal cancer.
DB00713OxacillinUsed in the treatment of resistant staphylococci infections.
DB00714ApomorphineFor the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.
DB00716NedocromilFor the treatment of mild to moderate asthma
DB00718Adefovir dipivoxilIndicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
DB00724ImiquimodFor the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
DB00726TrimipramineFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
DB00730ThiabendazoleFor the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.
DB00732Atracurium besylateFor use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
DB00736EsomeprazoleEsomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.
DB00739HetacillinHetacillin is a beta-lactam antibiotic prodrug used to treat bacterial infections. In the body it gets converted to ampicillin.
DB00740RiluzoleFor the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
DB00749EtodolacFor acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
DB00751EpinastineFor the prevention of itching associated with allergic conjunctivitis.
DB00757DolasetronFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
DB00758ClopidogrelClopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
DB00760MeropenemFor use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
DB00766Clavulanic acidClavulanic acid combined with other antibiotics is indicated to prevent the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.[L7880,L7904] The following conditions, when they produced beta-lactamases, have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acid[L7880,L7904]: Acute otitis media caused by H. influenzae and M. catarrhalis Sinusitis due to H. influenzae and M. catarrhalis Lower respiratory tract infections due to Haemophilus influenzae, S.aureus, Klebsiella species, and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus, Escherichia coli, and Klebsiella species Urinary Tract Infections due to E. coli, Klebsiella species of bacteria, and Enterobacter species of bacteria, S.marcescens, or S.aureus Gynecologic infections due to a variety of bacteria, including P.melaninogenicus, Enterobacter species, E.Coli species, Klebsiella species, S. aureus, S.epidermidis Septicemia due to a variety of bacteria, including Klebsiella species, E.Coli species, S.aureus, or Pseudomonas species Bone and joint infections due to S.aureus Intraabdominal infections due to E.Coli, K.pnemoniae, or B.fragilis group **A note on susceptibility** It should be noted that it is only to be administered in infections that are confirmed or highly likely to be caused by susceptible bacteria. Culture and susceptibility tests should be performed if possible and used in selecting whether this antibiotic is prescribed. When beta-lactamase enzyme production is not detected during microbiological testing, clavulanic acid should not be used. When these tests are not available patterns of local infection and susceptibility may be used to determine the appropriateness of using clavulanic acid.[L7880] Ticarcillin with clavulanate has shown particular efficacy in mixed infections in addition to empiric therapy before determining the susceptibility of causative organisms. The ticarcillin-clavulanic acid combination may prove to be an effective single-agent antibiotic therapy to treat infections where a regimen of several drugs may normally be used.[L7904]
DB00767BenzquinamideUsed to prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously.
DB00768OlopatadineOlopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution.[L6781] In nasal spray, olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older.[L6784]
DB00774HydroflumethiazideUsed as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
DB00776OxcarbazepineFor use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.
DB00777PropiomazinePropiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia.
DB00779Nalidixic acidFor the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.
DB00782PropanthelineFor the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.
DB00785CryptenamineFor the treatment of hypertension.
DB00787AcyclovirAn acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older.[L7303] Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox.[L7315] An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients.[L7318] An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older.[L7321] An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis.[L7324] An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.[L7327]
DB00790PerindoprilFor the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
DB00796Candesartan cilexetilMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
DB00800FenoldopamFor the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
DB00801HalazepamUsed to relieve anxiety, nervousness, and tension associated with anxiety disorders.
DB00806PentoxifyllineFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
DB00808IndapamideFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
DB00817RosoxacinFor the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.
DB00820TadalafilUsed for the treatment of erectile dysfunction.
DB00821CarprofenFor use as a pain reliever in the treatment of joint pain and post-surgical pain.
DB00824EnprofyllineUsed in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
DB00827CinoxacinFor the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.
DB00829DiazepamIn general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression [F3160]. Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens [F3160]. Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome" [F3160]. Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery [L5188]. In the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication [L5188].
DB00831TrifluoperazineFor the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
DB00833CefaclorFor the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
DB00842OxazepamFor the treatment of anxiety disorders and alcohol withdrawal.
DB00844NalbuphineFor the relief of moderate to severe pain.
DB00845ClofazimineFor the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
DB00850PerphenazineFor use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
DB00854LevorphanolFor the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate.
DB00872ConivaptanFor the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
DB00875FlupentixolFor use in the treatment of schizophrenia and depression
DB00880ChlorothiazideChlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
DB00881QuinaprilFor the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
DB00889GranisetronFor the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
DB00895Benzylpenicilloyl PolylysineFor use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G).
DB00897TriazolamFor the short-term treatment of insomnia.
DB00900DidanosineFor use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
DB00902MethdilazineUsed for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders
DB00904OndansetronIn the adult patient population: i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and - the prevention and treatment of postoperative nausea and vomiting ii) intravenously administered ondansetron injection formulations are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and - the prevention and treatment of postoperative nausea and vomiting In the pediatric (4-18 years of age) patient population: i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting, ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger, iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting In the geriatric (>65 years of age) patient population: i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population
DB00908QuinidineFor the treatment of ventricular pre-excitation and cardiac dysrhythmias
DB00918AlmotriptanFor the treatment of acute migraine headache in adults
DB00919SpectinomycinFor use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae.
DB00921BuprenorphineFor the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
DB00923CeforanideFor the treatment of infections caused by susceptible organisms.
DB00933MesoridazineUsed in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
DB00946PhenprocoumonUsed for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
DB00948MezlocillinUsed to treat serious gram–negative infections of the lungs, urinary tract, and skin.
DB00952NaratriptanFor the acute treatment of migraine attacks with or without aura in adults.
DB00953RizatriptanFor treatment of acute migraine attacks with or without aura.
DB00956HydrocodoneHydrocodone is indicated for the management of acute pain, sometimes in combination with [acetaminophen] or [ibuprofen], as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants.[label,L7991]
DB00966TelmisartanUsed alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
DB00969AlosetronOnly for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.
DB00970DactinomycinFor the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
DB00978LomefloxacinFor the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.
DB00981PhysostigmineFor the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.
DB00985DimenhydrinateDimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
DB00993AzathioprineFor use in rheumatoid arthritis, preventing renal transplant rejection, Crohn's disease, and colitis.
DB00998FrovatriptanFor the acute treatment of migraine attacks with or without aura in adults.
DB00999HydrochlorothiazideFor the treatment of high blood pressure and management of edema.
DB01000CyclacillinFor the treatment of bacterial infections caused by susceptible organisms.
DB01003Cromoglicic acidFor the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
DB01004GanciclovirFor induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
DB01021TrichlormethiazideUsed in the treatment of oedema (including that associated with heart failure) and hypertension.
DB01033MercaptopurineFor remission induction and maintenance therapy of acute lymphatic leukemia.
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB01044GatifloxacinFor the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes
DB01045RifampicinFor the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
DB01049Ergoloid mesylateIt was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.[A32926] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[L2637] To know more about the individual components of the ergoloid mixture, please visit [DB13345] and [DB11274]
DB01051NovobiocinFor the treatment of infections due to staphylococci and other susceptible organisms
DB01053BenzylpenicillinFor use in the treatment of severe infections caused by penicillin G-susceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia, meningitis, pericarditis, endocarditis and severe pneumonia.
DB01058PraziquantelFor the treatment of infections due to all species of schistosoma.
DB01059NorfloxacinFor the treatment of urinary tract infection
DB01060AmoxicillinFor the treatment of infections of the ear, nose, and throat, the genitourinary tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only b-lactamase-negative) strains of Streptococcus spp. (a- and b-hemolytic strains only), S. pneumoniae, Staphylococcus spp., H. influenzae, E. coli, P. mirabilis, or E. faecalis. Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral infections) due to N. gonorrhoeae (males and females).
DB01061AzlocillinFor the treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae.
DB01063AcetophenazineFor the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)
DB01065MelatoninUsed orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders.
DB01066CefditorenFor the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.
DB01068ClonazepamClonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures [FDA Label] [F3787]. Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides [FDA Label] [F3787]. Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V [FDA Label]. Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements [L5572, F3796]. Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy [F3796].
DB01069PromethazineFor the treatment of allergic disorders, and nausea/vomiting.
DB01071MequitazineFor the treatment of Hay fever, urticaria (hives) and allergic rhinitis
DB01073FludarabineFor the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
DB01079TegaserodTegaserod is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) [F4223, F4229]. The safety and effectiveness of tegaserod in men with IBS-C have not been established [F4223, F4229].
DB01084EmedastineFor the temporary relief of the signs and symptoms of allergic conjunctivitis.
DB01087PrimaquineFor the treatment of malaria.
DB01089DeserpidineFor the treatment of hypertension.
DB01094HesperetinFor lowering cholesterol and, possibly, otherwise favorably affecting lipids. In vitro research also suggests the possibility that hesperetin might have some anticancer effects and that it might have some anti-aromatase activity, as well as activity again.
DB01095FluvastatinTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
DB01096OxamniquineFor treatment of Schistosomiasis caused by Schistosoma mansoni
DB01100PimozideUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
DB01103QuinacrineFor the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
DB01112CefuroximeFor the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
DB01113PapaverineFor the treatment of impotence and vasospasms.
DB01118AmiodaroneIntravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
DB01119DiazoxideUsed parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma.
DB01123ProflavineTopical antiseptic used mainly in wound dressings.
DB01129RabeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB01135DoxacuriumUsed to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.
DB01136CarvedilolCarvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.[L7889,L7892]
DB01137LevofloxacinFor the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
DB01139CefapirinFor treatment of infections caused by susceptible bacteria.
DB01140CefadroxilFor the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
DB01142DoxepinOral doxepin is approved for the following indications: - Treatment of depression and/or anxiety.[A177163] - Treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders.[T249] - Treatment of psychotic depressive disorders with associated anxiety.[T249] - Treatment of involutional depression.[T249] - Treatment of manic-depressive disorder.[T249] - Treatment of insomnia characterized by difficulties with sleep maintenance.[A177163] Topical doxepin is also approved for short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis, pruritus or lichen simplex chronicus.[T249] Off-label, doxepin is used topically for the management of neuropathic pain.[A177172] Depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities. This condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environment.[L5980] Anxiety is a normal reaction of the body towards a normal danger. When the anxious state is exacerbated or appears on situations without danger, it is defined as an anxiety disorder. This disorders can appear in different forms such as phobias, panic, obsessive-compulsive disorder and post-traumatic stress disorder.[L5983] Insomnia is a sleep disorder that directly affects the quality of life of the individual. It is characterized by the complication either to fall asleep or to stay asleep. This condition can be occasional or chronic.[L5986] Pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch. It can be localized or generalized and it can appear in an acute or chronic manner.[L5989] Neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptors.[L5992]
DB01147CloxacillinUsed to treat infections caused by penicillinase-producing staphylococci, including pneumococci, group A beta-hemolytic streptococci, and penicillin G-sensitive and penicillin G-resistant staphylococci.
DB01148FlavoxateFor symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
DB01150CefprozilFor the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
DB01151DesipramineFor relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
DB01155GemifloxacinFor the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae.
DB01157TrimetrexateFor use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer.
DB01162TerazosinTerazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
DB01163AmdinocillinUsed in the treatment of urinary tract infections caused by some strains of E. coli and klebsiella and enterobacter species. Used mainly against Gram negative organisms.
DB01165OfloxacinFor the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
DB01166CilostazolIndicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
DB01175EscitalopramLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
DB01180RescinnamineFor the treatment of hypertension.
DB01183NaloxoneFor the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock.
DB01184DomperidoneFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
DB01186PergolideIndicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
DB01192OxymorphoneFor the treatment of moderate-to-severe pain.
DB01199TubocurarineUsed as a diagnosis agent for myasthenia gravis, and also to facilitate the intubation after induction of anesthesia in surgical procedure
DB01200BromocriptineFor the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
DB01201RifapentineFor the treatment of pulmonary tuberculosis.
DB01205FlumazenilFor the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.
DB01208SparfloxacinFor the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).
DB01212CeftriaxoneFor the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
DB01215EstazolamFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
DB01220RifaximinRifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
DB01223AminophyllineFor the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
DB01224QuetiapineFor the treatment of schizophrenia and related psychotic disorders.
DB01226MivacuriumFor inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
DB01232SaquinavirFor the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
DB01238AripiprazoleAripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].
DB01239ChlorprothixeneFor treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
DB01242ClomipramineMay be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
DB01243ChloroxineUsed in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp.
DB01246AlimemazineUsed to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions).
DB01252MitiglinideFor the treatment of type 2 diabetes.
DB01253ErgometrineUsed to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
DB01259LapatinibIndicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01273VareniclineFor use as an aid in smoking cessation.
DB01303OxtriphyllineUsed to treat the symptoms of asthma, bronchitis, COPD, and emphysema.
DB01324PolythiazidePolythiazide is a thiazide diuretic used to decrease edema and decrease blood pressure.
DB01325QuinethazoneUsed to treat hypertension.
DB01326CefamandoleFor the treatment of serious infections caused by susceptible strains of microorganisms.
DB01327CefazolinMainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.
DB01328CefonicidFor the treatment of bacterial infections caused by susceptible microorganisms.
DB01329CefoperazoneIndicated for the treatment of following infections caused by susceptible bacteria:[label] 1) Respiratory tract infections caused by _S. pneumoniae_, _H. influenzae_, _S. aureus_ (penicillinase and non-penicillinase producing strains), _S. pyogenes_ (Group A beta-hemolytic streptococci), _P. aeruginosa_, _Klebsiella pneumoniae_, _E. coli_, _Proteus mirabilis_, and Enterobacter species. 2) Peritonitis and other intra-abdominal infections caused by _E. coli_, _P. aeruginosa_, and anaerobic gram-negative bacilli (including _Bacteroides fragilis_). 3) Bacterial septicemia caused by _S. pneumoniae_, _S. agalactiae_, _S. aureus_, _Pseudomonas aeruginosa_, _E. coli_, _Klebsiella_ spp., _Klebsiella pneumoniae_, Proteus species (indole-positive and indole-negative), _Clostridium_ spp. and anaerobic gram-positive cocci. 4) Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa. 5) Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci. 6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa. 7) Enterococcal Infections. Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, _in vitro_ susceptibility testing may not correlate directly with _in vivo_ results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.
DB01330CefotetanFor prophylaxis and treatment of bacterial infections.
DB01331CefoxitinFor the treatment of serious infections caused by susceptible strains microorganisms.
DB01332CeftizoximeFor the treatment of infections due to susceptible strains of microorganisms.
DB01333CefradineNot Available
DB01336MetocurineMetocurine is a muscle relaxant.
DB01347SaprisartanSaprisartan is used in the treatment of hypertension and heart failure.
DB01366ProcaterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB01388MibefradilFor the treatment of angina and high blood pressure.
DB01392YohimbineIndicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
DB01403MethotrimeprazineFor the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
DB01405TemafloxacinFor the treatment of lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections.
DB01411PranlukastUsed as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
DB01412Theobrominetheobromine is used as a vasodilator, a diuretic, and heart stimulant. And similar to caffeine, it may be useful in management of fatigue and orthostatic hypotension.
DB01413CefepimeFor the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
DB01414CefacetrileCefacetrile is a broad-spectrum first generation cephalosporin antibiotic effective in Gram-positive and Gram-negative bacterial infections.
DB01415CeftibutenIndicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
DB01416CefpodoximeIndicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.
DB01418AcenocoumarolFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
DB01422NitroxolineNitroxoline is an antibiotic agent.
DB01426AjmalineFor use as an antiarrhythmic agent.
DB01430AlmitrineFor the treatment of chronic obstructive pulmonary disease.
DB014415-Methoxy-N,N-diisopropyltryptamineNot Available
DB01445BufotenineNot Available
DB01446IndopanNot Available
DB01450DihydroetorphineNot Available
DB01452DiamorphineDiamorphine, as a prescription medication in the United Kingdom, is indicated for use in the treatment of severe pain associated with surgical procedures, myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema [L4999].
DB01459BezitramideA narcotic analgesic once used for the treatment of severe chronic pain. [A14383]
DB01460DiethyltryptamineNot Available
DB01462EtonitazeneNot Available
DB01466EthylmorphineEthylmorphine is an analgesic used for pain relief.
DB01476HaloxazolamNot Available
DB01480CyprenorphineNot Available
DB01482FenethyllineNot Available
DB01488DimethyltryptamineSome people use this compound as a psychedelic inducing agent.
DB01489CamazepamCamazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression.
DB01497EtorphineEtorphine is only available for its use in veterinary. This main usage is related to the immobilization of large mammals.
DB01511DelorazepamMainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. [Wikipedia] Anti-anxiety effects also appear to be weaker in elderly patients. [1] Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal. [3]
DB01531DesomorphineNot Available
DB01544FlunitrazepamFor short-term treatment of severe insomnias, that are not responsive to other hypnotics.
DB01545Ethyl loflazepateNot Available
DB01546EtryptamineDeveloped in the 1960's for use as an antidepressant before market withdrawal in 1962.
DB01547DrotebanolNot Available
DB01548DiprenorphineDiprenorphine is indicated to reverse the effects of powerful opioids including etorphine and carfentanil, often used for tranquilizing large animals. This drug is not approved for use in humans.
DB01551DihydrocodeineDihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
DB01553CloxazolamUsed primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to surgery.
DB01558BromazepamFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
DB01565DihydromorphineDihydromorphine is an opioid analgesic used for moderate to severe pain relief.
DB01567FludiazepamUsed for the short-term treatment of anxiety disorders.
DB01587KetazolamKetazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
DB01588PrazepamFor the treatment of anxiety disorders.
DB01589QuazepamUsed to treat insomnia.
DB01591SolifenacinSolifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]
DB01594CinolazepamFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
DB01595NitrazepamUsed to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
DB01598ImipenemImipenem is indicated, in combination with [cilastatin] with or without [relebactam], for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.[L7526,L7568]
DB01602BacampicillinFor infections at the following sites: upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis, when due to sensitive strains of the following organisms: Gram-positive: streptococci (including S. faecalis and S. pneumoniae) and nonpenicillinase-producing staphylococci; Gram-negative: H. influenzae, N. gonorrhoeae, E. coli, P. mirabilis, Salmonellae and Shigellae.
DB01603MeticillinUsed to treat infections caused by susceptible Gram-positive bacteria, particularly beta-lactamase-producing organisms such as Staphylococcus aureus that would otherwise be resistant to most penicillins.
DB01604Pivampicillinor the treatment of respiratory tract infections (including acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia); ear, nose and throat infections; gynecological infections; urinary tract infections (including acute uncomplicated gonococcal urethritis) when caused by non penicillinase-producing susceptible strains of the following organisms: gram-positive organisms, e.g., streptococci, pneumococci and staphylococci; gram-negative organisms, e.g., H. influenzae, N. gonorrhoeae, E. coli, P. mirabilis.
DB01605PivmecillinamUsed to treat infections due to mecillinam-sensitive organisms such as urinary tract infections, salmonellosis and typhoid fever.
DB01606TazobactamTazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action, treating susceptible infections. As with any other antibiotic, tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drug. **Tazobactam-piperacillin** When combined with piperacillin, it is used to treat a variety of infections, including those caused by aerobic and facultative gram-positive and gram-negative bacteria, in addition to gram-positive and gram-negative anaerobes. Some examples of infections treated with piperacillin-tazobactam include cellulitis, diabetic foot infections, appendicitis, and postpartum endometritis infections.[L4417] Certain gram-negative bacilli infections with beta-lactamase producing organisms cannot be treated with piperacillin-tazobactam, due to a gene mutation conferring antibiotic resistance.[A179266] **Tazobactam-ceftolozane** Tazobactam-ceftolozane combined with metronidazole is used to treat complicated urinary tract infections (UTI) and complicated intra-abdominal infections, as well as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.[FDA label]. This combination increases efficacy against infections with gram-negative bacilli.[A7657]
DB01607TicarcillinFor the treatment of bacterial infections.
DB01608PericiazineFor use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness.
DB01610ValganciclovirValganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
DB01611HydroxychloroquineHydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by _P. falciparum_, _P. malariae_, _P. ovale_, or _P. vivax_), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.[L8072]
DB01614AcepromazineAcepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.
DB01615AceprometazineAceprometazine is often used in combination with meprobamate for the treatment of sleep disorders.
DB01618MolindoneMolindone is used for the management of the manifestations of psychotic disorders.
DB01621PipotiazineFor the maintenance treatment of chronic non-agitated schizophrenic patients.
DB01622ThioproperazineFor the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
DB01623ThiothixeneFor the management of schizophrenia.
DB01624ZuclopenthixolUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
DB01645GenisteinCurrently Genistein is being studied in clinical trials as a treatment for prostate cancer.
DB016524-hydroxybenzoyl-CoANot Available
DB016611-(5-phospho-D-ribosyl)-ATPNot Available
DB016678-azaguanineNot Available
DB01675Methacrylyl-Coenzyme ANot Available
DB01698RutinNot Available
DB01752S-adenosyl-L-homocysteineNot Available
DB01816CastanospermineNot Available
DB01829Desulfo-Coenzyme ANot Available
DB01853Bacteriochlorophyll ANot Available
DB01860Cordycepin TriphosphateNot Available
DB018758-AzaxanthineNot Available
DB01910SinefunginNot Available
DB01911N-MethylmesoporphyrinNot Available
DB019337-HydroxystaurosporineNot Available
DB019787,9-DimethylguanineNot Available
DB01992Coenzyme ANot Available
DB019973-Bromo-7-NitroindazoleNot Available
DB02010StaurosporineNot Available
DB02020AlrestatinNot Available
DB02052Indirubin-3'-MonoximeNot Available
DB02089CP-526423Not Available
DB02095IsatinNot Available
DB021136-MethylpurineNot Available
DB02115DaidzinNot Available
DB02116OlomoucineNot Available
DB021196-Hydroxymethyl-7,8-DihydropterinNot Available
DB02132ZenarestatInvestigated for use/treatment in neuropathy (diabetic).
DB02133Chlorophyll ANot Available
DB02134XanthineNot Available
DB02137Molybdenum cofactorNot Available
DB02152K-252aNot Available
DB02166PropidiumNot Available
DB02180Myristoyl-CoaNot Available
DB022077-NitroindazoleNot Available
DB02224TaxifolinNot Available
DB02240Quinacrine mustardNot Available
DB022457-DeazaguanineNot Available
DB022825'-Deoxy-5'-MethylthioadenosineNot Available
DB02285ProtoporphyrinNot Available
DB02315Cyclic GMPNot Available
DB023651,10-PhenanthrolineNot Available
DB02375MyricetinNot Available
DB02377GuanineNot Available
DB023802'-DeoxyinosineNot Available
DB02385D-threo-neopterinNot Available
DB02428Quinaldic AcidNot Available
DB02460Hydrogenobyrinic AcidNot Available
DB024899-MethylguanineNot Available
DB025028-Hydroxy-2'-DeoxyguanosineNot Available
DB02527Cyclic adenosine monophosphateNot Available
DB02563Hexanoyl-CoANot Available
DB02568PeldesineNot Available
DB02577MesohemeNot Available
DB025915,6-DimethylbenzimidazoleNot Available
DB02607Adenosine Phosphonoacetic AcidNot Available
DB02656LY-294002Not Available
DB02690NU1025Not Available
DB02709ResveratrolBeing investigated for the treatment of Herpes labialis infections (cold sores).
DB027403-Indolebutyric AcidNot Available
DB02756PyroquilonNot Available
DB027969-DeazainosineNot Available
DB02832SirohemeNot Available
DB02844S-Adenosyl-1,8-Diamino-3-ThiooctaneNot Available
DB02857GuanosineNot Available
DB02896MethylthioinosineNot Available
DB02910Octanoyl-Coenzyme ANot Available
DB02912Propanoyl-CoANot Available
DB02930Adenosine 5'-[γ-thio]triphosphateNot Available
DB02962BenzimidazoleNot Available
DB03059Acetoacetyl-CoANot Available
DB03083IC261Not Available
DB031006-NitroindazoleNot Available
DB03126Mant-AdpNot Available
DB031323-(2-Benzothiazolylthio)-1-Propanesulfonic AcidNot Available
DB03147Flavin adenine dinucleotideUsed to treat eye diseases caused by vitamin B2 deficiency, such as keratitis and blepharitis.
DB03172TubercidinNot Available
DB031775-methylbenzimidazoleNot Available
DB031976-HydroxymethylpterinNot Available
DB03222dATPNot Available
DB03247Flavin mononucleotideNot Available
DB03251RWJ-51084Not Available
DB032852',4,4'-TrihydroxychalconeNot Available
DB03313Cephalosporin CNot Available
DB03315Guanosine 3'-monophosphateNot Available
DB03317Heme CNot Available
DB03326deoxycytidylyl-3',5'-guanosineNot Available
DB033633-Acetylpyridine Adenine DinucleotideNot Available
DB03404HeminUsed in the management of porphyria attacks, particularly in acute intermittent porphyria.
DB03409Octahydroindole-2-Carboxylic AcidNot Available
DB034104-hydroxycoumarinNot Available
DB03418DiacetyldeuterohemeNot Available
DB03428SU9516Not Available
DB03467NaringeninNot Available
DB03469Heme DNot Available
DB034937-MethylguanosineNot Available
DB03496AlvocidibInvestigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
DB035092-(4-Chlorophenyl)-5-QuinoxalinecarboxamideNot Available
DB03550Isopenicillin NNot Available
DB036093-DeoxyguanosineNot Available
DB036123-Hydroxybutyryl-Coenzyme ANot Available
DB03614MethylcobalaminNot Available
DB03682Dibenzofuran-4,6-Dicarboxylic AcidNot Available
DB03693N-(2-Aminoethyl)-5-Chloroisoquinoline-8-SulfonamideNot Available
DB03699Succinyl-Coenzyme ANot Available
DB03708Adenosine 5'-phosphosulfateNot Available
DB037165'-Fluoro-5'-DeoxyadenosineNot Available
DB03727Coproporphyrin INot Available
DB03759FG-9041Not Available
DB03769D-EritadenineNot Available
DB03823EpigallocatechinNot Available
DB03825Rhodamine 6GNot Available
DB03886BiopterinNot Available
DB03913Coenzyme F420Not Available
DB03966ClorobiocinNot Available
DB04014AlsterpaulloneNot Available
DB04036Coenzyme a PersulfideNot Available
DB04045Methylmalonyl-Coenzyme ANot Available
DB04076HypoxanthineNot Available
DB040959-DeazahypoxanthineNot Available
DB041043-MethyladenineNot Available
DB04115BerberineNot Available
DB04175Mdl-29951Not Available
DB04179BenzofuranNot Available
DB04196Pteroic AcidNot Available
DB04209DequaliniumEffective local treatment as vaginal tablets for infections such as fluor vaginalis, bacterial vaginosis, aerobic vaginitis, vulvo-vaginal candidiasis and trichomoniasis. Used as a topical antimicrobial agent.
DB04216QuercetinNot Available
DB04220CGP 4832Not Available
DB04275N-acetylserotoninNot Available
DB04289Genz-10850Not Available
DB04329IsoquinolineNot Available
DB04335InosineThe primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.
DB04345LumichromeNot Available
DB043569-DeazaguanineNot Available
DB04400L-erythro-7,8-dihydrobiopterinNot Available
DB04418Adenylosuccinic acidNot Available
DB044257,8-DihydroneopterinNot Available
DB044294'-HydroxyflavanoneNot Available
DB04440NebularineNot Available
DB044412-FluoroadenosineNot Available
DB044593,4-DichloroisocoumarinNot Available
DB04461Coproporphyrinogen IIINot Available
DB04506Chlorophyll BNot Available
DB04524Malonyl-CoANot Available
DB04532IndoleNot Available
DB045345-NitroindazoleNot Available
DB04570LatamoxefLatamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.
DB04571TrioxsalenTrioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo.
DB04576FleroxacinFleroxacin is a broad-spectrum antimicrobial fluoroquinolone.
DB04582IMAZAQUINNot Available
DB046045-iodotubercidinNot Available
DB046055-AminoisoquinolineNot Available
DB04662OLOMOUCINE IINot Available
DB04665CoumarinNot Available
DB04703HesperidinNot Available
DB04707HydroxyfasudilNot Available
DB04751Purvalanol ANot Available
DB04776(2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-olNot Available
DB04787TanaprogetNot Available
DB047895-methyltetrahydrofolic acidNot Available
DB04803VerdohemeNot Available
DB04815ClioquinolUsed as a topical antifungal treatment.
DB04821NomifensineNot Available
DB04823OxyphenisatinNot Available
DB04829Lysergic acid diethylamideNot Available
DB04833MethaqualoneFor the treatment of insomnia, and as a sedative and muscle relaxant.
DB04840DebrisoquineFor the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
DB04844TetrabenazineTreatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
DB04847RoxadustatIn clinical development for the treatment of anemia of chronic inflammatory disease.
DB04849CediranibFor the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
DB04852ImplitapideFor the treatment of atherosclerosis.
DB04853BinodenosonFor cardiac pharmacologic stress SPECT imaging, which is used to diagnose coronary artery disease.
DB04855DronedaroneManagement of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm.
DB04857BrasofensineFor the treatment of Parkinson's Disease.
DB04859ZanapezilFor the treatment of dementia in subjects with Alzheimer’s disease.
DB04860IsatoribineFor the treatment of Hepatitis C.
DB04861NebivololNebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]
DB04865Omacetaxine mepesuccinateUsed in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
DB04866HalofuginoneFor the treatment of scleroderma, cancer, and restenosis.
DB04867LintitriptFor the treatment of pancreatic cancer and appetite disorders.
DB04869OlcegepantFor the treatment of migraine headaches.
DB04871LorcaserinFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
DB04873PiboserodFor the treatment of atrial fibrillation and irritable bowel syndrome (IBS).
DB04875PralnacasanFor the treatment of rheumatoid arthritis (RA).
DB04877VoacamineFor the treatment of malaria. Also under investigation for the modulation of multidrug resistance in cancer cells.
DB04881ElacridarFor the treatment of solid tumors.
DB04882EdotecarinClinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.
DB04885CilansetronFor the treatment of symptoms associated with irritable bowel syndrome.
DB04886Calanolide AFor use in combination treatment of HIV infection (AIDS).
DB04887BrecanavirFor the treatment of HIV-1 infection in combination with other antiretroviral agents.
DB04888BifeprunoxBifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.
DB04892PhenserineFor the treatment of Alzheimer's disease (AD).
DB04903PagocloneFor the potential treatment of panic and anxiety disorders.
DB04908FlibanserinFor the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
DB04909SitamaquineInvestigated for use/treatment in infectious and parasitic disease (unspecified).
DB04910OxibendazoleInvestigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications.
DB04912StannsoporfinInvestigated for use/treatment in liver disease, metabolic disease, and pediatric indications.
DB04915IdronoxilIntended for the treatment of various forms of cancer.
DB04918CeftobiproleFor the treatment of serious bacterial infections in hospitalised patients.
DB04934RifalazilInvestigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease.
DB04941CrofelemerFor the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
DB04954TecadenosonInvestigated for use/treatment in arrhythmia and atrial fibrillation.
DB04960TipifarnibInvestigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
DB04967LucanthoneIntended for use as a radiation sensitizer in the treatment of brain cancer.
DB04980LemuteporfinIntended for the treatment of benign prostatic hyperplasia and prostrate disorders.
DB04982TalampanelFor the treatment of epilepsy.
DB05009ApadenosonInvestigated for use/treatment in cardiovascular disorders and inflammatory disorders (unspecified).
DB05022AmonafideInvestigated for use/treatment in breast cancer, ovarian cancer, and prostate cancer.
DB05038AnatibantInvestigated for use/treatment in traumatic brain injuries.
DB05039IndacaterolFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
DB05050ADL5859Investigated for use/treatment in pain (acute or chronic).
DB05073SRT501Investigated for use/treatment in diabetes mellitus type 2 and neurologic disorders.
DB05109TrabectedinIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
DB05119RilapladibInvestigated for use/treatment in atherosclerosis and cardiovascular disorders.
DB05168VintafolideInvestigated for use/treatment in solid tumors.
DB05169AT9283Investigated for use/treatment in cancer/tumors (unspecified), leukemia (myeloid), and solid tumors.
DB05187ElafibranorInvestigated for use/treatment in atherosclerosis and diabetes mellitus type 2.
DB05189EPC2407Investigated for use/treatment in cancer/tumors (unspecified).
DB05191Atl146eInvestigated for use/treatment in inflammatory disorders (unspecified).
DB05197SofalconeInvestigated for use/treatment in gastroenteritis and ulcers.
DB05210SF1126For the treatment of various forms of cancer.
DB05223PracinostatFor the treatment of various forms of cancer.
DB05225AM103For the treatment of asthma and cardiovascular disease.
DB05232TetrodotoxinFor the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.
DB05234LGD2941For the treatment and prevention of osteoporosis.
DB05241XL765For the treatment of various forms of cancer.
DB05294VandetanibVandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
DB05296Motexafin lutetiumInvestigated for use/treatment in brain cancer, breast cancer, cervical dysplasia/cancer, prostate cancer, cancer/tumors (unspecified), coronary artery disease, macular degeneration, and peripheral vascular disease.
DB05351DexlansoprazoleDexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
DB05352Fx-1006AInvestigated for use/treatment in amyloidosis.
DB05372CP-945598Investigated for use/treatment in obesity.
DB05403CEP-1347Investigated for use/treatment in asthma and parkinson's disease.
DB05412TalmapimodInvestigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.
DB05414PipendoxifeneInvestigated for use/treatment in breast cancer.
DB05417GW 468816Investigated for use/treatment in tobacco dependence.
DB05422OPC-14523Investigated for use/treatment in bulimia, depression, and obsessive-compulsive disorders.
DB05423ORG-34517Investigated for use/treatment in depression.
DB05428motexafin gadoliniumInvestigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).
DB05457OSI-7904LInvestigated for use/treatment in gastric cancer.
DB05465TandutinibInvestigated for use/treatment in leukemia (myeloid).
DB05478Pradefovir MesylateInvestigated for use as a prodrug for Hepsera in treating hepatitis (viral, B).
DB05487CustirsenInvestigated for use/treatment in brain cancer and breast cancer.
DB05488Technetium Tc-99m ciprofloxacinInvestigated for use/treatment in infectious and parasitic disease (unspecified).
DB05490AMG-131Investigated for use/treatment in diabetes mellitus type 2.
DB05498KW-7158Investigated for use/treatment in urinary incontinence.
DB05511PiclidenosonInvestigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.
DB05519BudiodaroneInvestigated for use/treatment in arrhythmia and atrial fibrillation.
DB05524PelitinibInvestigated for use/treatment in colorectal cancer and lung cancer.
DB05549INO-1001Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction.
DB05552TG100-115Investigated for use/treatment in angioedema and myocardial infarction.
DB05553RegrelorInvestigated for use/treatment in cardiac surgery, coronary artery disease, thrombosis, and transfusion.
DB05575MotesanibInvestigated for use/treatment in solid tumors.
DB05585VerubulinInvestigated for use/treatment in brain cancer, lung cancer, melanoma, and solid tumors.
DB05586FaciniclineInvestigated for use/treatment in alzheimer's disease, neurologic disorders, and schizophrenia and schizoaffective disorders.
DB05608MKC-1Investigated for use/treatment in breast cancer, leukemia (unspecified), lung cancer, and solid tumors.
DB056164'-Methylene-5,8,10-trideazaaminopterinInvestigated for use/treatment in inflammatory disorders (unspecified), psoriasis and psoriatic disorders, and rheumatoid arthritis.
DB05659Faropenem medoxomilInvestigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications.
DB05676ApremilastApremilast is indicated for the treating of active psoriatic arthritis in adults, for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment. In addition, apremilast is now indicated for the treatment of oral ulcers associated with Behcet's disease in adults.[L7501]
DB05678SLx-4090Investigated for use/treatment in hyperlipidemia.
DB05687BL-1020Investigated for use/treatment in schizophrenia and schizoaffective disorders.
DB05710GantacuriumInvestigated for use/treatment in anesthesia (unspecified).
DB05721EVT 201Investigated for use/treatment in insomnia.
DB05735CefilavancinInvestigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.
DB05737Varespladib methylInvestigated for use/treatment in atherosclerosis and coronary artery disease.
DB05772RabeximodInvestigated for use/treatment in rheumatoid arthritis.
DB05796DaglutrilInvestigated for use/treatment in congestive heart failure and hypertension.
DB05838OPC-51803Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.
DB05861TasquinimodInvestigated for use/treatment in prostate cancer.
DB05868CiluprevirInvestigated for use/treatment in hepatitis (viral, C).
DB05874AEOL 10150Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).
DB05882CHF 4227Investigated for use/treatment in osteoporosis.
DB05913OSI-930Investigated for use/treatment in solid tumors.
DB05928DovitinibInvestigated for use/treatment in multiple myeloma and solid tumors.
DB05932DenibulinInvestigated for use/treatment in solid tumors.
DB05936CVT-6883Investigated for use/treatment in asthma.
DB05944VarlitinibInvestigated for use/treatment in cancer/tumors (unspecified).
DB06021AV-412Investigated for use/treatment in cancer/tumors (unspecified).
DB06070SNX-5422Investigated for use/treatment in cancer/tumors (unspecified).
DB06080ABT-869Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
DB06090BradaniclineInvestigated for use/treatment in neurologic disorders.
DB06140SUVN-502Investigated for use/treatment in neurologic disorders.
DB06144SertindoleUsed in the treatment of schizophrenia.
DB06148MianserinFor the treatment of depression.
DB06160GarenoxacinInvestigated for use/treatment in bacterial infection.
DB06163PlevitrexedInvestigated for use/treatment in pancreatic cancer, solid tumors, gastric cancer, lung cancer, and colorectal cancer.
DB06166FosdevirineInvestigated for use/treatment in HIV infection and acquired immune deficiency syndrome (AIDS) and aids-related infections.
DB06169IndibulinInvestigated for use/treatment in solid tumors.
DB06174NoscapineInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.
DB06178TalotrexinInvestigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid).
DB06185ForodesineInvestigated for use/treatment in lymphoma (non-hodgkin's) and leukemia (lymphoid).
DB06188IspinesibInvestigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.
DB06191ZosuquidarInvestigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.
DB06193PixantroneCurrently in Phase III investigation for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who have failed two prior lines of therapy. Presently, no standard therapy exists for patients with relapsed or refractory NHL. [2] After first line therapy has been initiated, most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracycline-induced congestive heart failure (CHF). Pixantrone is an attractive alternative as a second line agent, due to its lack of cardiac toxicity. [2] The phase III trial, PIX-R, is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large B-cell lymphoma (the most common type of NHL). Previous study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients. In myocardial strips which are doxorubicin naive, pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed, and once absorbed exhibits redox inactivity. [3] Pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia, diffuse large B-cell lymphoma, follicular lymphoma, metastatic breast cancer, low grade small lymphocytic lymphomas and general metastatic cancers.
DB06195SeliciclibInvestigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified).
DB06199AtrasentanInvestigated for use/treatment in prostate cancer and cancer/tumors (unspecified).
DB06207SilodosinTreatment for symptomatic relief of benign prostatic hyperplasia
DB06211DoripenemDoripenem is indicated in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, caused by designated susceptible bacteria.
DB06212TolvaptanTreatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
DB06213RegadenosonDiagnostic agent for radionuclide myocardial perfusion imaging (MPI)
DB06216AsenapineUsed for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.
DB06230NalmefeneIndicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification [L1024]. Indicated for the complete or partial reversal of opioid drug effects, including respiratory depression - induced by either natural or synthetic opioids - or in the management of known or suspected opioid overdose [FDA Label].
DB06234MaribavirInvestigated for use/treatment in viral infection, transplantation (organ or tissue), cytomegalovirus (CMV) retinitis, and retinal disorders (unspecified).
DB06235VadimezanInvestigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.
DB06240TariquidarInvestigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.
DB06266LonidamineInvestigated for use/treatment in benign prostatic hyperplasia, prostate disorders, and cancer/tumors (unspecified).
DB06281TorcetrapibInvestigated for use/treatment in peripheral vascular disease and hyperlipidemia.
DB06290SimeprevirIndicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis. Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
DB06306OnalespibInvestigated for use/treatment in cancer/tumors (unspecified).
DB06313BNC105Investigated for use/treatment in cancer/tumors (unspecified).
DB06346FiboflaponInvestigated for use/treatment in inflammatory disorders (unspecified).
DB06350ElinogrelInvestigated for use/treatment in cardiovascular disorders and myocardial infarction.
DB06354TezampanelInvestigated for use/treatment in pain (acute or chronic) and migraine and cluster headaches.
DB06362BecatecarinInvestigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).
DB06364XR5944Investigated for use/treatment in solid tumors.
DB06368AlamifovirInvestigated for use/treatment in hepatitis (viral, B).
DB06401BazedoxifeneIndicated for following conditions alone or in combination with conjugated estrogens in women with a uterus: - Treatment of moderate to severe vasomotor symptoms associated with menopause - Prevention of postmenopausal osteoporosis
DB06409Morphine glucuronideInvestigated for use/treatment in pain (acute or chronic).
DB06429TalnetantInvestigated for use/treatment in schizophrenia and schizoaffective disorders, irritable bowel syndrome (IBS), and chronic obstructive pulmonary disease (COPD).
DB06435TarazepideInvestigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).
DB06436SemaxanibInvestigated for use/treatment in colorectal cancer and lung cancer.
DB06441CangrelorFor use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
DB06455MeclinertantInvestigated for use/treatment in colorectal cancer, prostate cancer, schizophrenia and schizoaffective disorders, psychosis, depression, and lung cancer.
DB06457TecastemizoleInvestigated for use/treatment in allergic rhinitis.
DB06469LestaurtinibInvestigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).
DB06471NaxifyllineInvestigated for use/treatment in congestive heart failure.
DB06477SumaniroleInvestigated for use/treatment in parkinson's disease.
DB06478PorfiromycinInvestigated for use/treatment in head and neck cancer.
DB06479PropentofyllineInvestigated for use/treatment in alzheimer's disease.
DB06480PrucalopridePrucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.[L4882] CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following: -Straining during more than 25% of the bowel movements. -Lumpy or hard stools in 25% of the bowel movements. -Sensation of incomplete evacuation in more than 25% of all bowel movements. -Sensation of anorectal blockage or obstruction in more than 25% of the bowel movements. -Manual maneuvers required in more than 25% of the bowel movements. -Fewer than 3 bowel movements per week.[L4883]
DB06486EnzastaurinInvestigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
DB06499FuraprofenInvestigated for use/treatment in hepatitis (viral, C).
DB06504S-8510Investigated for use/treatment in alzheimer's disease and dementia.
DB06506RepinotanInvestigated for use/treatment in strokes, cerebral ischemia, and depression.
DB06538RobalzotanInvestigated for use/treatment in anxiety disorders and depression.
DB06555SiramesineInvestigated for use/treatment in anxiety disorders.
DB06575ValomaciclovirInvestigated for use/treatment in herpes zoster infections and viral infection.
DB06578TonabersatInvestigated for use/treatment in migraine and cluster headaches.
DB06580CelgosivirInvestigated for use/treatment in hepatitis (viral, C).
DB06582DextofisopamInvestigated for use/treatment in irritable bowel syndrome (IBS).
DB06586CetilistatInvestigated for use/treatment in obesity.
DB06588TriphendiolInvestigated for use/treatment in cancer/tumors (unspecified).
DB06590Ceftaroline fosamilCeftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.
DB06595MidostaurinInvestigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
DB06600NemonoxacinInvestigated for use/treatment in bacterial infection and pneumonia.
DB06603PanobinostatPanobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
DB06604IlepatrilInvestigated for use/treatment in hypertension.
DB06608TafenoquineTafenoquine is used for the treatment and prevention of relapse of Vivax malaria in patients 16 years and older. Tafenoquine is not indicated to treat acute vivax malaria.[A35671] Malaria is a disease that remains to occur in many tropical countries. Vivax malaria, caused by _Plasmodium vivax_, is known to be less virulent and seldom causes death. However, it causes a substantive illness-related burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months. This dormant form produces ongoing relapses.[A35671]
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB06619AmdoxovirInvestigated for use/treatment in HIV infection and acquired immune deficiency syndrome (AIDS) and aids-related infections.
DB06620AplindoreInvestigated for use/treatment in parkinson's disease and neurologic disorders.
DB06626AxitinibUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
DB06638QuarfloxinInvestigated for use/treatment in leukemia (lymphoid).
DB06659RostaporfinInvestigated for use/treatment in macular degeneration.
DB06673AlmorexantInvestigated for use/treatment in sleep disorders and insomnia.
DB06678EsmirtazapineInvestigated for use/treatment in insomnia and sleep disorders.
DB06684VilazodoneVilazodone is approved for treatment of major depressive disorder[Label,A38477,A177622].
DB06685LaquinimodInvestigated for use/treatment in multiple sclerosis.
DB06695Dabigatran etexilateDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials)[A177463,A6978,A6977]. In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial)[Label,A177463].
DB06727SparteineNot Available
DB06732beta-NaphthoflavoneNot Available
DB06737ZaltoprofenNot Available
DB06741GavestinelNot Available
DB06751DrotaverineUsed in the treatment of functional bowel disorders and alleviating pain in renal colic.
DB06766AlcaftadineFor the prevention of itching associated with allergic conjunctivitis.
DB06769BendamustineBendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
DB06771BesifloxacinTreatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*
DB06800MethylnaltrexoneTreatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
DB06813PralatrexateTreatment of relapsed or refractory peripheral T-cell lymphoma.
DB06816PyrviniumPyrvinium was once used in the treatment of pinworm infestations [T39].
DB07118HymecromoneNot Available
DB07232VeliparibNot Available
DB07238NesbuvirNot Available
DB073019H-CARBAZOLENot Available
DB07352ApigeninNot Available
DB07419S-23Not Available
DB07776FlavoneNot Available
DB07795FisetinNot Available
DB07885TalviralineNot Available
DB07933ErteberelNot Available
DB07950Indoleacetic acidNot Available
DB079543-isobutyl-1-methyl-7H-xanthineNot Available
DB079965-(2-methylpiperazine-1-sulfonyl)isoquinolineNot Available
DB08089LGD-2226Not Available
DB08162FasudilNot Available
DB082305,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONENot Available
DB08313nocodazoleNot Available
DB08437PuromycinNot Available
DB085507,8-Dichloro-1,2,3,4-tetrahydroisoquinolineNot Available
DB08624BENZOTHIAZOLENot Available
DB08794Ethyl biscoumacetateNot Available
DB08795AzidocillinFor treatment of infection (Respiratory, GI, UTI and meningitis) due to E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella, nonpenicillinase-producing N. gononhoeae, H. influenzae, staphylococci, streptococci including streptoc
DB08796PipazethateFor the treatment of cough.
DB08811TofisopamFor the treatment of anxiety and alcohol withdrawal.
DB08815LurasidoneTreatment of schizophrenia.
DB08816TicagrelorTicagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with ST elevation.
DB08820IvacaftorWhen used as monotherapy as the product Kalydeco, ivacaftor is indicated for the management of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D.[L768,L6838] When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are shown to be homozygous for the F508del mutation in the CFTR gene. When used in combination with [Tezacaftor] in the product Symdeko, it is used to manage CF in patients 12 years and older who have at least one mutation in the CFTR gene or patients aged 12 or older who are shown to be homozygous for the F508del mutation.[L6814]
DB08822Azilsartan medoxomilTreatment of hypertension (alone or as an adjunct).
DB08827LomitapideUsed in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
DB08839SerotoninNot Available
DB08843GS 0573Not Available
DB08844Uric acidAt present (August 2013), there is no approved indication for uric acid. The potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke.
DB08846Ellagic acidEllagic acid is being investigated for use in follicular lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines.
DB08860PitavastatinPitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). It is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.[F4667] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB08878AminopterinPrior to its withdrawal, aminopterin was initially used in the treatment of childhood leukemia; specifically to induce remissions. Later, aminopterin was used off-label in the United States to treat psoriasis, yielding dramatic lesion clearing. Aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index. Aminopterin (as well as methotrexate) has also been explored for use as an abortifacient. However, their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome.
DB08881VemurafenibVemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
DB08882LinagliptinLinagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].
DB08903BedaquilineBedaquiline is indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB08916AfatinibAfatinib is a kinase inhibitor indicated as monotherapy [L2937] for the first-line [FDA Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [FDA Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [FDA Label, L2937]. Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [L2939]. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I [L2939].
DB08922PerospironeFor the treatment of schizophrenia and acute cases of bipolar mania.
DB08930DolutegravirDolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kg.[A7520] The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031]
DB08950IndoraminNot Available
DB08951IndoprofenNot Available
DB08967DimetotiazineNot Available
DB08972FlumequineNot Available
DB08974FlubendazoleNot Available
DB08995DiosminNot Available
DB08996DimetacrineNot Available
DB09000CyamemazineNot Available
DB09003ClocapramineNot Available
DB09008CefaloridineNot Available
DB09012CarbazochromeIndicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura.
DB09027LedipasvirWhen used in combination with the antiviral medication [DB08934] as the commercially available product Harvoni, ledipasvir is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label]. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627].
DB09028CytisineIndicated for use in smoking cessation.
DB09047FinafloxacinFinafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.
DB09049NaloxegolIndicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
DB09050CeftolozaneThis drug is administered in combination with tazobactam for the treatment of complicated intra-abdominal infections (in combination with metronidazole) and complicated urinary tract infections[A179425], which may include pyelonephritis. Ceftolozane-tazobactam is also indicated in the treatment of bacterial ventilator-associated pneumonia and bacterial hospital-acquired pneumonia.[FDA label]
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB09062CefminoxNot Available
DB09071TasimelteonTasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
DB09078LenvatinibLenvatinib is indicated for the treatment of following conditions. - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DB09079NintedanibNintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DB09080OlodaterolOlodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
DB09083IvabradineIvabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more[FDA Label].
DB09084BenzydamineAvailable predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions. When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. [L1121] When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures. [ L1123]
DB09092XanthinolXanthinol is primarily used in diet supplements to increase the brain metabolism of glucose and obtain ATP. Xanthinol is also used as an agent to reduced cholesterol as it is a vasodilator.[L1080] Its action allows having an elevated rate of blood flow in the brain which helps improve memory function, concentration and awareness.[L1079] Thus, due to his actions, xanthinol is indicated to improve cerebrovascular and peripheral vascular disorders as well as hyperlipidaemias.[L1081]
DB09097QuinagolideIndicated for the treatment of hyperprolactinemia (idiopathic or originating from a prolactin-secreting pituitary microadenoma or macroadenoma).
DB09101ElvitegravirElvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
DB09115DiiodohydroxyquinolineUsed in the treatment of amoebiasis.
DB09119Eslicarbazepine acetateEslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients.
DB09128BrexpiprazoleAs an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
DB09151Flutemetamol (18F)Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
DB09166EtizolamIndicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.
DB09167DosulepinIndicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required.
DB09187LortalamineNot Available
DB09189DaledalinNot Available
DB09190TalopramNot Available
DB09192TandamineNot Available
DB09209PholcodinePholcodine is indicated as a cough suppressant for the temporary relief of non-productive dry cough. It is stated to present a required label indication of "temporary relief of dry cough."[L1200] Cough is the respiratory movement that occurs after an irritation signal is transmitted to the central nervous system and further stimulates the medulla oblongata. This stimulation causes a motor output that is sent through motoneurons to the respiratory muscles. A non-productive cough is a type of cough characterized by the absence of sputum, and it has a large inspiration that will cause continuous coughing.
DB09225ZotepineZotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108] It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857] Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]
DB09241Methylene blueIndicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Other clinical applications of methylene blue include improvement of hypotension associated with various clinical states, an antiseptic in urinary tract infections, treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome, and treatment of ifofosamide induced neurotoxicity.
DB09244PirlindoleFor the treatment of major depression. It is being studied in the treatment of fibromyalgia pain syndrome. One study determined that the effect of pirlindole on sensorimotor performance while driving a motor vehicle shows many similarities to that of placebo. The drug appears to stimulate the central nervous system, rather than exhibit a sedative effect, like many antidepressants. Because of its selective, reversible inhibition of monoamine oxidase (MAO-A) and short half-life, unpleasant "cheese effects" are avoided. This refers to the effects of consuming tyramine-rich foods, such as cheese while medicated with monoamine oxidase inhibitors, leading to severe headaches and hypertension [L1395]. of The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome [L1394].
DB09273DoxofyllineIndicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component.
DB09280LumacaftorWhen given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. [FDA Label]
DB09290RamosetronFor the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.
DB09295TalniflumateTalnifumate is a phthalidyl ester of nifumic acid, which has potent analgesic and anti-inflammatory effects and is widely used to treat inflammatory disorders, such as rheumatoid arthritis and osteoarthritis [L1409], and has also been studied for the management of cystic fibrosis [L1403].
DB09298SilibininCurrently being tested as a treatment of severe intoxications with hepatotoxic substances, such as death cap (Amanita phalloides) poisoning.
DB09299Tenofovir alafenamideTenofovir alafenamide is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease.[L6241] In combination with [emtricitabine] and other antiretrovirals, it is indicated for the treatment of HIV-1 infection in patients with a weight higher than 35 kg. When combined with antiretrovirals other than protease inhibitors that require a CYP3A inhibitor, it can be used in pediatric patients weighing between 25 and 35 kg.[L4388] In the combination product with emtricitabine and [bictegravir], tenofovir alafenamide is considered as a complete regimen for the treatment of HIV-1 infection in treatment-naive patients or in patients virologically suppressed for at least 3 months with no history of treatment failure.[L6277] Additionally, the combination product including [elvitegravir], [cobicistat], emtricitabine and tenofovir alafenamide and the combination product including emtricitabine, [rilpivirine] and tenofovir alafenamide can be used in the treatment of HIV-1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failure.[L6280] Lastly, the combination product including [darunavir], cobicistat, emtricitabine, and tenofovir alafenamide is indicated for the treatment of HIV-1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovir.[L6283]
DB09304SetiptilineFor the treatment of depression [A19792].
DB09305AptazapineInvestigated for the treatment of depression.
DB09306MetralindoleInvestigated for the treatment of depression.
DB09319CarindacillinFor the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria (due to susceptible strains Escherichia coli, Proteus mirabilis, Morganella morganii, Providencia rettgeri, Proteus vulgaris, Pseudomonas, Enterobacter, and Enterococci.). Also indicated in the treatment of prostatitis (due to susceptible strains Escherichia coli Enterococcus (S. faecalis), Proteus mirabilis Enterobacter sp.).
DB09320Procaine benzylpenicillinFor the treatment of a number of bacterial infections such as syphilis, anthrax, mouth infections, pneumonia and diphtheria.
DB09324SulbactamSulbactam is currently available in combination products with ampicillin. Within this formulation it is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp. Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).
DB09335AlatrofloxacinNot Available
DB09350Piperonyl butoxideFor the treatment of head, pubic (crab), and body lice.
DB09363Rauwolfia serpentina rootRauwolfia alkaloids are indicated in the treatment of hypertension [L1614]. Rauwolfia alkaloids have been used for relief of symptoms in agitated psychotic states such as schizophrenia; however, use as antipsychotics and sedatives have been replaced with the use of more effective, safer agents [L1614].
DB11115EnsulizoleIndicated to be used as an UV-B-absorbing molecule in sunscreen formulations.
DB11145OxyquinolineOxyquinoline is used as a biocidal component of several over the counter products. These products are marketed for the purposes of inhibiting abnormal biological growth in the vagina and restoring natural pH.
DB11191CobamamideNot Available
DB11251TocopherolTocopherol can be used as a dietary supplement for patients with a deficit of vitamin E; this is mainly prescribed in the alpha form.[A32443] Vitamin E deficiency is rare, and it is primarily found in premature babies of very low birth weight, patients with fat malabsorption or patients with abetalipoproteinemia.[L2120] Tocopherol, due to its antioxidant properties, is studied for its use in prevention or treatment in different complex diseases such as cancer,[A32436] atherosclerosis, cardiovascular diseases,[A32442] and age-related macular degeneration.[A32444]
DB11256Levomefolic acidFor the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272].
DB11259DiosmetinNot Available
DB11273DihydroergocornineTo know more about the approved indications please visit [DB01049]
DB11336KinetinNot Available
DB11337ZeatinNot Available
DB11363AlectinibAlectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB11366RoquinimexRoquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. As well, roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia.
DB11367CefroxadineWas used for the treatment of bacterial infections.
DB11378BuquinolateNot Available
DB11380CambendazoleNot Available
DB11385CefaloniumNot Available
DB11390CoumaphosNot Available
DB11393DanofloxacinNot Available
DB11394DecoquinateNot Available
DB11399DirlotapideNot Available
DB11410FenbendazoleNot Available
DB11419HaloxonNot Available
DB11426MarbofloxacinNot Available
DB11433NequinateNot Available
DB11443OrbifloxacinNot Available
DB11446OxfendazoleNot Available
DB11447PhenothiazineNot Available
DB11448PhosmetNot Available
DB11457RotenoneNot Available
DB11479ZilpaterolNot Available
DB11485CeftiofurNot Available
DB11490NalorphineUsed to reverse opioid overdose.
DB11491SarafloxacinNot Available
DB114962-mercaptobenzothiazoleNot Available
DB11511DifloxacinNot Available
DB11540PropiopromazineNot Available
DB11555ZolazepamNot Available
DB11561AminacrineNot Available
DB11562BicucullineNot Available
DB11574ElbasvirElbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].
DB11575GrazoprevirGrazoprevir is indicated in combination with [DB11574] (as the fixed dose combination product Zepatier) with or without [DB00811] for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
DB11577Indigotindisulfonic AcidThis drug was initially used as a kidney function test. The main application of indigo carmine at this time is localizing and visualizing ureteral orifices during cystoscopy and ureteral catheterization procedures [L2215].
DB11586AsunaprevirAsunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
DB11591BilastineFor symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older [FDA Label].
DB11592NitrocefinNot Available
DB11596LevoleucovorinLevoleucovorin is indicated for use as rescue therapy following high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA, dosed at one-half the usual dose of racemic d,l-leucovorin), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer (although they should not be mixed in the same infusion as a precipitate may form).
DB11613VelpatasvirVelpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label].
DB11629LaropiprantNot Available
DB11630TemoporfinFor use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy [FDA Label].
DB11635TocofersolanTocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age [L2371].
DB11641VinflunineFor use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy [L2381].
DB11644Tafamidis**Indicated** for: 1) The treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment in Europe.[L6247] 2) The treatment of cardiomyopathy in wild type or hereditary transthyretin-mediated amyloidosis in the US.[label] There is a distinction in dosage between tafamidis, dosed at 61mg daily, and tafamadis meglumine which is dosed at 80mg daily.
DB11651DactolisibNot Available
DB11655EvacetrapibNot Available
DB11656RebamipideNot Available
DB11658QAV-680Not Available
DB11663PictilisibNot Available
DB11664PsilocybineNot Available
DB11670SP-8203Not Available
DB11674EquolNot Available
DB11676GalidesivirNot Available
DB11679FruquintinibNot Available
DB11681TofimilastNot Available
DB11689SelumetinibNot Available
DB11691NaldemedineFor the treatment of opioid-induced constipation [FDA Label].
DB11692PavinetantNot Available
DB11699TropisetronFor the prevention of nausea and vomiting induced by cytotoxic therapy and postoperative.
DB11712TezacaftorTezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis (CF) in patients aged 12 years or older with two copies of the _F508del_ gene mutation or at least one mutation in the CFTR gene that is responsive to this drug.[L6814]
DB11713RuzasvirNot Available
DB11725LatrepirdineNot Available
DB11730RibociclibKisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
DB11736PF-00489791Not Available
DB11737IcotinibIcotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
DB11741FamitinibNot Available
DB11747BarasertibNot Available
DB11753RifamycinRifamycin is indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of _E. coli_. The status of the disease should not be complicated by fever or blood in the stool. To prevent drug-resistant bacteria, it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacteria.[L4802] Travallers' diarrhea is very common problem affecting 20-60% of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad. This condition is rarely life threatening but in severe cases it can produce dehydration and sepsis. The most common cause of travellers' diarrhea is a pathogen and from the pathogens identified, bacteria is the most common cause followed by norovirus, rotavirus and similar viruses.[A39995]
DB11757IstradefyllineNot Available
DB11761TenapanorNot Available
DB11769FunapideNot Available
DB11772PilaralisibNot Available
DB11774PazufloxacinNot Available
DB11782BirinapantNot Available
DB11793NiraparibNiraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy
DB11798TanzisertibNot Available
DB11799BictegravirBictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine [L1219, L1220].
DB11800TivozanibNot Available
DB11805SaracatinibNot Available
DB11812TalaporfinNot Available
DB11814PF-03882845Not Available
DB11819ASP-4058Not Available
DB11822TMC-647055Not Available
DB11828NeratinibFor use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
DB11829RuboxistaurinNot Available
DB11832CrenolanibNot Available
DB11836SapanisertibNot Available
DB11845LucitanibNot Available
DB11852TegobuvirNot Available
DB11870RG-4733Not Available
DB118753,3'-diindolylmethaneNot Available
DB11880Acridine CarboxamideNot Available
DB11884Vadastuximab TalirineNot Available
DB11885AnlotinibNot Available
DB11892PrulifloxacinNot Available
DB11900OC-459Not Available
DB11909VarespladibNot Available
DB11910MK-0249Not Available
DB11911GalunisertibNot Available
DB11913LY-2090314Not Available
DB11915ValbenazineFor the treatment of tardive dyskinesia in adults [FDA Label].
DB119196-O-benzylguanineNot Available
DB11929VaniprevirNot Available
DB11935FlomoxefNot Available
DB11937Kynurenic AcidNot Available
DB11943DelafloxacinDelafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis as well as the Gram-negative organisms Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa [FDA Label].
DB11952DuvelisibDuvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.[L4586] The CLL is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells. In leukemia, there is an overproduction of cells that are abnormal and do not mature into blood cells and thus, they just crowd out normal cells and impair their normal function. In lymphocyte leukemia, the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes. The CLL is the type of lymphocytic leukemia that develops slowly over months or years.[L4587] The SLL is a very similar disease to the CLL and these terms are usually referred interchangeably. The only difference between these two diseases is that in CLL the cells are found mostly in the blood and bone marrow while in SLL, the cells are mainly found in the lymph nodes.[L4588] As well, duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. This approval is still under the status of continued approval and it is restrained to confirmatory trials.[L4586] The follicular lymphoma is a B-cell lymphoma that clusters in the lymph nodes or other tissues.[L4589]
DB11957IdalopirdineNot Available
DB11963DacomitinibDacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812] Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201]
DB11964IlaprazoleNot Available
DB11965SJG-136Not Available
DB11966BMS-986094Not Available
DB11967Binimetinib On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335].
DB11968MK-7145Not Available
DB11973TesevatinibNot Available
DB11978GlasdegibGlasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy.[L5080] Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adults.[L4832]
DB11986EntrectinibNot Available
DB11987GSK-2018682Not Available
DB11992OmarigliptinNot Available
DB11999VosaroxinNot Available
DB12000ApabetaloneNot Available
DB12001Abemaciclib* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
DB12006BMS-906024Not Available
DB12011FevipiprantNot Available
DB12020TecovirimatSmallpox virus infection is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg [FDA label].
DB12027SerdemetanNot Available
DB12030Fluorescein lisicolNot Available
DB12037VedroprevirNot Available
DB12039EpicatechinNot Available
DB12041MapracoratNot Available
DB12049Dasolampanel etibutilNot Available
DB12051SetrobuvirNot Available
DB12052IcariinNot Available
DB12057ORM-12741Not Available
DB12058RecoflavoneNot Available
DB12061PardoprunoxNot Available
DB12062VolasertibNot Available
DB12070LetermovirFor use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label].
DB12071VabicaserinNot Available
DB12072OrantinibNot Available
DB12073AlbaconazoleNot Available
DB12082VesnarinoneNot Available
DB12093TetrahydropalmatineNot Available
DB12100AbediterolNot Available
DB12101CC-220Not Available
DB12114PoziotinibNot Available
DB12116Epigallocatechin gallateNot Available
DB12121EntospletinibNot Available
DB12125DianiclineNot Available
DB12127SultamicillinNot Available
DB12131VinpocetineNot Available
DB12134GepotidacinNot Available
DB12137GSK-256066Not Available
DB12147ErdafitinibErdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor [FDA Label][A177109, A177112, A177115] that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has: i) susceptible FGFR3 or FGFR2 genetic alterations and has [FDA Label], ii) progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [FDA Label]. The selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible FGFR genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic like the FDA approved therascreen FGFR RGQ RT-PCR Kit as developed by QIAGEN [FDA Label]. This above indication is approved under accelerated approval by the US FDA based on tumor response rate [FDA Label]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [FDA Label].
DB12149S-3304Not Available
DB12155NapabucasinNot Available
DB12156CordycepinNot Available
DB12161DeutetrabenazineIndicated for the treatment of chorea associated with Huntington’s disease [FDA Label].
DB12167LY-3023414Not Available
DB12170VeledimexNot Available
DB12174CUDC-101Not Available
DB12183SapitinibNot Available
DB12186SRT-2104Not Available
DB12190FaropenemNot Available
DB12200TivantinibNot Available
DB12203TozadenantNot Available
DB12210AZD-6280Not Available
DB12211PSI-697Not Available
DB12216BergaptenNot Available
DB12225BeclabuvirNot Available
DB12229CerlapirdineNot Available
DB12230BunazosinNot Available
DB12233IguratimodNot Available
DB12234BMS-214662Not Available
DB12245TriclabendazoleThis drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.[FDA label,L5452]
DB12251MoxaverineNot Available
DB12253GDC-0810Not Available
DB12262CRS-3123Not Available
DB12266EpofolateNot Available
DB12268CarmegliptinNot Available
DB12273EcopipamNot Available
DB12280AZD-5423Not Available
DB12288PiromelatineNot Available
DB12290PuerarinNot Available
DB12297GLPG-0187Not Available
DB12302CP-724714Not Available
DB12303MotolimodNot Available
DB12306CipargaminNot Available
DB12307ForetinibNot Available
DB12309GI-181771XNot Available
DB12319BenzbromaroneNot Available
DB12328CantharidinThe only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts (verruca vulgaris), periungual warts, plantar warts, and molluscum contagiosum [A32891, A32892, F32]. At the same time, such topical cantharidin applications have also been used for a number of off-label indications like callus removal, cutaneous leishmaniasis, herpes zoster, and acquired perforating dermatosis [A32892]. Furthermore, since most topical cantharidin applications are most commonly available in a 0.7% formulation or a more potent 1% mixture, the 0.7% formulation is most commonly indicated for the treatment of common warts, periungual warts, and molluscum contagiosum while the more potent 1% mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized off-label conditions [A32891, A32892, F32]. Moreover, there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment - either of which has yet to formally elucidate any results [A32892].
DB12332RucaparibIndicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.
DB12343TemocillinNot Available
DB12352BizelesinNot Available
DB12355NetazepideNot Available
DB12359BIIB021Not Available
DB12367SelurampanelNot Available
DB12368AZD-3839Not Available
DB12369SotrastaurinNot Available
DB12379IndirubinNot Available
DB12381MerestinibNot Available
DB12389ZamicastatNot Available
DB12391SagopiloneNot Available
DB12393FanapanelNot Available
DB12400VoxtalisibNot Available
DB12404RemimazolamNot Available
DB12406LisofyllineNot Available
DB12415GaleteroneNot Available
DB12418SaccharinNot Available
DB12420DiazepinomicinNot Available
DB12443SonedenosonNot Available
DB12447NadifloxacinNot Available
DB12454ZalypsisNot Available
DB12465KetanserinNot Available
DB12479ZabofloxacinNot Available
DB12483CopanlisibIndicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
DB12491FasiglifamNot Available
DB12505E-7820Not Available
DB12523MizolastineNot Available
DB12526BatefenterolNot Available
DB12531LobucavirNot Available
DB12537BenzodiazepineNot Available
DB12541SAR-405838Not Available
DB12543SamidorphanNot Available
DB12545IndobufenNot Available
DB12547LY-2886721Not Available
DB12549PyrazoloacridineNot Available
DB12551IdazoxanNot Available
DB12558AEE-788Not Available
DB12562SetipiprantNot Available
DB12565AbexinostatNot Available
DB12566DecernotinibNot Available
DB12569TonapofyllineNot Available
DB12574LY-295501Not Available
DB12575RonopterinNot Available
DB12582PiperineNot Available
DB12587RazupenemNot Available
DB12590IndiplonNot Available
DB12591BMS-911543Not Available
DB12593ApaziquoneNot Available
DB12611PF-477736Not Available
DB12638PU-H71Not Available
DB12640CP-609754Not Available
DB12643NelivaptanNot Available
DB12647TocotrienolNot Available
DB12658AFN-1252Not Available
DB12659SJ-733Not Available
DB12660SamatasvirNot Available
DB12665IsoquercetinNot Available
DB12666EmapunilNot Available
DB12670RolofyllineNot Available
DB12672IcaritinNot Available
DB12673ATX-914Not Available
DB12674LurbinectedinNot Available
DB12680IntepirdineNot Available
DB12685K-134Not Available
DB12687VesatolimodNot Available
DB12691UK-432097Not Available
DB12694CE-326597Not Available
DB12703OmipalisibNot Available
DB12706SeletalisibNot Available
DB12710PerazineNot Available
DB12714NerispirdineNot Available
DB12716NB-001Not Available
DB12719Turofexorate isopropylNot Available
DB12721RO-5028442Not Available
DB12725TD-8954Not Available
DB12739BindaritNot Available
DB12744CGI-1842Not Available
DB12749ButylphthalideNot Available
DB12756TAK-901Not Available
DB12762RabacfosadineNot Available
DB12769LometrexolNot Available
DB12776E-6005Not Available
DB12779HigenamineNot Available
DB12780QuinfamideNot Available
DB12781BalaglitazoneNot Available
DB12799LaniquidarNot Available
DB12804DaniquidoneNot Available
DB12812Palomid 529Not Available
DB12823TecarfarinNot Available
DB12830CebranopadolNot Available
DB12833TandospironeNot Available
DB12846ReproterolNot Available
DB12868IntoplicineNot Available
DB12874QuizartinibNot Available
DB12875MavatrepNot Available
DB12881Indole-3-carbinolNot Available
DB12888EzutromidNot Available
DB12890DihydrexidineNot Available
DB12903DEBIO-1347Not Available
DB12912NolatrexedNot Available
DB12920PinometostatNot Available
DB12921ChlorsulfaquinoxalineNot Available
DB12924OzenoxacinOzenoxacin cream is indicated for the topical treatment of impetigo caused by *Staphylococcus aureus* or *Streptococcus pyogenes* in patients aged 2 months of age and older [FDA Label].
DB12925CrolibulinNot Available
DB12926CafedrineNot Available
DB12927TheodrenalineNot Available
DB12930OpipramolNot Available
DB129468-cyclopentyl-1,3-dipropylxanthineNot Available
DB12964LerisetronNot Available
DB12971PactimibeNot Available
DB12973SerlopitantNot Available
DB12975PyronaridineNot Available
DB12983PhthalocyanineNot Available
DB12986VS-5584Not Available
DB12989NeosaxitoxinNot Available
DB12998PF-00217830Not Available
DB13000PCI-27483Not Available
DB13001TinoridineNot Available
DB13004MavoglurantNot Available
DB13005RebastinibNot Available
DB13009CarbendazimNot Available
DB13017Rovalpituzumab TesirineNot Available
DB13019HenatinibNot Available
DB13022LY-2874455Not Available
DB13028BiapenemNot Available
DB13029MK-0873Not Available
DB13035AG-24322Not Available
DB13036RamatrobanNot Available
DB13041OdalasvirNot Available
DB13042FenoverineNot Available
DB13046TocladesineNot Available
DB13053CP-195543Not Available
DB13059PF-03814735Not Available
DB13061MLN8054Not Available
DB13062ME-344Not Available
DB13074MacimorelinIndicated for the diagnosis of adult growth hormone deficiency (AGHD) [FDA Label].
DB13080RoluperidoneNot Available
DB13083TalarozoleNot Available
DB13088AZD-0424Not Available
DB13098CT-2584Not Available
DB13111ChromanolNot Available
DB13118PaquinimodNot Available
DB13119GSK-364735Not Available
DB13122TrabodenosonNot Available
DB13124TroxerutinNot Available
DB13126BMS-986115Not Available
DB13135AGN-201904Not Available
DB13141Ambroxol acefyllinateNot Available
DB13155EsculinAs medication, esculin is sometimes used as a vasoprotective agent. Esculin is also used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria), as all strains of Group D Streptococci hydrolyze æsculin in 40% bile.
DB13156Inosine pranobexInosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.
DB13165RipasudilRipasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension. It is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema.
DB131774-methylumbelliferyl beta-D-glucosideNot Available
DB13182DaidzeinNot Available
DB13203BamifyllineNot Available
DB13213ButaperazineNot Available
DB13222TilbroquinolNot Available
DB13225DibenzepinNot Available
DB13228FlosequinanNot Available
DB13242BucladesineNot Available
DB13246QuinupramineNot Available
DB13252TropatepineNot Available
DB13256ClothiapineNot Available
DB13261SitafloxacinNot Available
DB13264PenimepicyclineNot Available
DB13266CefatrizineNot Available
DB13277BenziodaroneNot Available
DB13279CarbocromenNot Available
DB13291CloridarolNot Available
DB13292PimethixeneNot Available
DB13295AtracuriumNot Available
DB13300EpicillinNot Available
DB13306ChlorquinaldolChlorquinaldol was used historically as a topical antiseptic agent for skin infections.[F4549] It maintains use in European countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infections.[F4552]
DB13310OrmeloxifeneNot Available
DB13317FlunoxaprofenNot Available
DB13324TetrazepamNot Available
DB13326EuflavineNot Available
DB13333EfloxateNot Available
DB13335PinazepamNot Available
DB13345DihydroergocristineDihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.[L2649] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].
DB13355VisnadineNot Available
DB13367CloricromenNot Available
DB13374VincamineNot Available
DB13379ChiniofonNot Available
DB13382ChlorproethazineNot Available
DB13385DihydroergocryptineNot Available
DB13387HematinNot Available
DB13393EmetineNot Available
DB13399TergurideNot Available
DB13411LofepramineNot Available
DB13420ThiazinamNot Available
DB13430MebutizideNot Available
DB13437MedazepamNot Available
DB13449ProxyphyllineNot Available
DB13451TioclomarolNot Available
DB13454NicomorphineNot Available
DB13463OxetoroneNot Available
DB13465CiclobendazoleNot Available
DB13469PhanquinoneNot Available
DB13470CefodizimeNot Available
DB13471NalfurafineNot Available
DB13481TenidapNot Available
DB13482DimeflineNot Available
DB13490HidrosminNot Available
DB13496IprindoleNot Available
DB13499CefsulodinNot Available
DB13501BendazacPrior to the withdrawal of bendazac from various international regions of use due to concerns for hepatotoxicity [A39891, A39892, A39893, L4778] the chemical had demonstrated potential usefulness predominantly as the prescription medication bendazac lysine for the indication of managing the level of vision in patients with mild to moderate cataracts to facilitate delaying the need for surgical intervention [A39863, A39869, A39890]. Elsewhere bendazac may still be available in a limited capacity as a non-prescription topical cream product for treating conditions like local pain, inflammation, dermatitis, eczema, pruritis, hives, insect bites, burns, erythema, and others [L4780] - although such products may also be facing general discontinuation [L4781].
DB13504CefetametNot Available
DB13506CarfecillinNot Available
DB13514PranoprofenNot Available
DB13520MetergolineNot Available
DB13527ProglumetacinNot Available
DB13532CyclopenthiazideNot Available
DB13536BroxyquinolineNot Available
DB13541IprazochromeNot Available
DB13551CinchophenNot Available
DB13553CarumonamNot Available
DB13555PrajmalineNot Available
DB13557ThiopropazateNot Available
DB13573AcefyllineNot Available
DB13575BietaserpineNot Available
DB13579MepixanoxNot Available
DB13592EtamiphyllineNot Available
DB13606PhenazocineNot Available
DB13609UmifenovirNot Available
DB13611ChlormidazoleNot Available
DB13617ClorexoloneNot Available
DB13618IpriflavoneNot Available
DB13627Oxolinic acidNot Available
DB13634PentifyllineNot Available
DB13635TiracizineNot Available
DB13638CefbuperazoneNot Available
DB13641MetisazoneNot Available
DB13643LoprazolamNot Available
DB13645EthacizineNot Available
DB13648AlcuroniumNot Available
DB13649ProquazoneNot Available
DB13651LorajmineNot Available
DB13660PropicillinNot Available
DB13667CefozopranNot Available
DB13668IpidacrineNot Available
DB13674CridanimodNot Available
DB13676MosapramineNot Available
DB13682CefpiromeNot Available
DB13683QuinisocaineNot Available
DB13692TretoquinolNot Available
DB13693SulbenicillinNot Available
DB13706EosinNot Available
DB13708FenquizoneNot Available
DB13711TritoqualineNot Available
DB13718HydroquinineNot Available
DB13727AzapetineNot Available
DB13739PenamecillinNot Available
DB13762DexrabeprazoleNot Available
DB13772RufloxacinNot Available
DB13778CefazedoneNot Available
DB13782Imipramine oxideNot Available
DB13783AcemetacinAcemetacin is not FDA, Canada or EMA approved, but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis, osteoarthritis, low back pain and post-surgical pain.[L1045] It is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis, treatment of ankylosing spondylitis, treatment of irritation in the joints and spinal column caused by degenerative disorders, treatment of inflammatory soft-tissue rheumatism syndrome and painful swelling and inflammation caused by injury.[L1044, L1046]
DB13784DixyrazineNot Available
DB13793VinburnineNot Available
DB13806LinopirdineNot Available
DB13807TisopurineNot Available
DB13808MebhydrolinNot Available
DB13810DimemorfanNot Available
DB13812BufyllineNot Available
DB13814TalampicillinNot Available
DB13816AspoxicillinNot Available
DB13820OxomemazineNot Available
DB13821CeftezoleNot Available
DB13835CaroverineNot Available
DB13836MetampicillinNot Available
DB13837DoxefazepamNot Available
DB13841ClopenthixolNot Available
DB13865DehydroemetineNot Available
DB13868AdefovirNot Available
DB13871Albendazole oxideNot Available
DB13872LormetazepamFor the treatment of short-term insomnia [L927]
DB13875HarmalineNot Available
DB13878PibrentasvirIndicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DB13879GlecaprevirIndicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DB13911Phloxine BFor use in dental disclosing products, allowing for highlighting of bacterial placques.
DB13912Coumermycin A1Not Available
DB13914VolixibatVolixibat is an investigational drug that has not been approved for use in any conditions.
DB13919CandesartanNot Available
DB13927anle138bNot Available
DB13929RelcovaptanNot Available
DB13937LGD-3303Not Available
DB13938S-40503Not Available
DB13941PiperaquineFor the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB11638].
DB13950WIN 55212-2Not Available
DB13978SelisistatNot Available
DB13991PipequalineNot Available
DB13993MRK-409Not Available
DB13994AZD-7325Not Available
DB14001alpha-Tocopherol succinateThe primary health-related use for which alpha-tocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin E deficiency. At the same time, vitamin E deficiency is generally quite rare but may occur in premature babies of very low birth weight (< 1500 grams), individuals with fat-malabsorption disorders (as fat is required for the digestive tract to absorb vitamin E), or individuals with abetalipoproteinemia - a rare, inherited disorder that causes poor absorption of dietary fat - who require extremely large doses of supplemental vitamin E daily (around 100 mg/kg or 5-10 g/day) [L2120]. In all such cases, alpha-tocopherol is largely the preferred form of vitamin E to be administered. Elsewhere, vitamin E's chemical profile as a fat-soluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin E possesses like cardiovascular diseases, diabetes, ocular conditions, immune illnesses, cancer, and more [T166]. None of these ongoing studies have yet to elucidate any formally significant evidence, however [T166]. Similarly, more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alpha-tocopherol succinate's capability to act as an anti-cancer therapy or as a regulator of inflammation [L2699, A32958, A32959].
DB14003alpha-Tocopherol acetateThe primary health-related use for which alpha-tocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin E deficiency. At the same time, vitamin E deficiency is generally quite rare but may occur in premature babies of very low birth weight (< 1500 grams), individuals with fat-malabsorption disorders (as fat is required for the digestive tract to absorb vitamin E), or individuals with abetalipoproteinemia - a rare, inherited disorder that causes poor absorption of dietary fat - who require extremely large doses of supplemental vitamin E daily (around 100 mg/kg or 5-10 g/day) [L2120]. In all such cases, alpha-tocopherol is largely the preferred form of vitamin E to be administered. Elsewhere, vitamin E's chemical profile as a fat-soluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin E possesses like cardiovascular diseases, diabetes, ocular conditions, immune illnesses, cancer, and more [T166]. None of these ongoing studies have yet to elucidate any formally significant evidence, however [T166].
DB14008HispidulinNot Available
DB14018BromotheophyllineBromotheophylline is used as a diuretic and also, in combination with [DB00316], it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.[L2737]
DB14025ClinafloxacinNot Available
DB14028NordazepamNot Available
DB14029FurafyllineNot Available
DB14035EnglitazoneNot Available
DB14061HycanthoneNot Available
DB14066TetrandrineNot Available
DB14067DofequidarNot Available
DB14070HM-30181Not Available
DB14086CianidanolNot Available
DB14094TocopherylquinoneNot Available
DB14098CobalaminNot Available
DB141077-Aminodesacetoxycephalosporanic acidNot Available
DB14122DihydroxymethoxychalconeNot Available
DB14125BenazeprilatNot Available
DB14126TenofovirTenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.[A178330] To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
DB14128NadideNot Available
DB141328-chlorotheophyllineWhen used in combination with [DB01075] as the antiemetic [DB00985], 8-chlorotheophylline is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
DB14146LoxicodegolLoxicodegol was developed as an opioid analgesic with low abuse potential for use in treating chronic pain [L3263]. An application has been filed for FDA approval of Loxicodegol for use in treating chronic lower back pain.
DB14185Aripiprazole lauroxilAripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
DB14200ThiohexamThiohexam is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.
DB142012,2'-Dibenzothiazyl disulfide2,2'-Dibenzothiazyl disulfide is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.
DB14202MorpholinylmercaptobenzothiazoleNot Available
DB14208RamiprilatNot Available
DB14209TrandolaprilatNot Available
DB14210MoexiprilatNot Available
DB14213PerindoprilatNot Available
DB14217QuinaprilatNot Available
DB14231Quinoline Yellow WSNot Available
DB14371MangostinNot Available
DB14581CPI-1205Not Available
DB14586Citrus bioflavonoidsNot Available
DB14627Oxyphenisatin acetateNot Available
DB14651Perphenazine enanthateNot Available
DB14672Oxazepam acetateNot Available
DB14682DextrorphanNot Available
DB14715CinazepamNot Available
DB14718PyrazolamNot Available
DB14725Cefamandole nafateNot Available
DB14726DabigatranNot Available
DB14727Riboflavin tetrabutyrateNot Available
DB14729RebeccamycinNot Available
DB14732QueuineCurrent and on-going research suggests queuine is a natural biochemical compound that can be found endogenously in the human body and plays an essential role in the generation of other critical bodily chemicals including tyrosine, serotonin, dopamine, epinephrine, norepinephrine, nitric oxide, lipids, and others [A173830, A173833, A173851]. Such research subsequently proposes that if queuine could be utilized as a pharmaceutic, that it may be considered a so-called 'putative longevity vitamin' indicated for age-delaying and/or prolonged survival functionality (perhaps via maintaining the ongoing generation of the aforementioned bodily chemicals) for the human body [A173830, A173833, A173851].
DB14733Ceftobiprole medocarilNot Available
DB14773LifirafenibNot Available
DB14791GDC-0425Not Available
DB14795AZD-3759Not Available
DB14801LanifibranorNot Available
DB14802ONO-2952Not Available
DB14822SB-649868Not Available
DB14828ABX-464Not Available
DB14844ONC-201Not Available
DB14850DeleobuvirNot Available
DB14857AvadomideNot Available
DB14868AZD-8848Not Available
DB14878LiafensineNot Available
DB14879CefiderocolNot Available
DB14882CEP-9722Not Available
DB14883LorecivivintNot Available
DB14890ObicetrapibNot Available
DB14903Rovafovir etalafenamideNot Available
DB14925Tenofovir exalidexNot Available
DB14935SerabelisibNot Available
DB14951Etirinotecan pegolNot Available
DB14971IomazenilNot Available
DB14986LinrodostatNot Available
DB14989UmbralisibNot Available
DB14993PyrotinibNot Available
DB15009PF-04937319Not Available
DB15023BMS-791826Not Available
DB15029AZD-8186Not Available
DB15033FlortaucipirNot Available
DB15039ITI-214Not Available
DB15050NeopterinNot Available
DB15054TAS-117Not Available
DB15055ABT-639Not Available
DB15058FlutemetamolNot Available
DB15091UpadacitinibNot Available
DB1509618-methoxycoronaridineNot Available
DB15099GW-468816Not Available
DB15120GSK-239512Not Available
DB15122PCS-499Not Available
DB15130DexpramipexoleNot Available
DB15138AZD-9496Not Available
DB15143PF-06650833Not Available
DB15147TinostamustineNot Available
DB15157VoruciclibNot Available
DB15169H3B-6527Not Available
DB15189BirabresibNot Available
DB15197RSV-604Not Available
DB15212PemafibrateNot Available
DB1521325-desacetylrifapentineNot Available
DB15215KRN-5500Not Available
DB15221PF-06260414Not Available
DB15224LisavanbulinNot Available
DB152432-(1-hexyloxyethyl)-2-devinylpyropheophorbide aNot Available
DB15254RO-5126766 free baseNot Available
DB15266TAK-580Not Available
DB15288EtamicastatNot Available
DB15294SB-1578Not Available
DB15300HydroquinidineNot Available
DB15308RidinilazoleNot Available
DB15317PosiphenNot Available
DB15333AZD-1386Not Available
DB15334Biochanin ANot Available
DB15335FormononetinNot Available
DB15345GSK-945237Not Available
DB15359XanthohumolNot Available
DB15375TozuleristideNot Available
DB15382SAR-125844Not Available
DB15394gamma-TocopherolNot Available
DB15408SilmitasertibNot Available
DB15425CYC-065Not Available
DB15456VericiguatNot Available
DB15464Urolithin ANot Available
DB14575EslicarbazepineNot Available
DrugDrug NameTargetType
DB00115CyanocobalaminMethionine synthase reductasetarget
DB00115CyanocobalaminMethylmalonic aciduria type A protein, mitochondrialtarget
DB00115CyanocobalaminMethylmalonyl-CoA mutase, mitochondrialtarget
DB00115CyanocobalaminMethylmalonic aciduria and homocystinuria type C proteintarget
DB00115CyanocobalaminMethionine synthasetarget
DB00115CyanocobalaminMethylenetetrahydrofolate reductasetarget
DB00115CyanocobalaminProtein amnionlesstransporter
DB00115CyanocobalaminTranscobalamin-1transporter
DB00115CyanocobalaminTranscobalamin-2transporter
DB00115CyanocobalaminCob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrialenzyme
DB00115CyanocobalaminGastric intrinsic factortransporter
DB00115CyanocobalaminCubilintransporter
DB00115CyanocobalaminBifunctional adenosylcobalamin biosynthesis protein CobUenzyme
DB00115CyanocobalaminLow-density lipoprotein receptor-related protein 2transporter
DB00115CyanocobalaminMultidrug resistance-associated protein 1transporter
DB00115CyanocobalaminPancreatic proteasesenzyme
DB00116Tetrahydrofolic acidC-1-tetrahydrofolate synthase, cytoplasmictarget
DB00116Tetrahydrofolic acidBifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrialtarget
DB00116Tetrahydrofolic acidAminomethyltransferase, mitochondrialtarget
DB00116Tetrahydrofolic acidCytosolic 10-formyltetrahydrofolate dehydrogenasetarget
DB00116Tetrahydrofolic acidMethionine synthasetarget
DB00116Tetrahydrofolic acidFormimidoyltransferase-cyclodeaminasetarget
DB00116Tetrahydrofolic acidBifunctional purine biosynthesis protein PURHtarget
DB00116Tetrahydrofolic acidSerine hydroxymethyltransferase, cytosolictarget
DB00116Tetrahydrofolic acidSerine hydroxymethyltransferase, mitochondrialtarget
DB00116Tetrahydrofolic acidMethylenetetrahydrofolate reductasetarget
DB00116Tetrahydrofolic acidSerine hydroxymethyltransferasetarget
DB00116Tetrahydrofolic acidMethionyl-tRNA formyltransferase, mitochondrialtarget
DB00116Tetrahydrofolic acidCanalicular multispecific organic anion transporter 1transporter
DB00118AdemetionineGlycine N-methyltransferasetarget
DB00118AdemetionineS-adenosylmethionine decarboxylase proenzymetarget
DB00118AdemetionineS-adenosylmethionine synthase isoform type-2target
DB00118AdemetionineCystathionine beta-synthasetarget
DB00118AdemetionineS-adenosylmethionine synthase isoform type-1target
DB00118AdemetionineCytochrome P450 2E1enzyme
DB00118AdemetionineCatechol O-methyltransferasetarget
DB00118AdemetionineSpermidine synthaseenzyme
DB00118AdemetionineCap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1target
DB00118AdemetionineArsenite methyltransferasetarget
DB00131Adenosine phosphate5'-AMP-activated protein kinase subunit beta-1target
DB00131Adenosine phosphateAcetyl-coenzyme A synthetase 2-like, mitochondrialtarget
DB00131Adenosine phosphateAcetyl-coenzyme A synthetase, cytoplasmictarget
DB00131Adenosine phosphate5'-AMP-activated protein kinase catalytic subunit alpha-1target
DB00131Adenosine phosphate5'-AMP-activated protein kinase subunit beta-2target
DB00131Adenosine phosphateAdenylate cyclase type 1target
DB00131Adenosine phosphateLong-chain-fatty-acid--CoA ligase 1target
DB00131Adenosine phosphateCyclic AMP-responsive element-binding protein 1target
DB00131Adenosine phosphateDNAtarget
DB00131Adenosine phosphateSerine/threonine-protein kinase pim-1target
DB00131Adenosine phosphatecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00131Adenosine phosphateGlycogen phosphorylase, liver formtarget
DB00131Adenosine phosphateHistidine triad nucleotide-binding protein 1target
DB00131Adenosine phosphatecAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB00131Adenosine phosphateFructose-1,6-bisphosphatase 1target
DB00131Adenosine phosphateAMP deaminase 1enzyme
DB00131Adenosine phosphateAdenine phosphoribosyltransferaseenzyme
DB00131Adenosine phosphateAdenosine kinasetarget
DB00140RiboflavinFlavin reductase (NADPH)target
DB00140RiboflavinRiboflavin kinasetarget
DB00140RiboflavinRiboflavin synthasetarget
DB00140RiboflavinAmine oxidase [flavin-containing] Aenzyme
DB00140RiboflavinMethylenetetrahydrofolate reductaseenzyme
DB00140RiboflavinSolute carrier family 22 member 6transporter
DB00157NADHUDP-glucose 6-dehydrogenasetarget
DB00157NADHAlcohol dehydrogenase 1Atarget
DB00157NADHSorbitol dehydrogenasetarget
DB00157NADHAlcohol dehydrogenase 4target
DB00157NADHAlcohol dehydrogenase 1Ctarget
DB00157NADHAlcohol dehydrogenase 1Btarget
DB00157NADHAlcohol dehydrogenase class 4 mu/sigma chaintarget
DB00157NADHGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmictarget
DB00157NADHL-lactate dehydrogenase A-like 6Atarget
DB00157NADHAlcohol dehydrogenase class-3target
DB00157NADHAldose reductasetarget
DB00157NADH3-hydroxyacyl-CoA dehydrogenase type-2target
DB00157NADHMalate dehydrogenase, mitochondrialtarget
DB00157NADHL-lactate dehydrogenase A chaintarget
DB00157NADHNAD-dependent malic enzyme, mitochondrialtarget
DB00157NADHPeroxisomal multifunctional enzyme type 2target
DB00157NADHL-lactate dehydrogenase A-like 6Btarget
DB00157NADHL-lactate dehydrogenase C chaintarget
DB00157NADHL-lactate dehydrogenase B chaintarget
DB00157NADHPeroxisomal bifunctional enzymetarget
DB00157NADHHydroxyacyl-coenzyme A dehydrogenase, mitochondrialtarget
DB00157NADHNADP-dependent malic enzyme, mitochondrialtarget
DB00157NADHD-beta-hydroxybutyrate dehydrogenase, mitochondrialtarget
DB00157NADHMalate dehydrogenase, cytoplasmictarget
DB00157NADH3-hydroxyisobutyrate dehydrogenase, mitochondrialtarget
DB00157NADHTestosterone 17-beta-dehydrogenase 3target
DB00157NADH3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00157NADHNADP-dependent malic enzymetarget
DB00157NADHD-3-phosphoglycerate dehydrogenasetarget
DB00157NADH3-keto-steroid reductasetarget
DB00157NADHIsocitrate dehydrogenase [NAD] subunit gamma, mitochondrialtarget
DB00157NADHIsocitrate dehydrogenase [NAD] subunit beta, mitochondrialtarget
DB00157NADHIsocitrate dehydrogenase [NAD] subunit alpha, mitochondrialtarget
DB00157NADHEstradiol 17-beta-dehydrogenase 1target
DB00157NADHEstradiol 17-beta-dehydrogenase 2target
DB00157NADH11-cis retinol dehydrogenasetarget
DB00157NADHGDH/6PGL endoplasmic bifunctional proteintarget
DB00157NADHEstradiol 17-beta-dehydrogenase 8target
DB00157NADHAldo-keto reductase family 1 member C4target
DB00157NADHInosine-5'-monophosphate dehydrogenase 2target
DB00157NADHAldo-keto reductase family 1 member C3target
DB00157NADH15-hydroxyprostaglandin dehydrogenase [NAD(+)]target
DB00157NADHGDP-L-fucose synthasetarget
DB00157NADHAldo-keto reductase family 1 member C1target
DB00157NADHCorticosteroid 11-beta-dehydrogenase isozyme 1target
DB00157NADH3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2target
DB00157NADH3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB00157NADHInosine-5'-monophosphate dehydrogenase 1target
DB00157NADHTrifunctional enzyme subunit alpha, mitochondrialtarget
DB00157NADHAldehyde dehydrogenase, mitochondrialtarget
DB00157NADHCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB00157NADHAldo-keto reductase family 1 member C2target
DB00157NADHSterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylatingtarget
DB00157NADHAldehyde dehydrogenase family 3 member B2target
DB00157NADHMethylmalonate-semialdehyde dehydrogenase [acylating], mitochondrialtarget
DB00157NADHAldehyde dehydrogenase, dimeric NADP-preferringtarget
DB00157NADHRetinal dehydrogenase 1target
DB00157NADHGlyceraldehyde-3-phosphate dehydrogenase, testis-specifictarget
DB00157NADH4-trimethylaminobutyraldehyde dehydrogenasetarget
DB00157NADHAldehyde dehydrogenase family 1 member A3target
DB00157NADHAldehyde dehydrogenase X, mitochondrialtarget
DB00157NADHAldehyde dehydrogenase family 3 member B1target
DB00157NADHGlyceraldehyde-3-phosphate dehydrogenasetarget
DB00157NADHRetinal dehydrogenase 2target
DB00157NADHFatty aldehyde dehydrogenasetarget
DB00157NADHSuccinate-semialdehyde dehydrogenase, mitochondrialtarget
DB00157NADHAlpha-aminoadipic semialdehyde dehydrogenasetarget
DB00157NADHFlavin reductase (NADPH)target
DB00157NADHPyrroline-5-carboxylate reductase 2target
DB00157NADHPyrroline-5-carboxylate reductase 1, mitochondrialtarget
DB00157NADHGlutamate dehydrogenase 1, mitochondrialtarget
DB00157NADHPyruvate dehydrogenase E1 component subunit beta, mitochondrialtarget
DB00157NADHPyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrialtarget
DB00157NADHPyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrialtarget
DB00157NADHBiliverdin reductase Atarget
DB00157NADHShort-chain specific acyl-CoA dehydrogenase, mitochondrialtarget
DB00157NADHDihydrofolate reductasetarget
DB00157NADH2-oxoglutarate dehydrogenase, mitochondrialtarget
DB00157NADHGlutamate dehydrogenase 2, mitochondrialtarget
DB00157NADH7-dehydrocholesterol reductasetarget
DB00157NADHRibosyldihydronicotinamide dehydrogenase [quinone]target
DB00157NADHNADH-ubiquinone oxidoreductase chain 2target
DB00157NADHAlpha-aminoadipic semialdehyde synthase, mitochondrialtarget
DB00157NADHNADH-ubiquinone oxidoreductase chain 3target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialtarget
DB00157NADHC-1-tetrahydrofolate synthase, cytoplasmictarget
DB00157NADHBifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrialtarget
DB00157NADHDelta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrialtarget
DB00157NADHNADH-cytochrome b5 reductase 3target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11target
DB00157NADHNADH-ubiquinone oxidoreductase chain 4target
DB00157NADHDihydropteridine reductasetarget
DB00157NADHNADH-ubiquinone oxidoreductase chain 1target
DB00157NADHNAD(P) transhydrogenase, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrialtarget
DB00157NADHNADH-ubiquinone oxidoreductase chain 4Ltarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1target
DB00157NADHNADH-ubiquinone oxidoreductase chain 6target
DB00157NADHNADH-ubiquinone oxidoreductase chain 5target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6target
DB00157NADHAcyl carrier protein, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 subunit C2target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1target
DB00157NADHNADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7target
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6target
DB00157NADHNADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrialtarget
DB00157NADHDihydrolipoyl dehydrogenase, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialtarget
DB00157NADHGlutathione reductase, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 5target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13target
DB00157NADHCysteine dioxygenase type 1target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrialtarget
DB00157NADHNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2target
DB00157NADHNADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialtarget
DB00157NADHCytochrome P450 4A11target
DB00157NADHDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialtarget
DB00157NADHAminomethyltransferase, mitochondrialtarget
DB00157NADHMethylsterol monooxygenase 1target
DB00157NADHHeme oxygenase 1target
DB00157NADHHeme oxygenase 2target
DB00157NADHSteroid 17-alpha-hydroxylase/17,20 lyasetarget
DB00157NADHTyrosinasetarget
DB00157NADHXanthine dehydrogenase/oxidaseenzyme
DB00157NADHAldehyde oxidaseenzyme
DB00157NADHAlcohol dehydrogenase 6enzyme
DB00157NADHAlcohol dehydrogenase [NADP(+)]enzyme
DB00157NADHAlcohol dehydrogenase 1Aenzyme
DB00157NADHAlcohol dehydrogenase 1Benzyme
DB00157NADHAlcohol dehydrogenase 4enzyme
DB00157NADHAlcohol dehydrogenase class-3enzyme
DB00157NADHAlcohol dehydrogenase class 4 mu/sigma chainenzyme
DB00158Folic acidFolate receptor gammatarget
DB00158Folic acidFolate receptor betatarget
DB00158Folic acidMethylenetetrahydrofolate reductaseenzyme
DB00158Folic acidMultidrug resistance-associated protein 4transporter
DB00158Folic acidSolute carrier family 22 member 6transporter
DB00158Folic acidCanalicular multispecific organic anion transporter 2transporter
DB00158Folic acidATP-binding cassette sub-family C member 11transporter
DB00158Folic acidATP-binding cassette sub-family G member 2transporter
DB00158Folic acidProton-coupled folate transportertransporter
DB00158Folic acidMitochondrial folate transporter/carriertransporter
DB00158Folic acidGamma-glutamyl hydrolaseenzyme
DB00158Folic acidFolate receptor alphatarget
DB00158Folic acidDihydrofolate reductaseenzyme
DB00163Vitamin ESEC14-like protein 4target
DB00163Vitamin ESEC14-like protein 3target
DB00163Vitamin ESEC14-like protein 2target
DB00163Vitamin ENuclear receptor subfamily 1 group I member 2target
DB00163Vitamin EProtein kinase C beta typetarget
DB00163Vitamin EArachidonate 5-lipoxygenasetarget
DB00163Vitamin EProtein kinase C alpha typetarget
DB00163Vitamin EDiacylglycerol kinase alphatarget
DB00163Vitamin ESerine/threonine-protein phosphatase 2A catalytic subunit beta isoformtarget
DB00163Vitamin ESerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformtarget
DB00163Vitamin EAlpha-tocopherol transfer proteincarrier
DB00163Vitamin EGlutathione S-transferase A2enzyme
DB00163Vitamin EGlutathione S-transferase Penzyme
DB00163Vitamin EGlutathione S-transferase omega-1enzyme
DB00163Vitamin EGlutathione S-transferase Mu 3enzyme
DB00163Vitamin EGlutamate--cysteine ligase catalytic subunitenzyme
DB00163Vitamin ENAD(P)H dehydrogenase [quinone] 1enzyme
DB00163Vitamin EHeme oxygenase 1enzyme
DB00163Vitamin ESuperoxide dismutase [Cu-Zn]enzyme
DB00163Vitamin EScavenger receptor class B member 1transporter
DB00163Vitamin EATP-binding cassette sub-family A member 1transporter
DB00163Vitamin ENiemann-Pick C1-like protein 1transporter
DB00163Vitamin EATP-binding cassette sub-family G member 1transporter
DB00163Vitamin ESEC14-like protein 2carrier
DB00163Vitamin ESEC14-like protein 3carrier
DB00163Vitamin EPhospholipid transfer proteincarrier
DB00163Vitamin ECytochrome P450 3A4enzyme
DB00171ATPAbelson tyrosine-protein kinase 2target
DB00171ATPATP-binding cassette sub-family A member 1target
DB00171ATPAcetyl-coenzyme A synthetase, cytoplasmictarget
DB00171ATPALK tyrosine kinase receptortarget
DB00171ATPNEDD8-activating enzyme E1 regulatory subunittarget
DB00171ATP5'-AMP-activated protein kinase catalytic subunit alpha-1target
DB00171ATPSerine/threonine-protein kinase A-Raftarget
DB00171ATPSerine/threonine-protein kinase receptor R3target
DB00171ATPLong-chain-fatty-acid--CoA ligase 1target
DB00171ATPCytosolic purine 5'-nucleotidasetarget
DB00171ATPATPase ASNA1target
DB00171ATPATP-binding cassette sub-family C member 9target
DB00171ATPRAC-alpha serine/threonine-protein kinasetarget
DB00171ATPBeta-adrenergic receptor kinase 1target
DB00171ATPApoptotic protease-activating factor 1target
DB00171ATPAcetyl-coenzyme A synthetase 2-like, mitochondrialtarget
DB00171ATPActivin receptor type-1Btarget
DB00171ATPActivin receptor type-1target
DB00171ATPBile salt export pumptarget
DB00171ATPAsparagine synthetase [glutamine-hydrolyzing]target
DB00171ATPCyclin-dependent kinase 15target
DB00171ATPADP/ATP translocase 1target
DB00171ATPATP-binding cassette sub-family C member 8target
DB00171ATPArgininosuccinate synthasetarget
DB00171ATPAFG3-like protein 2target
DB00171ATPBeta-adrenergic receptor kinase 2target
DB00171ATPAnti-Muellerian hormone type-2 receptortarget
DB00171ATPActivated CDC42 kinase 1target
DB00171ATPTyrosine-protein kinase ABL1target
DB00171ATPAdenylate cyclase type 1target
DB00171ATPMultidrug resistance protein 1target
DB00171ATPATP-binding cassette sub-family G member 1target
DB00171ATPCanalicular multispecific organic anion transporter 1target
DB00171ATPAdenosine kinaseenzyme
DB00171ATPMultidrug resistance-associated protein 6target
DB00171ATPMultidrug resistance-associated protein 4target
DB00171ATPMultidrug resistance-associated protein 1target
DB00171ATPCystic fibrosis transmembrane conductance regulatortarget
DB00171ATPPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB00171ATPCasein kinase II subunit alphatarget
DB00171ATPCasein kinase II subunit betatarget
DB00171ATPP2Y purinoceptor 11target
DB00171ATPSerine/threonine-protein phosphatase 5target
DB00173AdenineAdenine phosphoribosyltransferasetarget
DB00173AdenineDNAtarget
DB00173AdenineS-methyl-5'-thioadenosine phosphorylasetarget
DB00173AdenineNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferasetarget
DB00173AdenineAcetyl-CoA carboxylase 2target
DB00173AdenineLow molecular weight phosphotyrosine protein phosphatasetarget
DB00173Adenine5'-methylthioadenosine/S-adenosylhomocysteine nucleosidasetarget
DB00173AdeninePeroxisomal trans-2-enoyl-CoA reductasetarget
DB00173AdenineA/G-specific adenine glycosylasetarget
DB00173AdenineNucleoside deoxyribosyltransferase-Itarget
DB00173AdenineSRSF protein kinase 2target
DB00173AdenineHolliday junction ATP-dependent DNA helicase RuvBtarget
DB00173AdenineUDP-glucuronosyltransferase 1-1enzyme
DB00178RamiprilAngiotensin-converting enzymetarget
DB00178RamiprilSolute carrier family 15 member 1transporter
DB00178RamiprilSolute carrier family 15 member 2transporter
DB00178RamiprilCholinesteraseenzyme
DB00178RamiprilB1 bradykinin receptortarget
DB00186LorazepamTranslocator proteintarget
DB00186LorazepamUDP-glucuronosyltransferase 2B15enzyme
DB00186LorazepamGABA-A receptor (anion channel)target
DB00186LorazepamCytochrome P450 3A4enzyme
DB00194VidarabineDNAtarget
DB00194VidarabineDNA polymerase catalytic subunittarget
DB00194VidarabineThymidine kinasetarget
DB00194VidarabineThymidine kinasetarget
DB00194VidarabineAdenosine deaminaseenzyme
DB00197TroglitazonePeroxisome proliferator-activated receptor gammatarget
DB00197TroglitazoneLong-chain-fatty-acid--CoA ligase 4target
DB00197TroglitazonePlasminogen activator inhibitor 1target
DB00197TroglitazoneEquilibrative nucleoside transporter 1target
DB00197TroglitazoneCytochrome P450 3A4enzyme
DB00197TroglitazoneCytochrome P450 2C19enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-1enzyme
DB00197TroglitazoneCytochrome P450 2C8enzyme
DB00197TroglitazoneBile salt export pumptransporter
DB00197TroglitazoneSolute carrier organic anion transporter family member 1B1transporter
DB00197TroglitazoneEstrogen-related receptor gammatarget
DB00197TroglitazoneSteroid hormone receptor ERR1target
DB00197TroglitazoneCytochrome P450 19A1enzyme
DB00197TroglitazoneCytochrome P450 1A1enzyme
DB00197TroglitazoneCytochrome P450 2B6enzyme
DB00197TroglitazoneCytochrome P450 2C9enzyme
DB00197TroglitazoneCytochrome P450 3A5enzyme
DB00197TroglitazoneCytochrome P450 3A7enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-3enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-4enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-6enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-7enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-8enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-9enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 1-10enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 2B7enzyme
DB00197TroglitazoneUDP-glucuronosyltransferase 2B15enzyme
DB00197TroglitazonePeroxisome proliferator-activated receptor deltatarget
DB00197TroglitazonePeroxisome proliferator-activated receptor alphatarget
DB00197TroglitazoneGlutathione S-transferase Ptarget
DB00200HydroxocobalaminMethylmalonic aciduria type A protein, mitochondrialtarget
DB00200HydroxocobalaminProtein amnionlesstarget
DB00200HydroxocobalaminTranscobalamin-1target
DB00200HydroxocobalaminMethylmalonyl-CoA mutase, mitochondrialtarget
DB00200HydroxocobalaminMethionine synthase reductasetarget
DB00200HydroxocobalaminCob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrialtarget
DB00200HydroxocobalaminMethionine synthasetarget
DB00200HydroxocobalaminCubilintarget
DB00200HydroxocobalaminMethylmalonic aciduria and homocystinuria type C proteintarget
DB00200HydroxocobalaminTranscobalamin-2carrier
DB00201CaffeineAdenosine receptor A1target
DB00201CaffeinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00201CaffeineAdenosine receptor A2atarget
DB00201CaffeineCytochrome P450 1A2enzyme
DB00201CaffeineRyanodine receptor 1target
DB00201CaffeineCytochrome P450 3A4enzyme
DB00201CaffeineCytochrome P450 3A5enzyme
DB00201CaffeineCytochrome P450 3A7enzyme
DB00201CaffeineMultidrug resistance protein 1transporter
DB00201CaffeineCytochrome P450 2E1enzyme
DB00201CaffeineCytochrome P450 2C8enzyme
DB00201CaffeineCytochrome P450 2C9enzyme
DB00201CaffeineCytochrome P450 1A1enzyme
DB00201CaffeineCytochrome P450 1B1enzyme
DB00201CaffeineCytochrome P450 2D6enzyme
DB00201CaffeineCyclic nucleotide phosphodiesterasetarget
DB00201CaffeineDNA-dependent protein kinase catalytic subunittarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformtarget
DB00201CaffeineInositol 1,4,5-trisphosphate receptortarget
DB00201CaffeineSerine-protein kinase ATMtarget
DB00203SildenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00203SildenafilCytochrome P450 2C9enzyme
DB00203SildenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilCytochrome P450 3A4enzyme
DB00203SildenafilCytochrome P450 3A5enzyme
DB00203SildenafilCytochrome P450 3A7enzyme
DB00203SildenafilMultidrug resistance-associated protein 4transporter
DB00203SildenafilMultidrug resistance-associated protein 5transporter
DB00203SildenafilMultidrug resistance-associated protein 7transporter
DB00203SildenafilCytochrome P450 2C19enzyme
DB00203SildenafilCytochrome P450 2D6enzyme
DB00203SildenafilCytochrome P450 2E1enzyme
DB00203SildenafilSolute carrier organic anion transporter family member 1B1transporter
DB00203SildenafilMultidrug resistance protein 1transporter
DB00206ReserpineSynaptic vesicular amine transportertarget
DB00206ReserpineMultidrug resistance protein 1transporter
DB00206ReserpineSolute carrier family 22 member 1transporter
DB00206ReserpineBile salt export pumptransporter
DB00206ReserpineCanalicular multispecific organic anion transporter 1transporter
DB00206ReserpineSolute carrier family 22 member 2transporter
DB00206ReserpineCytochrome P450 3A5enzyme
DB00206ReserpineChromaffin granule amine transportertarget
DB00206ReserpineBaculoviral IAP repeat-containing protein 5target
DB00206ReserpineSolute carrier organic anion transporter family member 1B1transporter
DB00206ReserpineSolute carrier organic anion transporter family member 2B1transporter
DB00208TiclopidineP2Y purinoceptor 12target
DB00208TiclopidineCytochrome P450 2C19enzyme
DB00208TiclopidineCytochrome P450 2B6enzyme
DB00208TiclopidineCytochrome P450 2C9enzyme
DB00208TiclopidineCytochrome P450 2D6enzyme
DB00208TiclopidineMyeloperoxidaseenzyme
DB00208TiclopidineCytochrome P450 1A2enzyme
DB00208TiclopidineCytochrome P450 2C8enzyme
DB00208TiclopidineCytochrome P450 2E1enzyme
DB00213PantoprazolePotassium-transporting ATPase alpha chain 1target
DB00213PantoprazoleCytochrome P450 2C19enzyme
DB00213PantoprazoleCytochrome P450 3A4enzyme
DB00213PantoprazoleMultidrug resistance protein 1transporter
DB00213PantoprazoleATP-binding cassette sub-family G member 2transporter
DB00213PantoprazoleSolute carrier family 22 member 8transporter
DB00213PantoprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramMultidrug resistance protein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB00216Eletriptan5-hydroxytryptamine receptor 1Dtarget
DB00216Eletriptan5-hydroxytryptamine receptor 7target
DB00216Eletriptan5-hydroxytryptamine receptor 1Atarget
DB00216Eletriptan5-hydroxytryptamine receptor 1Etarget
DB00216Eletriptan5-hydroxytryptamine receptor 2Btarget
DB00216Eletriptan5-hydroxytryptamine receptor 1Ftarget
DB00216Eletriptan5-hydroxytryptamine receptor 1Btarget
DB00216EletriptanCytochrome P450 3A4enzyme
DB00216EletriptanCytochrome P450 2D6enzyme
DB00216EletriptanCytochrome P450 2C9enzyme
DB00216EletriptanCytochrome P450 2C19enzyme
DB00216EletriptanProstaglandin G/H synthase 1enzyme
DB00216EletriptanCytochrome P450 2A6enzyme
DB00216EletriptanMultidrug resistance protein 1transporter
DB00218MoxifloxacinDNA gyrase subunit Atarget
DB00218MoxifloxacinDNA topoisomerase 4 subunit Atarget
DB00218MoxifloxacinDNA topoisomerase 2-alphatarget
DB00218MoxifloxacinCytochrome P450 1A2enzyme
DB00220NelfinavirHIV-1 proteasetarget
DB00220NelfinavirCytochrome P450 2C19enzyme
DB00220NelfinavirCytochrome P450 3A4enzyme
DB00220NelfinavirCytochrome P450 2B6enzyme
DB00220NelfinavirCytochrome P450 3A5enzyme
DB00220NelfinavirCytochrome P450 3A7enzyme
DB00220NelfinavirMultidrug resistance protein 1transporter
DB00220NelfinavirSolute carrier family 22 member 1transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 1A2transporter
DB00220NelfinavirATP-binding cassette sub-family G member 2transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 1B1transporter
DB00220NelfinavirCytochrome P450 2D6enzyme
DB00220NelfinavirSerum albumincarrier
DB00220NelfinavirUDP-glucuronosyltransferase 1-1enzyme
DB00220NelfinavirSolute carrier organic anion transporter family member 1B3transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 2B1transporter
DB00220NelfinavirBile salt export pumptransporter
DB00220NelfinavirCytochrome P450 2C9enzyme
DB00229CefotiamPenicillin-binding protein 1Atarget
DB00229CefotiamSolute carrier family 22 member 6transporter
DB00229CefotiamSolute carrier family 22 member 8transporter
DB00231TemazepamTranslocator proteintarget
DB00231TemazepamCytochrome P450 2C19enzyme
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit pitarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00231TemazepamCytochrome P450 3A4enzyme
DB00231TemazepamCytochrome P450 2B6enzyme
DB00231TemazepamCytochrome P450 2C9enzyme
DB00231TemazepamGABA-A receptor (anion channel)target
DB00232MethyclothiazideSolute carrier family 12 member 1target
DB00232MethyclothiazideCarbonic anhydrase 4target
DB00232MethyclothiazideCarbonic anhydrase 2target
DB00232MethyclothiazideCarbonic anhydrase 1target
DB00242CladribinePurine nucleoside phosphorylasetarget
DB00242CladribineDNAtarget
DB00242CladribineDeoxycytidine kinaseenzyme
DB00242CladribineRibonucleoside-diphosphate reductase large subunittarget
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2target
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2 Btarget
DB00242CladribineDNA polymerase alpha catalytic subunittarget
DB00242CladribineDNA polymerase epsilon catalytic subunit Atarget
DB00242CladribineDNA polymerase epsilon subunit 2target
DB00242CladribineDNA polymerase epsilon subunit 3target
DB00242CladribineDNA polymerase epsilon subunit 4target
DB00242CladribineATP-binding cassette sub-family G member 2transporter
DB00242CladribineSolute carrier family 28 member 3transporter
DB00247Methysergide5-hydroxytryptamine receptor 2Atarget
DB00247Methysergide5-hydroxytryptamine receptor 1Atarget
DB00247Methysergide5-hydroxytryptamine receptor 7target
DB00247Methysergide5-hydroxytryptamine receptor 2Ctarget
DB00247Methysergide5-hydroxytryptamine receptor 2Btarget
DB00247Methysergide5-hydroxytryptamine receptor 1Btarget
DB00247Methysergide5-hydroxytryptamine receptor 1Ftarget
DB00247Methysergide5-hydroxytryptamine receptor 1Etarget
DB00247MethysergideCytochrome P450 3A4enzyme
DB00248CabergolineD(2) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Btarget
DB00248CabergolineD(3) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Atarget
DB00248CabergolineAlpha-2B adrenergic receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Dtarget
DB00248CabergolineD(4) dopamine receptortarget
DB00248CabergolineAlpha-2A adrenergic receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Atarget
DB00248CabergolineAlpha-2C adrenergic receptortarget
DB00248CabergolineD(1B) dopamine receptortarget
DB00248CabergolineD(1A) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Btarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Ctarget
DB00248CabergolineCytochrome P450 3A4enzyme
DB00248Cabergoline5-hydroxytryptamine receptor 7target
DB00248CabergolineAlpha-1A adrenergic receptortarget
DB00248CabergolineAlpha-1B adrenergic receptortarget
DB00248CabergolineAlpha-1D adrenergic receptortarget
DB00248CabergolineBeta-1 adrenergic receptortarget
DB00248CabergolineBeta-2 adrenergic receptortarget
DB00248CabergolineD(1) dopamine receptortarget
DB00248CabergolineD(2S) dopamine receptortarget
DB00248CabergolineD(2L) dopamine receptortarget
DB00248CabergolineMultidrug resistance protein 1transporter
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00261AnagrelideCytochrome P450 1A2enzyme
DB00266DicoumarolVitamin K epoxide reductase complex subunit 1target
DB00266DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DB00266DicoumarolQuinone oxidoreductasetarget
DB00266DicoumarolCytochrome P450 2C9enzyme
DB00266DicoumarolSerum albumincarrier
DB00266DicoumarolCytochrome P450 2C6enzyme
DB00266DicoumarolCytochrome P450 2C11enzyme
DB00267CefmenoximePenicillin-binding protein 1Atarget
DB00267CefmenoximePeptidoglycan synthase FtsItarget
DB00268RopiniroleD(2) dopamine receptortarget
DB00268RopiniroleD(3) dopamine receptortarget
DB00268RopiniroleD(4) dopamine receptortarget
DB00268RopiniroleCytochrome P450 1A2enzyme
DB00268RopiniroleAlpha adrenergic receptortarget
DB00274CefmetazolePenicillin binding protein 2atarget
DB00274CefmetazoleSerum albumincarrier
DB00274CefmetazoleSolute carrier family 15 member 1transporter
DB00274CefmetazoleSolute carrier family 15 member 2transporter
DB00274CefmetazolePenicillin-binding protein 1Atarget
DB00274CefmetazolePenicillin-binding protein 1Btarget
DB00274CefmetazolePeptidoglycan synthase FtsItarget
DB00274CefmetazoleD-alanyl-D-alanine carboxypeptidase DacAtarget
DB00274CefmetazoleD-alanyl-D-alanine carboxypeptidase DacCtarget
DB00276AmsacrineDNA topoisomerase 2-alphatarget
DB00276AmsacrineDNAtarget
DB00276AmsacrinePotassium voltage-gated channel subfamily H member 2target
DB00276AmsacrineMultidrug resistance protein 1transporter
DB00276AmsacrineAlpha-1-acid glycoprotein 1target
DB00276AmsacrineSerum albumintarget
DB00277TheophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00277TheophyllineAdenosine receptor A2btarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00277TheophyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00277TheophyllineAdenosine receptor A1target
DB00277TheophyllineAdenosine receptor A2atarget
DB00277TheophyllineCytochrome P450 1A2enzyme
DB00277TheophyllineAdenosine deaminaseenzyme
DB00277TheophyllineCytochrome P450 2E1enzyme
DB00277TheophyllineCytochrome P450 3A4enzyme
DB00277TheophyllineSolute carrier family 22 member 7transporter
DB00277TheophyllineCytochrome P450 1A1enzyme
DB00277TheophyllineCytochrome P450 1B1enzyme
DB00277TheophyllineCytochrome P450 2D6enzyme
DB00277TheophyllineHistone deacetylase 2target
DB00277TheophyllineCopine-1target
DB00277TheophyllineMinor histocompatibility antigen H13target
DB00277TheophyllineNodal modulator 1target
DB00277TheophyllinePoly [ADP-ribose] polymerase 1target
DB00277TheophyllineProtein RIC-3target
DB00277TheophyllineTubulin monoglycylase TTLL3target
DB00293RaltitrexedThymidylate synthasetarget
DB00293RaltitrexedFolylpolyglutamate synthase, mitochondrialtarget
DB00295MorphineMu-type opioid receptortarget
DB00295MorphineDelta-type opioid receptortarget
DB00295MorphineKappa-type opioid receptortarget
DB00295MorphineCytochrome P450 2D6enzyme
DB00295MorphineMultidrug resistance protein 1transporter
DB00295MorphineCytochrome P450 2C8enzyme
DB00295MorphineCytochrome P450 3A4enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B7enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-1enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-8enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B15enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B4enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-3enzyme
DB00295MorphineLymphocyte antigen 96target
DB00295MorphineSerum albumincarrier
DB00299PenciclovirDNA polymerase catalytic subunittarget
DB00299PenciclovirThymidine kinasetarget
DB00300Tenofovir disoproxilReverse transcriptase/RNaseHtarget
DB00300Tenofovir disoproxilSolute carrier family 22 member 6transporter
DB00300Tenofovir disoproxilSolute carrier family 22 member 8transporter
DB00300Tenofovir disoproxilMultidrug resistance-associated protein 7transporter
DB00300Tenofovir disoproxilMultidrug resistance-associated protein 4transporter
DB00300Tenofovir disoproxilCanalicular multispecific organic anion transporter 1transporter
DB00300Tenofovir disoproxilAdenylate kinase 2, mitochondrialenzyme
DB00300Tenofovir disoproxilAdenylate kinase 4, mitochondrialenzyme
DB00300Tenofovir disoproxilMultidrug resistance protein 1transporter
DB00300Tenofovir disoproxilNucleoside diphosphokinaseenzyme
DB00300Tenofovir disoproxilCreatine Kinasesenzyme
DB00300Tenofovir disoproxilDNA polymerase/reverse transcriptasetarget
DB00301FlucloxacillinPenicillin-binding protein 1Atarget
DB00301FlucloxacillinCytochrome P450 3A4enzyme
DB00301FlucloxacillinBile salt export pumptransporter
DB00303ErtapenemPenicillin-binding protein 2target
DB00303ErtapenemPeptidoglycan synthase FtsItarget
DB00303ErtapenemPenicillin-binding protein 1Atarget
DB00303ErtapenemD-alanyl-D-alanine carboxypeptidase DacCtarget
DB00303ErtapenemD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00303ErtapenemPenicillin-binding protein 1Btarget
DB00303ErtapenemPeptidoglycan synthase FtsItarget
DB00303ErtapenemPenicillin-binding protein 2target
DB00305MitomycinDNAtarget
DB00305MitomycinNADPH--cytochrome P450 reductaseenzyme
DB00309VindesineTubulin beta-1 chaintarget
DB00309VindesineCytochrome P450 3A4enzyme
DB00310ChlorthalidoneSolute carrier family 12 member 1target
DB00310ChlorthalidoneSerum albumincarrier
DB00310ChlorthalidoneCarbonic anhydrase 1target
DB00311EthoxzolamideCarbonic anhydrase 1target
DB00311EthoxzolamideSolute carrier family 22 member 6transporter
DB00311EthoxzolamideCarbonic anhydrase 2target
DB00311EthoxzolamideCarbonic anhydrase 4target
DB00311EthoxzolamideCarbonic anhydrase 7target
DB00311EthoxzolamideCarbonic anhydrase 3target
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Dtarget
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Btarget
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Ftarget
DB00315ZolmitriptanCytochrome P450 1A2enzyme
DB00315ZolmitriptanAmine oxidase [flavin-containing] Aenzyme
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Atarget
DB00317GefitinibEpidermal growth factor receptortarget
DB00317GefitinibCytochrome P450 3A4enzyme
DB00317GefitinibCytochrome P450 2D6enzyme
DB00317GefitinibMultidrug resistance protein 1transporter
DB00317GefitinibATP-binding cassette sub-family G member 2transporter
DB00317GefitinibCytochrome P450 3A5enzyme
DB00317GefitinibCytochrome P450 1A1enzyme
DB00317GefitinibCytochrome P450 2C9enzyme
DB00317GefitinibCytochrome P450 2C19enzyme
DB00317GefitinibSerum albumincarrier
DB00317GefitinibAlpha-1-acid glycoprotein 1carrier
DB00318CodeineMu-type opioid receptortarget
DB00318CodeineDelta-type opioid receptortarget
DB00318CodeineKappa-type opioid receptortarget
DB00318CodeineCytochrome P450 2D6enzyme
DB00318CodeineCytochrome P450 3A4enzyme
DB00318CodeineSolute carrier family 22 member 1transporter
DB00318CodeineUDP-glucuronosyltransferase 2B7enzyme
DB00318CodeineUDP-glucuronosyltransferase 2B4enzyme
DB00318CodeineMagnesium stearatecarrier
DB00318CodeineLactose monohydratecarrier
DB00318CodeineStarch, pregelatinizedcarrier
DB00318CodeineSodium starch glycolatecarrier
DB00319PiperacillinSolute carrier family 22 member 6transporter
DB00319PiperacillinPenicillin-binding protein 3target
DB00319PiperacillinPenicillin-binding protein 2Btarget
DB00319PiperacillinPenicillin-binding protein 2atarget
DB00319PiperacillinPenicillin-binding protein 1btarget
DB00319PiperacillinSolute carrier family 22 member 8transporter
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Dtarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Btarget
DB00320DihydroergotamineCytochrome P450 3A4enzyme
DB00320DihydroergotamineAlpha-2A adrenergic receptortarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 2Btarget
DB00320DihydroergotamineMultidrug resistance protein 1transporter
DB00327HydromorphoneMu-type opioid receptortarget
DB00327HydromorphoneDelta-type opioid receptortarget
DB00327HydromorphoneKappa-type opioid receptortarget
DB00327HydromorphoneCytochrome P450 3A4enzyme
DB00327HydromorphoneCytochrome P450 2C9enzyme
DB00327HydromorphoneUDP-glucuronosyltransferase 1-3enzyme
DB00327HydromorphoneUDP-glucuronosyltransferase 2B7enzyme
DB00327HydromorphoneSerum albumincarrier
DB00328IndomethacinProstaglandin G/H synthase 1target
DB00328IndomethacinProstaglandin G/H synthase 2target
DB00328IndomethacinCytochrome P450 2C19enzyme
DB00328IndomethacinUDP-glucuronosyltransferase 1-9enzyme
DB00328IndomethacinPhospholipase A2, membrane associatedtarget
DB00328IndomethacinProstaglandin reductase 2target
DB00328IndomethacinLactoylglutathione lyasetarget
DB00328IndomethacinProstaglandin D2 receptor 2target
DB00328IndomethacinPeroxisome proliferator-activated receptor gammatarget
DB00328IndomethacinSerum albumincarrier
DB00328IndomethacinCanalicular multispecific organic anion transporter 2transporter
DB00328IndomethacinMultidrug resistance-associated protein 4transporter
DB00328IndomethacinMultidrug resistance-associated protein 6transporter
DB00328IndomethacinMultidrug resistance protein 1transporter
DB00328IndomethacinMultidrug resistance-associated protein 1transporter
DB00328IndomethacinSolute carrier organic anion transporter family member 1A2transporter
DB00328IndomethacinSolute carrier family 22 member 6transporter
DB00328IndomethacinSolute carrier family 22 member 8transporter
DB00328IndomethacinCanalicular multispecific organic anion transporter 1transporter
DB00328IndomethacinATP-binding cassette sub-family C member 11transporter
DB00328IndomethacinSolute carrier family 22 member 11transporter
DB00328IndomethacinSodium/bile acid cotransportertransporter
DB00328IndomethacinSolute carrier family 22 member 7transporter
DB00328IndomethacinCytochrome P450 2C9enzyme
DB00328IndomethacinUDP-glucuronosyltransferase 1-1enzyme
DB00328IndomethacinLiver carboxylesterase 1enzyme
DB00328IndomethacinUDP-glucuronosyltransferase 2B7enzyme
DB00328IndomethacinPeroxisome proliferator-activated receptor alphatarget
DB00328IndomethacinAldo-keto reductase family 1 member C3target
DB00328IndomethacinSolute carrier organic anion transporter family member 1B1transporter
DB00328IndomethacinBile salt export pumptransporter
DB00334OlanzapineD(1A) dopamine receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineD(4) dopamine receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineD(2) dopamine receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineD(3) dopamine receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineD(1B) dopamine receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineMultidrug resistance protein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineBeta adrenergic receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 1target
DB00334OlanzapineGABA-A receptor (benzodiazepine site)target
DB00334OlanzapineCytochrome P450 2C9enzyme
DB00334OlanzapineUDP-glucuronosyltransferase 1-4enzyme
DB00338OmeprazolePotassium-transporting ATPase alpha chain 1target
DB00338OmeprazoleCytochrome P450 2C19enzyme
DB00338OmeprazoleCytochrome P450 3A4enzyme
DB00338OmeprazoleCytochrome P450 2C9enzyme
DB00338OmeprazoleCytochrome P450 1A2enzyme
DB00338OmeprazoleCanalicular multispecific organic anion transporter 2transporter
DB00338OmeprazoleMultidrug resistance protein 1transporter
DB00338OmeprazoleATP-binding cassette sub-family G member 2transporter
DB00338OmeprazoleCytochrome P450 1A1enzyme
DB00338OmeprazoleCytochrome P450 1B1enzyme
DB00338OmeprazoleCytochrome P450 2C18enzyme
DB00338OmeprazoleCytochrome P450 2C8enzyme
DB00338OmeprazoleCytochrome P450 2D6enzyme
DB00338OmeprazoleAryl hydrocarbon receptortarget
DB00340MetixeneMuscarinic acetylcholine receptor M2target
DB00340MetixeneMuscarinic acetylcholine receptor M1target
DB00340MetixeneMuscarinic acetylcholine receptor M4target
DB00340MetixeneMuscarinic acetylcholine receptor M5target
DB00340MetixeneMuscarinic acetylcholine receptor M3target
DB00343DiltiazemVoltage-dependent calcium channel gamma-1 subunittarget
DB00343DiltiazemCytochrome P450 3A4enzyme
DB00343DiltiazemCytochrome P450 2C19enzyme
DB00343DiltiazemCytochrome P450 2D6enzyme
DB00343DiltiazemCytochrome P450 3A5enzyme
DB00343DiltiazemCytochrome P450 3A7enzyme
DB00343DiltiazemMultidrug resistance protein 1transporter
DB00343DiltiazemCytochrome P450 2C8enzyme
DB00343DiltiazemSerum albumincarrier
DB00343DiltiazemAlpha-1-acid glycoprotein 1carrier
DB00343DiltiazemVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00346AlfuzosinAlpha-1A adrenergic receptortarget
DB00346AlfuzosinAlpha-1B adrenergic receptortarget
DB00346AlfuzosinAlpha-1D adrenergic receptortarget
DB00346AlfuzosinCytochrome P450 3A4enzyme
DB00346AlfuzosinPotassium voltage-gated channel subfamily H member 2target
DB00349ClobazamCytochrome P450 2C19enzyme
DB00349ClobazamCytochrome P450 3A4enzyme
DB00349ClobazamCytochrome P450 2B6enzyme
DB00349ClobazamCytochrome P450 2C18enzyme
DB00349ClobazamSodium- and chloride-dependent GABA transporter 1transporter
DB00349ClobazamSodium- and chloride-dependent GABA transporter 3transporter
DB00349ClobazamMultidrug resistance protein 1transporter
DB00349ClobazamGABA-A receptor (anion channel)target
DB00349ClobazamCytochrome P450 2D6enzyme
DB00352TioguanineDNAtarget
DB00352TioguanineMultidrug resistance-associated protein 4transporter
DB00352TioguanineHypoxanthine-guanine phosphoribosyltransferaseenzyme
DB00353MethylergometrineD(1A) dopamine receptortarget
DB00353MethylergometrineCytochrome P450 3A4enzyme
DB00353Methylergometrine5-hydroxytryptamine receptor 2Btarget
DB00355AztreonamPenicillin-binding protein 3target
DB00355AztreonamBeta-lactamasetarget
DB00356ChlorzoxazoneCalcium-activated potassium channel subunit alpha-1target
DB00356ChlorzoxazoneCytochrome P450 2E1enzyme
DB00356ChlorzoxazoneCytochrome P450 1A2enzyme
DB00356ChlorzoxazoneCytochrome P450 2A6enzyme
DB00356ChlorzoxazoneCytochrome P450 1A1enzyme
DB00356ChlorzoxazoneCytochrome P450 2D6enzyme
DB00356ChlorzoxazoneCytochrome P450 3A4enzyme
DB00358MefloquineHemoglobin subunit alphatarget
DB00358MefloquineCholinesteraseenzyme
DB00358MefloquineCytochrome P450 3A4enzyme
DB00358MefloquineAdenosine receptor A2atarget
DB00358MefloquineFe(II)-protoporphyrin IXtarget
DB00358MefloquineMultidrug resistance protein 1transporter
DB00358MefloquineCytochrome P450 19A1enzyme
DB00358MefloquineAcetylcholinesteraseenzyme
DB00360SapropterinPhenylalanine-4-hydroxylasetarget
DB00360SapropterinNitric oxide synthase, endothelialtarget
DB00360SapropterinTyrosine 3-monooxygenasetarget
DB00360SapropterinTryptophan 5-hydroxylase 1target
DB00360SapropterinProstaglandin G/H synthase 2enzyme
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineMultidrug resistance protein 1transporter
DB00361VinorelbineCytochrome P450 2D6enzyme
DB00363ClozapineD(4) dopamine receptortarget
DB00363ClozapineHistamine H1 receptortarget
DB00363ClozapineD(2) dopamine receptortarget
DB00363ClozapineNeuron-specific vesicular protein calcyontarget
DB00363ClozapineHistamine H4 receptortarget
DB00363Clozapine5-hydroxytryptamine receptor 2Atarget
DB00363Clozapine5-hydroxytryptamine receptor 1Atarget
DB00363Clozapine5-hydroxytryptamine receptor 2Ctarget
DB00363ClozapineD(1A) dopamine receptortarget
DB00363ClozapineCytochrome P450 1A2enzyme
DB00363ClozapineCytochrome P450 2D6enzyme
DB00363ClozapineD(3) dopamine receptortarget
DB00363ClozapineMuscarinic acetylcholine receptor M1target
DB00363ClozapineMuscarinic acetylcholine receptor M2target
DB00363ClozapineMuscarinic acetylcholine receptor M3target
DB00363ClozapineMuscarinic acetylcholine receptor M4target
DB00363ClozapineMuscarinic acetylcholine receptor M5target
DB00363Clozapine5-hydroxytryptamine receptor 1Btarget
DB00363Clozapine5-hydroxytryptamine receptor 1Dtarget
DB00363Clozapine5-hydroxytryptamine receptor 1Etarget
DB00363Clozapine5-hydroxytryptamine receptor 3Atarget
DB00363Clozapine5-hydroxytryptamine receptor 6target
DB00363Clozapine5-hydroxytryptamine receptor 7target
DB00363ClozapineAlpha-1A adrenergic receptortarget
DB00363ClozapineAlpha-1B adrenergic receptortarget
DB00363ClozapineAlpha-2A adrenergic receptortarget
DB00363ClozapineAlpha-2B adrenergic receptortarget
DB00363ClozapineAlpha-2C adrenergic receptortarget
DB00363ClozapineCytochrome P450 2C9enzyme
DB00363ClozapineMultidrug resistance protein 1transporter
DB00363ClozapineCytochrome P450 3A4enzyme
DB00363ClozapineCytochrome P450 2C19enzyme
DB00363ClozapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00363ClozapineUDP-glucuronosyltransferase 1-4enzyme
DB00363ClozapineCytochrome P450 1A1enzyme
DB00363ClozapineCytochrome P450 2A6enzyme
DB00363ClozapineCytochrome P450 2C8enzyme
DB00363ClozapineCytochrome P450 2E1enzyme
DB00363ClozapineGlutathione S-transferase Ptarget
DB00365GrepafloxacinDNA gyrase subunit Atarget
DB00365GrepafloxacinDNA topoisomerase 4 subunit Atarget
DB00365GrepafloxacinCytochrome P450 3A4enzyme
DB00365GrepafloxacinCytochrome P450 1A2enzyme
DB00365GrepafloxacinSolute carrier family 22 member 2transporter
DB00365GrepafloxacinSolute carrier family 22 member 5transporter
DB00365GrepafloxacinCanalicular multispecific organic anion transporter 1transporter
DB00365GrepafloxacinMultidrug resistance protein 1transporter
DB00365GrepafloxacinMultidrug resistance-associated protein 1transporter
DB00365GrepafloxacinSolute carrier family 22 member 6transporter
DB00370Mirtazapine5-hydroxytryptamine receptor 2Atarget
DB00370Mirtazapine5HT3 serotonin receptortarget
DB00370MirtazapineAlpha-2A adrenergic receptortarget
DB00370Mirtazapine5-hydroxytryptamine receptor 2Ctarget
DB00370MirtazapineKappa-type opioid receptortarget
DB00370MirtazapineHistamine H1 receptortarget
DB00370MirtazapineCytochrome P450 1A2enzyme
DB00370MirtazapineCytochrome P450 3A4enzyme
DB00370MirtazapineCytochrome P450 2D6enzyme
DB00370MirtazapineAlpha-1 adrenergic receptorstarget
DB00370MirtazapineSodium-dependent serotonin transportertransporter
DB00372ThiethylperazineD(1A) dopamine receptortarget
DB00372ThiethylperazineD(4) dopamine receptortarget
DB00372ThiethylperazineD(2) dopamine receptortarget
DB00377Palonosetron5-hydroxytryptamine receptor 3Atarget
DB00377PalonosetronCytochrome P450 2D6enzyme
DB00377PalonosetronCytochrome P450 3A4enzyme
DB00377PalonosetronCytochrome P450 1A2enzyme
DB00382TacrineAcetylcholinesterasetarget
DB00382TacrineCytochrome P450 1A2enzyme
DB00382TacrineCholinesterasetarget
DB00382TacrineMultidrug resistance protein 1transporter
DB00382TacrineLiver carboxylesterase 1target
DB00384TriamtereneAmiloride-sensitive sodium channel subunit gammatarget
DB00384TriamtereneAmiloride-sensitive sodium channel subunit alphatarget
DB00384TriamtereneAmiloride-sensitive sodium channel subunit betatarget
DB00384TriamtereneAmiloride-sensitive sodium channel subunit deltatarget
DB00384TriamtereneCytochrome P450 1A2enzyme
DB00392ProfenamineGlutamate receptor ionotropic, NMDA 3Atarget
DB00392ProfenamineMuscarinic acetylcholine receptor M1target
DB00392ProfenamineCholinesteraseenzyme
DB00392ProfenamineMuscarinic acetylcholine receptor M2target
DB00400GriseofulvinTubulin beta chaintarget
DB00400GriseofulvinTubulin alpha chaintarget
DB00400GriseofulvinKeratin, type I cytoskeletal 12target
DB00400GriseofulvinCytochrome P450 1A2enzyme
DB00400GriseofulvinCytochrome P450 3A4enzyme
DB00400GriseofulvinCytochrome P450 2D6enzyme
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00404AlprazolamTranslocator proteintarget
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00404AlprazolamCytochrome P450 3A4enzyme
DB00404AlprazolamCytochrome P450 2C9enzyme
DB00404AlprazolamCytochrome P450 3A5enzyme
DB00404AlprazolamCytochrome P450 3A7enzyme
DB00404AlprazolamGABA-A receptor (anion channel)target
DB00404AlprazolamSerum albumincarrier
DB00404Alprazolamalpha1-acid glycoproteincarrier
DB00408LoxapineD(1A) dopamine receptortarget
DB00408LoxapineD(2) dopamine receptortarget
DB00408Loxapine5-hydroxytryptamine receptor 2Atarget
DB00408Loxapine5-hydroxytryptamine receptor 2Ctarget
DB00408Loxapine5-hydroxytryptamine receptor 1Atarget
DB00408Loxapine5-hydroxytryptamine receptor 1Btarget
DB00408Loxapine5-hydroxytryptamine receptor 1Dtarget
DB00408Loxapine5-hydroxytryptamine receptor 1Etarget
DB00408Loxapine5-hydroxytryptamine receptor 3Atarget
DB00408Loxapine5-hydroxytryptamine receptor 5Atarget
DB00408Loxapine5-hydroxytryptamine receptor 6target
DB00408Loxapine5-hydroxytryptamine receptor 7target
DB00408LoxapineAlpha-1A adrenergic receptortarget
DB00408LoxapineAlpha-1B adrenergic receptortarget
DB00408LoxapineAlpha-2A adrenergic receptortarget
DB00408LoxapineAlpha-2B adrenergic receptortarget
DB00408LoxapineAlpha-2C adrenergic receptortarget
DB00408LoxapineBeta-1 adrenergic receptortarget
DB00408LoxapineMuscarinic acetylcholine receptor M1target
DB00408LoxapineMuscarinic acetylcholine receptor M2target
DB00408LoxapineMuscarinic acetylcholine receptor M3target
DB00408LoxapineMuscarinic acetylcholine receptor M4target
DB00408LoxapineMuscarinic acetylcholine receptor M5target
DB00408LoxapineD(1) dopamine receptortarget
DB00408LoxapineD(3) dopamine receptortarget
DB00408LoxapineD(4) dopamine receptortarget
DB00408LoxapineD(1B) dopamine receptortarget
DB00408LoxapineHistamine H1 receptortarget
DB00408LoxapineHistamine H2 receptortarget
DB00408LoxapineHistamine H4 receptortarget
DB00408LoxapineSodium-dependent serotonin transportertarget
DB00408LoxapineSodium-dependent noradrenaline transportertarget
DB00408LoxapineSodium-dependent dopamine transportertarget
DB00413PramipexoleD(3) dopamine receptortarget
DB00413PramipexoleD(4) dopamine receptortarget
DB00413PramipexoleD(2) dopamine receptortarget
DB00413Pramipexole5-hydroxytryptamine receptor 1Atarget
DB00413PramipexoleAlpha-2A adrenergic receptortarget
DB00413PramipexoleSolute carrier family 22 member 2transporter
DB00413PramipexoleSolute carrier family 22 member 1transporter
DB00413PramipexoleSolute carrier family 22 member 3transporter
DB00415AmpicillinSerum albumincarrier
DB00415AmpicillinSolute carrier family 22 member 5transporter
DB00415AmpicillinSolute carrier family 15 member 1transporter
DB00415AmpicillinSolute carrier family 15 member 2transporter
DB00415AmpicillinPenicillin-binding protein 2atarget
DB00415AmpicillinPenicillin-binding protein 1btarget
DB00415AmpicillinPenicillin-binding protein 3target
DB00415AmpicillinPenicillin-binding protein 1Atarget
DB00415AmpicillinPenicillin-binding protein 2Btarget
DB00415AmpicillinMonocarboxylate transporter 1transporter
DB00415AmpicillinSolute carrier family 15 member 1target
DB00415AmpicillinSolute carrier family 15 member 2target
DB00415AmpicillinAngiopoietin-1 receptortarget
DB00416Metocurine IodideNeuronal acetylcholine receptor subunit alpha-2target
DB00417PhenoxymethylpenicillinPenicillin-binding protein 1Atarget
DB00417PhenoxymethylpenicillinMecA PBP2' (penicillin binding protein 2')target
DB00417PhenoxymethylpenicillinD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00417PhenoxymethylpenicillinPenicillin acylasetarget
DB00417PhenoxymethylpenicillinSolute carrier family 15 member 1target
DB00420PromazineD(2) dopamine receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M4target
DB00420PromazineMuscarinic acetylcholine receptor M2target
DB00420PromazineMuscarinic acetylcholine receptor M3target
DB00420PromazineAlpha-1B adrenergic receptortarget
DB00420PromazineD(1A) dopamine receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M5target
DB00420Promazine5-hydroxytryptamine receptor 2Atarget
DB00420Promazine5-hydroxytryptamine receptor 2Ctarget
DB00420PromazineAlpha-1A adrenergic receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M1target
DB00420PromazineD(4) dopamine receptortarget
DB00420PromazineHistamine H1 receptortarget
DB00420PromazineAlpha-1D adrenergic receptortarget
DB00420PromazineCytochrome P450 2C19enzyme
DB00420PromazineCytochrome P450 1A2enzyme
DB00420PromazineCytochrome P450 3A4enzyme
DB00420PromazineCytochrome P450 2C9enzyme
DB00420PromazineCytochrome P450 2D6enzyme
DB00422MethylphenidateSodium-dependent dopamine transportertarget
DB00422MethylphenidateSodium-dependent noradrenaline transportertarget
DB00422MethylphenidateCarboxylesteraseenzyme
DB00422Methylphenidate5-hydroxytryptamine receptor 1Atarget
DB00426FamciclovirDNA polymerase catalytic subunittarget
DB00426FamciclovirDNA polymerase catalytic subunittarget
DB00426FamciclovirAldehyde oxidaseenzyme
DB00430CefpiramidePenicillin binding protein 2atarget
DB00430CefpiramideSerum albumincarrier
DB00430CefpiramidePeptidoglycan synthase FtsItarget
DB00430CefpiramidePenicillin-binding protein 1Btarget
DB00430CefpiramidePenicillin-binding protein 1Atarget
DB00430CefpiramidePenicillin-binding protein 1Btarget
DB00430CefpiramideD-alanyl-D-alanine carboxypeptidase DacCtarget
DB00430CefpiramidePenicillin-binding protein 1Atarget
DB00433ProchlorperazineD(2) dopamine receptortarget
DB00433ProchlorperazineCytochrome P450 2D6enzyme
DB00433ProchlorperazineHistamine H1 receptortarget
DB00433ProchlorperazineAlpha-1 adrenergic receptorstarget
DB00433ProchlorperazineAlpha-2 adrenergic receptorstarget
DB00436BendroflumethiazideSolute carrier family 12 member 3target
DB00436BendroflumethiazideCarbonic anhydrase 1target
DB00436BendroflumethiazideCarbonic anhydrase 2target
DB00436BendroflumethiazideCarbonic anhydrase 4target
DB00436BendroflumethiazideCalcium-activated potassium channel subunit alpha-1target
DB00436BendroflumethiazideThiopurine S-methyltransferaseenzyme
DB00437AllopurinolXanthine dehydrogenase/oxidasetarget
DB00437AllopurinolSolute carrier family 22 member 8transporter
DB00437AllopurinolSolute carrier family 22 member 7transporter
DB00437AllopurinolAldehyde oxidaseenzyme
DB00437AllopurinolXanthine dehydrogenase/oxidaseenzyme
DB00437AllopurinolATP-binding cassette sub-family G member 2transporter
DB00437AllopurinolSolute carrier family 22 member 2transporter
DB00438CeftazidimeSolute carrier family 22 member 5transporter
DB00438CeftazidimeSolute carrier family 15 member 1transporter
DB00438CeftazidimeSolute carrier family 15 member 2transporter
DB00438CeftazidimeSolute carrier family 22 member 6transporter
DB00438CeftazidimePeptidoglycan synthase FtsItarget
DB00438CeftazidimePenicillin-binding protein 3target
DB00438CeftazidimePenicillin-binding protein 1Atarget
DB00438CeftazidimePenicillin-binding protein 1Atarget
DB00438CeftazidimePenicillin-binding protein 1Btarget
DB00438CeftazidimePenicillin-binding protein 1Btarget
DB00438CeftazidimePenicillin-binding protein 2target
DB00438CeftazidimePenicillin-binding protein 2target
DB00438CeftazidimeD-alanyl-D-alanine endopeptidasetarget
DB00442EntecavirDNAtarget
DB00447LoracarbefPenicillin-binding protein 1Atarget
DB00447LoracarbefSolute carrier family 15 member 1transporter
DB00447LoracarbefSolute carrier family 15 member 2transporter
DB00447LoracarbefPenicillin-binding protein 3target
DB00448LansoprazolePotassium-transporting ATPase alpha chain 1target
DB00448LansoprazoleCytochrome P450 2C19enzyme
DB00448LansoprazoleCytochrome P450 2C9enzyme
DB00448LansoprazoleCytochrome P450 3A4enzyme
DB00448LansoprazoleMultidrug resistance protein 1transporter
DB00448LansoprazoleATP-binding cassette sub-family G member 2transporter
DB00448LansoprazoleCytochrome P450 1A1enzyme
DB00448LansoprazoleCytochrome P450 1B1enzyme
DB00448LansoprazoleCytochrome P450 2C18enzyme
DB00448LansoprazoleCytochrome P450 2C8enzyme
DB00448LansoprazoleCytochrome P450 2D6enzyme
DB00448LansoprazoleMicrotubule-associated protein tautarget
DB00448LansoprazoleSolute carrier family 22 member 8transporter
DB00448LansoprazoleSolute carrier family 22 member 1transporter
DB00448LansoprazoleSolute carrier family 22 member 2transporter
DB00448LansoprazoleSolute carrier family 22 member 3transporter
DB00450DroperidolD(2) dopamine receptortarget
DB00450DroperidolAlpha-1A adrenergic receptortarget
DB00456CefalotinPenicillin-binding protein 1Atarget
DB00456CefalotinD-alanyl-D-alanine carboxypeptidasetarget
DB00456CefalotinBeta-lactamasetarget
DB00456CefalotinSolute carrier family 22 member 5transporter
DB00456CefalotinSolute carrier family 15 member 1transporter
DB00456CefalotinSolute carrier family 15 member 2transporter
DB00456CefalotinSolute carrier family 22 member 6transporter
DB00456CefalotinSolute carrier family 22 member 8transporter
DB00456CefalotinSolute carrier family 22 member 11transporter
DB00456CefalotinSolute carrier family 22 member 7transporter
DB00456CefalotinPenicillin-binding protein 1Atarget
DB00456CefalotinPenicillin-binding protein 1btarget
DB00456CefalotinPenicillin-binding protein 3target
DB00456CefalotinPenicillin-binding protein 2atarget
DB00456CefalotinPenicillin-binding protein 2Btarget
DB00456CefalotinSerum albumincarrier
DB00457PrazosinAlpha-1A adrenergic receptortarget
DB00457PrazosinAlpha-1B adrenergic receptortarget
DB00457PrazosinAlpha-1D adrenergic receptortarget
DB00457PrazosinPotassium voltage-gated channel subfamily H member 2target
DB00457PrazosinAlpha-1-acid glycoprotein 1carrier
DB00457PrazosinSolute carrier family 22 member 1transporter
DB00457PrazosinSolute carrier family 22 member 3transporter
DB00457PrazosinMultidrug resistance protein 1transporter
DB00457PrazosinATP-binding cassette sub-family G member 2transporter
DB00457PrazosinAlpha-2A adrenergic receptortarget
DB00457PrazosinAlpha-2B adrenergic receptortarget
DB00457PrazosinAlpha-1 adrenergic receptorstarget
DB00458ImipramineSodium-dependent noradrenaline transportertarget
DB00458ImipramineSodium-dependent serotonin transportertarget
DB00458ImipramineCytochrome P450 1A2enzyme
DB00458ImipramineCytochrome P450 2C19enzyme
DB00458ImipramineCytochrome P450 2D6enzyme
DB00458ImipramineHistamine H1 receptortarget
DB00458ImipramineAlpha-1A adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 2Atarget
DB00458ImipramineMuscarinic acetylcholine receptor M1target
DB00458ImipramineMuscarinic acetylcholine receptor M2target
DB00458ImipramineMuscarinic acetylcholine receptor M3target
DB00458ImipramineMuscarinic acetylcholine receptor M4target
DB00458ImipramineMuscarinic acetylcholine receptor M5target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 2target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 3target
DB00458ImipramineAlpha-1D adrenergic receptortarget
DB00458ImipramineAlpha-1-acid glycoprotein 1carrier
DB00458ImipramineSolute carrier family 22 member 2transporter
DB00458ImipramineSolute carrier family 22 member 3transporter
DB00458ImipramineMultidrug resistance protein 1transporter
DB00458ImipramineSolute carrier family 22 member 4transporter
DB00458ImipramineCytochrome P450 3A4enzyme
DB00458ImipramineCytochrome P450 2B6enzyme
DB00458ImipramineCytochrome P450 2C18enzyme
DB00458ImipramineCytochrome P450 2E1enzyme
DB00458ImipramineCytochrome P450 3A7enzyme
DB00458Imipramine5-hydroxytryptamine receptor 2Ctarget
DB00458ImipramineAlpha-1B adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 7target
DB00458ImipramineD(1) dopamine receptortarget
DB00458ImipramineD(2) dopamine receptortarget
DB00458ImipraminePotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent dopamine transportertarget
DB00458Imipramine5-hydroxytryptamine receptor 1Atarget
DB00458Imipramine5-hydroxytryptamine receptor 6target
DB00458ImipraminePotassium voltage-gated channel subfamily H member 1target
DB00458ImipramineSerum albumincarrier
DB00458ImipramineAlpha-1-acid glycoprotein 2target
DB00465KetorolacProstaglandin G/H synthase 1target
DB00465KetorolacProstaglandin G/H synthase 2target
DB00465KetorolacUDP-glucuronosyltransferase 2B7enzyme
DB00465KetorolacCytochrome P450 2C8enzyme
DB00465KetorolacCytochrome P450 2C9enzyme
DB00467EnoxacinDNA gyrase subunit Atarget
DB00467EnoxacinDNA topoisomerase 4 subunit Atarget
DB00467EnoxacinDNA topoisomerase 2-alphatarget
DB00467EnoxacinCytochrome P450 1A2enzyme
DB00468QuininePlatelet glycoprotein IXtarget
DB00468QuinineIntermediate conductance calcium-activated potassium channel protein 4target
DB00468QuinineCytochrome P450 3A4enzyme
DB00468QuinineCytochrome P450 3A5enzyme
DB00468QuinineCytochrome P450 1A1enzyme
DB00468QuinineCytochrome P450 2D6enzyme
DB00468QuinineCytochrome P450 1A2enzyme
DB00468QuinineCytochrome P450 2C8enzyme
DB00468QuinineCytochrome P450 2C9enzyme
DB00468QuinineCytochrome P450 2C19enzyme
DB00468QuinineCytochrome P450 2E1enzyme
DB00468QuinineCytochrome P450 3A7enzyme
DB00468QuinineSolute carrier family 22 member 2transporter
DB00468QuinineSolute carrier family 22 member 1transporter
DB00468QuinineSolute carrier family 22 member 5transporter
DB00468QuinineMultidrug resistance protein 1transporter
DB00468QuinineSolute carrier organic anion transporter family member 1A2transporter
DB00468QuinineSolute carrier family 22 member 4transporter
DB00468QuinineFe(II)-protoporphyrin IXtarget
DB00468QuinineSolute carrier organic anion transporter family member 1B1transporter
DB00471MontelukastCysteinyl leukotriene receptor 1target
DB00471MontelukastArachidonate 5-lipoxygenasetarget
DB00471MontelukastCytochrome P450 3A4enzyme
DB00471MontelukastCytochrome P450 2C9enzyme
DB00471MontelukastCytochrome P450 2C8enzyme
DB00471MontelukastSolute carrier organic anion transporter family member 2B1transporter
DB00471MontelukastProstaglandin G/H synthase 1enzyme
DB00471MontelukastCytochrome P450 2A6enzyme
DB00475ChlordiazepoxideGABA-A receptor (anion channel)target
DB00477ChlorpromazineD(2) dopamine receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 2Atarget
DB00477ChlorpromazineCytochrome P450 2D6enzyme
DB00477ChlorpromazineCholinesteraseenzyme
DB00477ChlorpromazineCytochrome P450 1A2enzyme
DB00477ChlorpromazineSerum albumincarrier
DB00477ChlorpromazineMultidrug resistance protein 1transporter
DB00477ChlorpromazineD(1A) dopamine receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 1Atarget
DB00477ChlorpromazineAlpha-1A adrenergic receptortarget
DB00477ChlorpromazineAlpha-1B adrenergic receptortarget
DB00477ChlorpromazineCytochrome P450 2E1enzyme
DB00477ChlorpromazineCytochrome P450 3A4enzyme
DB00477ChlorpromazineHistamine H1 receptortarget
DB00477ChlorpromazinePotassium voltage-gated channel subfamily H member 2target
DB00477ChlorpromazineD(1) dopamine receptortarget
DB00477ChlorpromazineD(3) dopamine receptortarget
DB00477ChlorpromazineD(4) dopamine receptortarget
DB00477ChlorpromazineD(1B) dopamine receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 2Ctarget
DB00477Chlorpromazine5-hydroxytryptamine 2 receptortarget
DB00477ChlorpromazineAlpha-1 adrenergic receptorstarget
DB00477ChlorpromazineAlpha-2 adrenergic receptorstarget
DB00477ChlorpromazineMuscarinic acetylcholine receptor M1target
DB00477ChlorpromazineMuscarinic acetylcholine receptor M3target
DB00477ChlorpromazineSphingomyelin phosphodiesterasetarget
DB00477ChlorpromazineCalmodulintarget
DB00477Chlorpromazinealpha1-acid glycoproteintarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 6target
DB00477Chlorpromazine5-hydroxytryptamine receptor 7target
DB00477ChlorpromazineHistamine H4 receptortarget
DB00477ChlorpromazineBile salt export pumptransporter
DB00480LenalidomideProstaglandin G/H synthase 2target
DB00480LenalidomideTumor necrosis factor ligand superfamily member 11target
DB00480LenalidomideCadherin-5target
DB00480LenalidomideProtein cereblontarget
DB00480LenalidomideMultidrug resistance protein 1transporter
DB00484BrimonidineAlpha-2A adrenergic receptortarget
DB00484BrimonidineAlpha-2B adrenergic receptortarget
DB00484BrimonidineAlpha-2C adrenergic receptortarget
DB00484BrimonidineAldehyde oxidaseenzyme
DB00485DicloxacillinSolute carrier family 15 member 1transporter
DB00485DicloxacillinSolute carrier family 15 member 2transporter
DB00485DicloxacillinPenicillin-binding protein 3target
DB00485DicloxacillinPenicillin-binding protein 1btarget
DB00485DicloxacillinPenicillin-binding protein 2atarget
DB00485DicloxacillinPenicillin-binding protein 3target
DB00485DicloxacillinPenicillin-binding protein 1Atarget
DB00485DicloxacillinPenicillin-binding protein 2Btarget
DB00485DicloxacillinCytochrome P450 3A4enzyme
DB00487PefloxacinDNA gyrase subunit Atarget
DB00487PefloxacinDNA topoisomerase 4 subunit Atarget
DB00487PefloxacinDNA topoisomerase 2-alphatarget
DB00487PefloxacinCytochrome P450 1A2enzyme
DB00487PefloxacinDNA topoisomerase 1target
DB00493CefotaximePenicillin-binding protein 3target
DB00493CefotaximeSolute carrier family 15 member 1transporter
DB00493CefotaximeSolute carrier family 15 member 2transporter
DB00493CefotaximeSolute carrier family 22 member 6transporter
DB00493CefotaximeSolute carrier family 22 member 8transporter
DB00493CefotaximeSolute carrier family 22 member 11transporter
DB00493CefotaximeSolute carrier family 22 member 7transporter
DB00493CefotaximePenicillin-binding protein 1btarget
DB00493CefotaximePenicillin-binding protein 2atarget
DB00493CefotaximePenicillin-binding protein 1Atarget
DB00493CefotaximePenicillin-binding protein 2Btarget
DB00493CefotaximeSolute carrier family 22 member 6target
DB00493CefotaximeSolute carrier family 22 member 8target
DB00493CefotaximeSolute carrier family 22 member 11target
DB00493CefotaximeSolute carrier family 22 member 7target
DB00493CefotaximeSolute carrier family 15 member 1target
DB00493CefotaximeSerum albumintarget
DB00493CefotaximeBeta-lactamasetarget
DB00493CefotaximeSolute carrier family 15 member 2target
DB00496DarifenacinMuscarinic acetylcholine receptor M3target
DB00496DarifenacinCytochrome P450 3A4enzyme
DB00496DarifenacinCytochrome P450 2D6enzyme
DB00496DarifenacinMuscarinic acetylcholine receptor M1target
DB00496DarifenacinMuscarinic acetylcholine receptor M2target
DB00496DarifenacinMuscarinic acetylcholine receptor M4target
DB00496DarifenacinMuscarinic acetylcholine receptor M5target
DB00497OxycodoneMu-type opioid receptortarget
DB00497OxycodoneKappa-type opioid receptortarget
DB00497OxycodoneDelta-type opioid receptortarget
DB00497OxycodoneCytochrome P450 2D6enzyme
DB00497OxycodoneCytochrome P450 3A4enzyme
DB00497OxycodoneCytochrome P450 3A5enzyme
DB00497OxycodoneKappa-type opioid receptor 2btarget
DB00497OxycodoneSerum albumincarrier
DB00497Oxycodonealpha1-acid glycoproteincarrier
DB00504LevallorphanMu-type opioid receptortarget
DB00508TriflupromazineD(1A) dopamine receptortarget
DB00508TriflupromazineD(2) dopamine receptortarget
DB00508TriflupromazineMuscarinic acetylcholine receptor M1target
DB00508TriflupromazineMuscarinic acetylcholine receptor M2target
DB00508Triflupromazine5-hydroxytryptamine receptor 2Btarget
DB00508TriflupromazineMultidrug resistance protein 1transporter
DB00508TriflupromazineCholinesteraseenzyme
DB00514DextromethorphanSigma non-opioid intracellular receptor 1target
DB00514DextromethorphanHCG20471, isoform CRA_ctarget
DB00514DextromethorphanNeuronal acetylcholine receptor subunit alpha-2target
DB00514DextromethorphanSodium-dependent serotonin transportertarget
DB00514DextromethorphanGlutamate receptor ionotropic, NMDA 3Atarget
DB00514DextromethorphanCytochrome P450 2D6enzyme
DB00514DextromethorphanCytochrome P450 3A4enzyme
DB00514DextromethorphanCytochrome P450 3A7enzyme
DB00514DextromethorphanCytochrome P450 2C9enzyme
DB00514DextromethorphanCytochrome P450 2B6enzyme
DB00514DextromethorphanCytochrome P450 2C19enzyme
DB00514DextromethorphanMembrane-associated progesterone receptor component 1target
DB00514DextromethorphanNeuronal acetylcholine receptor subunit alpha-3target
DB00514DextromethorphanNeuronal acetylcholine receptor subunit alpha-4target
DB00514DextromethorphanNeuronal acetylcholine receptor subunit beta-4target
DB00514DextromethorphanNeuronal acetylcholine receptor subunit beta-2target
DB00514DextromethorphanNeuronal acetylcholine receptor subunit alpha-7target
DB00514DextromethorphanMu-type opioid receptortarget
DB00514DextromethorphanDelta-type opioid receptortarget
DB00514DextromethorphanKappa-type opioid receptortarget
DB00514DextromethorphanNADPH oxidasetarget
DB00514DextromethorphanSodium-dependent noradrenaline transportertarget
DB00518AlbendazoleTubulin alpha-1A chaintarget
DB00518AlbendazoleTubulin beta-4B chaintarget
DB00518AlbendazoleCytochrome P450 3A4enzyme
DB00518AlbendazoleFumarate reductase flavoprotein subunittarget
DB00518AlbendazoleMultidrug resistance protein 1transporter
DB00518AlbendazoleCytochrome P450 1A1enzyme
DB00518AlbendazoleCytochrome P450 1A2enzyme
DB00518AlbendazoleTubulin beta-2 chaintarget
DB00518AlbendazoleCytochrome P450 2C19enzyme
DB00519TrandolaprilAngiotensin-converting enzymetarget
DB00519TrandolaprilSolute carrier family 15 member 1transporter
DB00519TrandolaprilSolute carrier family 15 member 2transporter
DB00519TrandolaprilLiver carboxylesterase 1enzyme
DB00521CarteololBeta-2 adrenergic receptortarget
DB00521CarteololBeta-1 adrenergic receptortarget
DB00521CarteololCytochrome P450 2D6enzyme
DB00524MetolazoneSolute carrier family 12 member 3target
DB00527CinchocaineSodium channel protein type 5 subunit alphatarget
DB00527CinchocaineSodium channel protein type 10 subunit alphatarget
DB00527CinchocaineCalmodulintarget
DB00527CinchocaineCholinesteraseenzyme
DB00530ErlotinibEpidermal growth factor receptortarget
DB00530ErlotinibCytochrome P450 3A4enzyme
DB00530ErlotinibATP-binding cassette sub-family G member 2transporter
DB00530ErlotinibMultidrug resistance protein 1transporter
DB00530ErlotinibNuclear receptor subfamily 1 group I member 2target
DB00530ErlotinibCytochrome P450 3A5enzyme
DB00530ErlotinibCytochrome P450 1A1enzyme
DB00530ErlotinibCytochrome P450 1A2enzyme
DB00530ErlotinibCytochrome P450 1B1enzyme
DB00530ErlotinibCytochrome P450 2D6enzyme
DB00530ErlotinibCytochrome P450 2C8enzyme
DB00530ErlotinibUDP-glucuronosyltransferase 1-1enzyme
DB00530ErlotinibSerum albumincarrier
DB00530ErlotinibAlpha-1-acid glycoprotein 1carrier
DB00530ErlotinibSolute carrier organic anion transporter family member 2B1transporter
DB00535CefdinirMyeloperoxidasetarget
DB00535CefdinirPenicillin-binding protein 2target
DB00535CefdinirPBP3target
DB00535CefdinirSolute carrier family 22 member 5transporter
DB00535CefdinirSolute carrier family 15 member 1transporter
DB00535CefdinirSolute carrier family 15 member 2transporter
DB00535CefdinirSolute carrier family 22 member 6transporter
DB00535CefdinirSolute carrier family 22 member 8transporter
DB00535CefdinirPeptidoglycan transpeptidasetarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 2-alphatarget
DB00537CiprofloxacinCytochrome P450 1A2enzyme
DB00537CiprofloxacinCytochrome P450 3A4enzyme
DB00537CiprofloxacinCytochrome P450 3A5enzyme
DB00537CiprofloxacinCytochrome P450 3A7enzyme
DB00537CiprofloxacinMultidrug resistance protein 1transporter
DB00537CiprofloxacinPotassium voltage-gated channel subfamily H member 2target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Btarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug resistance protein MdtKtarget
DB00537CiprofloxacinGyrase Atarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug and toxin extrusion protein 1transporter
DB00537CiprofloxacinMultidrug and toxin extrusion protein 2transporter
DB00537CiprofloxacinSerum albumincarrier
DB00541VincristineTubulin beta chaintarget
DB00541VincristineCytochrome P450 3A4enzyme
DB00541VincristineCytochrome P450 3A5enzyme
DB00541VincristineCytochrome P450 3A7enzyme
DB00541VincristineMultidrug resistance protein 1transporter
DB00541VincristineCanalicular multispecific organic anion transporter 2transporter
DB00541VincristineSolute carrier family 22 member 3transporter
DB00541VincristineMultidrug resistance-associated protein 1transporter
DB00541VincristineMultidrug resistance-associated protein 7transporter
DB00541VincristineCanalicular multispecific organic anion transporter 1transporter
DB00541VincristineBile salt export pumptransporter
DB00541VincristineATP-binding cassette sub-family G member 2transporter
DB00541VincristineTubulin alpha-4A chaintarget
DB00541VincristineRalA-binding protein 1transporter
DB00541VincristineSolute carrier organic anion transporter family member 1B1transporter
DB00541VincristineSolute carrier organic anion transporter family member 1B3transporter
DB00542BenazeprilAngiotensin-converting enzymetarget
DB00542BenazeprilMethylenetetrahydrofolate reductaseenzyme
DB00542BenazeprilSolute carrier family 15 member 1transporter
DB00542BenazeprilSolute carrier family 15 member 2transporter
DB00543AmoxapineSodium-dependent serotonin transportertarget
DB00543AmoxapineSodium-dependent noradrenaline transportertarget
DB00543AmoxapineAlpha-2A adrenergic receptortarget
DB00543AmoxapineD(2) dopamine receptortarget
DB00543AmoxapineAlpha-1A adrenergic receptortarget
DB00543AmoxapineD(1A) dopamine receptortarget
DB00543AmoxapineMuscarinic acetylcholine receptor M1target
DB00543AmoxapineGamma-aminobutyric acid receptor subunit alpha-1target
DB00543AmoxapineAlpha-1-acid glycoprotein 1carrier
DB00543AmoxapineCytochrome P450 2D6enzyme
DB00543Amoxapine5-hydroxytryptamine receptor 2Atarget
DB00543Amoxapine5-hydroxytryptamine receptor 2Ctarget
DB00543Amoxapine5-hydroxytryptamine receptor 6target
DB00543Amoxapine5-hydroxytryptamine receptor 7target
DB00543AmoxapineD(3) dopamine receptortarget
DB00543AmoxapineD(4) dopamine receptortarget
DB00543AmoxapineHistamine H1 receptortarget
DB00543AmoxapineAlpha-1 adrenergic receptorstarget
DB00543AmoxapineMuscarinic acetylcholine receptortarget
DB00543Amoxapine5-hydroxytryptamine receptor 2Btarget
DB00543Amoxapine5-hydroxytryptamine receptor 3Atarget
DB00543Amoxapine5-hydroxytryptamine receptor 1Atarget
DB00543Amoxapine5-hydroxytryptamine receptor 1Btarget
DB00543AmoxapineAlpha-2 adrenergic receptorstarget
DB00543AmoxapineHistamine H4 receptortarget
DB00543AmoxapineGABA-A receptor (anion channel)target
DB00543AmoxapineSodium-dependent dopamine transportertarget
DB00546AdinazolamCytochrome P450 2C19enzyme
DB00546AdinazolamCytochrome P450 3A4enzyme
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit deltatarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit pitarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-3target
DB00553MethoxsalenDNAtarget
DB00553MethoxsalenCytochrome P450 2A6enzyme
DB00553MethoxsalenCytochrome P450 1A2enzyme
DB00553MethoxsalenCytochrome P450 1A1enzyme
DB00553MethoxsalenCytochrome P450 2A13enzyme
DB00562BenzthiazideSolute carrier family 12 member 3target
DB00562BenzthiazideCarbonic anhydrase 1target
DB00562BenzthiazideCarbonic anhydrase 2target
DB00562BenzthiazideCarbonic anhydrase 4target
DB00562BenzthiazideCarbonic anhydrase 9target
DB00562BenzthiazideCarbonic anhydrase 12target
DB00563MethotrexateDihydrofolate reductasetarget
DB00563MethotrexateAldehyde oxidaseenzyme
DB00563MethotrexateMethylenetetrahydrofolate reductaseenzyme
DB00563MethotrexateSerum albumincarrier
DB00563MethotrexateCanalicular multispecific organic anion transporter 2transporter
DB00563MethotrexateMultidrug resistance-associated protein 4transporter
DB00563MethotrexateMultidrug resistance-associated protein 1transporter
DB00563MethotrexateSolute carrier family 22 member 6transporter
DB00563MethotrexateMultidrug resistance-associated protein 7transporter
DB00563MethotrexateSolute carrier family 22 member 8transporter
DB00563MethotrexateCanalicular multispecific organic anion transporter 1transporter
DB00563MethotrexateMultidrug resistance protein 1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1A2transporter
DB00563MethotrexateMonocarboxylate transporter 1transporter
DB00563MethotrexateATP-binding cassette sub-family C member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B3transporter
DB00563MethotrexateSolute carrier family 22 member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1C1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 3A1transporter
DB00563MethotrexateATP-binding cassette sub-family G member 2transporter
DB00563MethotrexateSolute carrier family 22 member 7transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B1transporter
DB00563Methotrexate6-phosphogluconate dehydrogenase, decarboxylatingenzyme
DB00563MethotrexateProton-coupled folate transportertransporter
DB00563MethotrexateFolylpolyglutamate synthase, mitochondrialenzyme
DB00563MethotrexateGamma-glutamyl hydrolaseenzyme
DB00563MethotrexateDihydrofolate reductaseenzyme
DB00563MethotrexateThymidylate synthaseenzyme
DB00563MethotrexateBifunctional purine biosynthesis protein PURHenzyme
DB00563MethotrexateSolute carrier organic anion transporter family member 4C1transporter
DB00563MethotrexateFolate transporter 1transporter
DB00563MethotrexateFolate receptor alphatransporter
DB00563MethotrexateCytochrome P450 3A4enzyme
DB00563MethotrexateThymidylate synthasetarget
DB00563MethotrexateBifunctional purine biosynthesis protein PURHtarget
DB00563MethotrexateFolate receptor betatransporter
DB00563MethotrexateSolute carrier family 15 member 1transporter
DB00563MethotrexateProton-coupled amino acid transporter 1transporter
DB00564CarbamazepineVoltage gated sodium channeltarget
DB00564CarbamazepineCytochrome P450 2C8enzyme
DB00564CarbamazepineCytochrome P450 2B6enzyme
DB00564CarbamazepineCytochrome P450 3A4enzyme
DB00564CarbamazepineCytochrome P450 1A2enzyme
DB00564CarbamazepineCytochrome P450 2C19enzyme
DB00564CarbamazepineCytochrome P450 2C9enzyme
DB00564CarbamazepineMultidrug resistance protein 1transporter
DB00564CarbamazepineCytochrome P450 3A5enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 2B7enzyme
DB00564CarbamazepineRalA-binding protein 1transporter
DB00564CarbamazepineCanalicular multispecific organic anion transporter 1transporter
DB00564CarbamazepineNeuronal acetylcholine receptor subunit alpha-4target
DB00564CarbamazepineNuclear receptor subfamily 1 group I member 2target
DB00564CarbamazepineUDP-glucuronosyltransferase 1-1enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 1-6enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 1-7enzyme
DB00565CisatracuriumNeuronal acetylcholine receptor subunit alpha-2target
DB00567CephalexinSerum albumincarrier
DB00567CephalexinSolute carrier family 22 member 5transporter
DB00567CephalexinSolute carrier family 15 member 1transporter
DB00567CephalexinSolute carrier family 15 member 2transporter
DB00567CephalexinSolute carrier family 22 member 6transporter
DB00567CephalexinSolute carrier family 22 member 8transporter
DB00567CephalexinMultidrug and toxin extrusion protein 1transporter
DB00567CephalexinPenicillin-binding protein 3target
DB00567CephalexinPenicillin-binding protein 2atarget
DB00567CephalexinPenicillin-binding protein 1btarget
DB00567CephalexinPenicillin-binding protein 1Atarget
DB00567CephalexinPenicillin-binding protein 2Btarget
DB00570VinblastineTubulin beta chaintarget
DB00570VinblastineTranscription factor AP-1target
DB00570VinblastineCytochrome P450 3A4enzyme
DB00570VinblastineMultidrug resistance protein 1transporter
DB00570VinblastineMultidrug resistance-associated protein 1transporter
DB00570VinblastineCanalicular multispecific organic anion transporter 1transporter
DB00570VinblastineMultidrug resistance-associated protein 6transporter
DB00570VinblastineBile salt export pumptransporter
DB00570VinblastineTubulin alpha-1A chaintarget
DB00570VinblastineTubulin delta chaintarget
DB00570VinblastineTubulin epsilon chaintarget
DB00570VinblastineTubulin gamma-1 chaintarget
DB00570VinblastineCytochrome P450 2D6enzyme
DB00570VinblastineSolute carrier organic anion transporter family member 1B1transporter
DB00577ValaciclovirThymidine kinasetarget
DB00577ValaciclovirDNA polymerase catalytic subunittarget
DB00577ValaciclovirSolute carrier family 15 member 1transporter
DB00577ValaciclovirSolute carrier family 15 member 2transporter
DB00577ValaciclovirSolute carrier family 22 member 8transporter
DB00577ValaciclovirSolute carrier family 22 member 6transporter
DB00577ValaciclovirSodium- and chloride-dependent neutral and basic amino acid transporter B(0+)transporter
DB00577ValaciclovirIleal sodium/bile acid cotransportertransporter
DB00577ValaciclovirGuanylate kinaseenzyme
DB00577ValaciclovirHerpes simplex virus 1target
DB00577ValaciclovirVaricella Zoster Virus (VZV) (Human herpes virus 3)target
DB00577ValaciclovirCytomegalovirustarget
DB00577ValaciclovirHerpes simplex virus 2target
DB00577ValaciclovirEpstein-Barr Virus (EBV) (human herpes virus 4)target
DB00577ValaciclovirThymidine kinaseenzyme
DB00578CarbenicillinSolute carrier family 22 member 6transporter
DB00578CarbenicillinPenicillin-binding proteintarget
DB00578CarbenicillinCytosolic phospholipase A2enzyme
DB00579MazindolSodium-dependent noradrenaline transportertarget
DB00579MazindolSodium-dependent dopamine transportertarget
DB00579MazindolSodium-dependent serotonin transportertarget
DB00579MazindolSynaptic vesicular amine transportertarget
DB00589LisurideD(1A) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Atarget
DB00589LisurideD(2) dopamine receptortarget
DB00589LisurideAlpha-2A adrenergic receptortarget
DB00589LisurideAlpha-2B adrenergic receptortarget
DB00589LisurideAlpha-2C adrenergic receptortarget
DB00589LisurideD(3) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Dtarget
DB00589Lisuride5-hydroxytryptamine receptor 2Btarget
DB00589Lisuride5-hydroxytryptamine receptor 2Atarget
DB00589LisurideD(4) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 2Ctarget
DB00589LisurideD(1B) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Btarget
DB00589LisurideCytochrome P450 2D6enzyme
DB00589LisurideCytochrome P450 3A4enzyme
DB00589Lisuride5-hydroxytryptamine receptor 7target
DB00590DoxazosinAlpha-1A adrenergic receptortarget
DB00590DoxazosinAlpha-1D adrenergic receptortarget
DB00590DoxazosinHERG human cardiac K+ channeltarget
DB00590DoxazosinMultidrug resistance protein 1transporter
DB00590DoxazosinCytochrome P450 2C19enzyme
DB00590DoxazosinCytochrome P450 2D6enzyme
DB00590DoxazosinSolute carrier family 22 member 1transporter
DB00590DoxazosinCytochrome P450 3A4enzyme
DB00590DoxazosinAlpha-1B adrenergic receptortarget
DB00590DoxazosinCytochrome P450 2C9enzyme
DB00606CyclothiazideSodium/potassium-transporting ATPase subunit gammatarget
DB00606CyclothiazideCarbonic anhydrase 1target
DB00606CyclothiazideCarbonic anhydrase 2target
DB00606CyclothiazideCarbonic anhydrase 4target
DB00606CyclothiazideSolute carrier family 22 member 6transporter
DB00606CyclothiazideSecreted frizzled-related protein 4target
DB00607NafcillinCytochrome P450 1A2enzyme
DB00607NafcillinCytochrome P450 3A4enzyme
DB00607NafcillinSolute carrier family 22 member 6transporter
DB00607NafcillinPenicillin-binding protein 1btarget
DB00607NafcillinPenicillin-binding protein 2Btarget
DB00607NafcillinPenicillin-binding protein 2atarget
DB00607NafcillinPenicillin-binding protein 3target
DB00607NafcillinPenicillin-binding protein 1Atarget
DB00607NafcillinSerum albumincarrier
DB00608ChloroquineTumor necrosis factortarget
DB00608ChloroquineToll-like receptor 9target
DB00608ChloroquineGlutathione S-transferase A2target
DB00608ChloroquineCytochrome P450 2D6enzyme
DB00608ChloroquineCytochrome P450 3A4enzyme
DB00608ChloroquineCytochrome P450 1A1enzyme
DB00608ChloroquineCytochrome P450 2C8enzyme
DB00608ChloroquineCytochrome P450 3A5enzyme
DB00608ChloroquineFe(II)-protoporphyrin IXtarget
DB00608ChloroquineGlutathione S-transferasetarget
DB00608ChloroquineMultidrug resistance protein 1transporter
DB00611ButorphanolKappa-type opioid receptortarget
DB00611ButorphanolMu-type opioid receptortarget
DB00611ButorphanolDelta-type opioid receptortarget
DB00613AmodiaquineHistamine N-methyltransferasetarget
DB00613AmodiaquineCytochrome P450 2C8enzyme
DB00613AmodiaquineCytochrome P450 2D6enzyme
DB00613AmodiaquineFe(II)-protoporphyrin IXtarget
DB00613AmodiaquineCytochrome P450 1A1enzyme
DB00613AmodiaquineCytochrome P450 1B1enzyme
DB00613AmodiaquineCytochrome P450 2C9enzyme
DB00613AmodiaquineMultidrug resistance protein 1transporter
DB00615RifabutinDNA-directed RNA polymerase subunit alphatarget
DB00615RifabutinHeat shock protein HSP 90-alphatarget
DB00615RifabutinEndoplasmintarget
DB00615RifabutinCytochrome P450 3A4enzyme
DB00615RifabutinDNA-directed RNA polymerase subunit betatarget
DB00615RifabutinDNA-directed RNA polymerase subunit beta'target
DB00615RifabutinCytochrome P450 2C19enzyme
DB00615RifabutinCytochrome P450 2B6enzyme
DB00615RifabutinCytochrome P450 2C8enzyme
DB00615RifabutinCytochrome P450 2C9enzyme
DB00615RifabutinCytochrome P450 2D6enzyme
DB00615RifabutinMultidrug resistance protein 1transporter
DB00623FluphenazineD(2) dopamine receptortarget
DB00623FluphenazineCalmodulintarget
DB00623FluphenazineD(1A) dopamine receptortarget
DB00623FluphenazineCytochrome P450 2D6enzyme
DB00623FluphenazineMultidrug resistance protein 1transporter
DB00623FluphenazineCytochrome P450 2E1enzyme
DB00623FluphenazineAndrogen receptortarget
DB00623Fluphenazine5-hydroxytryptamine receptor 2Atarget
DB00623Fluphenazine5-hydroxytryptamine receptor 2Ctarget
DB00625EfavirenzCytochrome P450 2B6enzyme
DB00625EfavirenzCytochrome P450 3A4enzyme
DB00625EfavirenzCytochrome P450 2C19enzyme
DB00625EfavirenzCytochrome P450 2C9enzyme
DB00625EfavirenzCytochrome P450 1A2enzyme
DB00625EfavirenzCytochrome P450 2D6enzyme
DB00625EfavirenzReverse transcriptase/RNaseHtarget
DB00625EfavirenzCytochrome P450 2C8enzyme
DB00625EfavirenzSerum albumincarrier
DB00625EfavirenzCytochrome P450 3A5enzyme
DB00625EfavirenzCytochrome P450 3A7enzyme
DB00625EfavirenzUDP-glucuronosyltransferase 1-1enzyme
DB00625EfavirenzBile salt export pumptransporter
DB00625EfavirenzSolute carrier family 22 member 1transporter
DB00628Clorazepic acidTranslocator proteintarget
DB00628Clorazepic acidCytochrome P450 3A4enzyme
DB00628Clorazepic acidGABA-A receptor (anion channel)target
DB00631ClofarabineDNA polymerase alpha catalytic subunittarget
DB00631ClofarabineRibonucleoside-diphosphate reductase large subunittarget
DB00631ClofarabineDeoxycytidine kinaseenzyme
DB00631ClofarabineDNAtarget
DB00631ClofarabineATP-binding cassette sub-family G member 2transporter
DB00637AstemizoleHistamine H1 receptortarget
DB00637AstemizolePotassium voltage-gated channel subfamily H member 2target
DB00637AstemizoleCytochrome P450 3A4enzyme
DB00637AstemizoleCytochrome P450 3A5enzyme
DB00637AstemizoleCytochrome P450 3A7enzyme
DB00637AstemizoleMultidrug resistance protein 1transporter
DB00637AstemizoleCytochrome P450 2D6enzyme
DB00637AstemizoleCytochrome P450 2J2enzyme
DB00637AstemizolePotassium voltage-gated channel subfamily H member 1target
DB00637AstemizoleMicrotubule-associated protein tautarget
DB00637AstemizoleBile salt export pumptransporter
DB00640AdenosineAdenosine receptor A3target
DB00640AdenosineAdenosine deaminaseenzyme
DB00640AdenosineAdenosine kinaseenzyme
DB00640AdenosineAdenosine receptor A1target
DB00640AdenosineAdenosine receptor A2atarget
DB00640AdenosineAdenosine receptor A2btarget
DB00640AdenosineSolute carrier family 28 member 3transporter
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00642PemetrexedSolute carrier family 22 member 8transporter
DB00643MebendazoleTubulin alpha-1A chaintarget
DB00643MebendazoleTubulin beta-4B chaintarget
DB00643MebendazoleCytochrome P450 1A1enzyme
DB00643MebendazoleCYP3Aenzyme
DB00650LeucovorinSolute carrier family 22 member 8transporter
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB00651DyphyllineHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7Atarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 7Btarget
DB00651DyphyllineAdenosine receptor A1target
DB00651DyphyllineAdenosine receptor A2atarget
DB00652PentazocineMu-type opioid receptortarget
DB00652PentazocineKappa-type opioid receptortarget
DB00652PentazocineSigma non-opioid intracellular receptor 1target
DB00669Sumatriptan5-hydroxytryptamine receptor 1Dtarget
DB00669Sumatriptan5-hydroxytryptamine receptor 1Btarget
DB00669Sumatriptan5-hydroxytryptamine receptor 1Ftarget
DB00669SumatriptanAmine oxidase [flavin-containing] Aenzyme
DB00669Sumatriptan5-hydroxytryptamine receptor 1Atarget
DB00669SumatriptanSolute carrier organic anion transporter family member 1A2transporter
DB00669SumatriptanMultidrug resistance protein 1transporter
DB00669SumatriptanATP-binding cassette sub-family G member 2transporter
DB00669SumatriptanSolute carrier organic anion transporter family member 1B1transporter
DB00670PirenzepineMuscarinic acetylcholine receptor M1target
DB00671CefiximePenicillin-binding protein 2target
DB00671CefiximeSolute carrier family 22 member 5transporter
DB00671CefiximeSolute carrier family 15 member 1transporter
DB00671CefiximeSolute carrier family 15 member 2transporter
DB00674GalantamineAcetylcholinesterasetarget
DB00674GalantamineCytochrome P450 3A4enzyme
DB00674GalantamineCytochrome P450 2D6enzyme
DB00674GalantamineAcetylcholine receptor subunit alphatarget
DB00674GalantamineAcetylcholine receptor subunit betatarget
DB00674GalantamineAcetylcholine receptor subunit deltatarget
DB00674GalantamineAcetylcholine receptor subunit gammatarget
DB00674GalantamineAcetylcholine receptor subunit epsilontarget
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-2target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-3target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-4target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-5target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-6target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-7target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-9target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-10target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-2target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-3target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-4target
DB00674GalantamineCholinesterasetarget
DB00679ThioridazineAlpha-1A adrenergic receptortarget
DB00679ThioridazineD(2) dopamine receptortarget
DB00679Thioridazine5-hydroxytryptamine receptor 2Atarget
DB00679ThioridazineD(1A) dopamine receptortarget
DB00679ThioridazineCytochrome P450 2C19enzyme
DB00679ThioridazineCytochrome P450 2D6enzyme
DB00679ThioridazineAlpha-1B adrenergic receptortarget
DB00679ThioridazinePotassium voltage-gated channel subfamily H member 2target
DB00679ThioridazineCytochrome P450 2E1enzyme
DB00680MoricizineSodium channel protein type 5 subunit alphatarget
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00683MidazolamCytochrome P450 3A4enzyme
DB00683MidazolamCytochrome P450 3A5enzyme
DB00683MidazolamUDP-glucuronosyltransferase 1-4enzyme
DB00683MidazolamCytochrome P450 3A7enzyme
DB00685TrovafloxacinDNA gyrase subunit Atarget
DB00685TrovafloxacinDNA topoisomerase 4 subunit Atarget
DB00685TrovafloxacinDNA topoisomerase 2-alphatarget
DB00685TrovafloxacinCytochrome P450 1A2enzyme
DB00689CephaloglycinSolute carrier family 22 member 5transporter
DB00689CephaloglycinPenicillin-binding protein 1 (PBP1)target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit pitarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00690FlurazepamCytochrome P450 3A4enzyme
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00690FlurazepamMultidrug resistance protein 1transporter
DB00690FlurazepamCytochrome P450 2E1enzyme
DB00690FlurazepamCytochrome P450 2A6enzyme
DB00690FlurazepamSolute carrier family 22 member 2transporter
DB00691MoexiprilAngiotensin-converting enzymetarget
DB00691MoexiprilSolute carrier family 15 member 1transporter
DB00691MoexiprilSolute carrier family 15 member 2transporter
DB00691MoexiprilAngiotensin-converting enzyme 2target
DB00693FluoresceinIg kappa chain V-II region RPMI 6410target
DB00693FluoresceinDNAtarget
DB00693FluoresceinSolute carrier family 22 member 6transporter
DB00693FluoresceinBile salt export pumptransporter
DB00693FluoresceinMultidrug resistance-associated protein 1transporter
DB00696ErgotamineAlpha-1A adrenergic receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Dtarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Btarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Atarget
DB00696ErgotamineAlpha-2A adrenergic receptortarget
DB00696ErgotamineD(2) dopamine receptortarget
DB00696ErgotamineAlpha-2B adrenergic receptortarget
DB00696ErgotamineSodium-dependent noradrenaline transportertarget
DB00696ErgotamineCytochrome P450 3A4enzyme
DB00696ErgotamineAlpha-1B adrenergic receptortarget
DB00696ErgotamineAlpha-1D adrenergic receptortarget
DB00696ErgotamineMultidrug resistance protein 1transporter
DB00696ErgotamineD(1) dopamine receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Atarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Ftarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Ctarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Btarget
DB00699NicergolineAlpha-1A adrenergic receptortarget
DB00699NicergolineCytochrome P450 2D6enzyme
DB00704NaltrexoneMu-type opioid receptortarget
DB00704NaltrexoneKappa-type opioid receptortarget
DB00704NaltrexoneDelta-type opioid receptortarget
DB00704NaltrexoneHCG20471, isoform CRA_ctarget
DB00704NaltrexoneUDP-glucuronosyltransferase 1-1enzyme
DB00705DelavirdineCytochrome P450 3A4enzyme
DB00705DelavirdineCytochrome P450 2C9enzyme
DB00705DelavirdineCytochrome P450 2D6enzyme
DB00705DelavirdineCytochrome P450 3A5enzyme
DB00705DelavirdineCytochrome P450 3A7enzyme
DB00705DelavirdineCytochrome P450 2C19enzyme
DB00705DelavirdineReverse transcriptase/RNaseHtarget
DB00707Porfimer sodiumLow-density lipoprotein receptortarget
DB00707Porfimer sodiumHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00713OxacillinPenicillin-binding protein 1Atarget
DB00713OxacillinSolute carrier family 15 member 1transporter
DB00713OxacillinSolute carrier family 15 member 2transporter
DB00713OxacillinPenicillin-binding protein 3target
DB00713OxacillinPenicillin-binding protein 2atarget
DB00713OxacillinPenicillin-binding protein 1Atarget
DB00713OxacillinPenicillin-binding protein 2Btarget
DB00713OxacillinPenicillin-binding protein 1btarget
DB00713OxacillinSolute carrier family 15 member 1target
DB00713OxacillinPenicillin-binding protein 2target
DB00713OxacillinSolute carrier family 15 member 2target
DB00714ApomorphineD(2) dopamine receptortarget
DB00714ApomorphineD(1A) dopamine receptortarget
DB00714ApomorphineD(4) dopamine receptortarget
DB00714ApomorphineD(3) dopamine receptortarget
DB00714ApomorphineD(1B) dopamine receptortarget
DB00714ApomorphineNeuron-specific vesicular protein calcyontarget
DB00714ApomorphineAlpha-2C adrenergic receptortarget
DB00714ApomorphineAlpha-2B adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Ctarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Atarget
DB00714Apomorphine5-hydroxytryptamine receptor 2Btarget
DB00714ApomorphineAlpha-2A adrenergic receptortarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Dtarget
DB00714Apomorphine5-hydroxytryptamine receptor 1Btarget
DB00716NedocromilCysteinyl leukotriene receptor 1target
DB00716NedocromilCysteinyl leukotriene receptor 2target
DB00716NedocromilProstaglandin D2 receptortarget
DB00716NedocromilfMet-Leu-Phe receptortarget
DB00716NedocromilHeat shock protein HSP 90-alphatarget
DB00718Adefovir dipivoxilDNA polymerase/reverse transcriptasetarget
DB00718Adefovir dipivoxilSolute carrier family 22 member 6transporter
DB00718Adefovir dipivoxilMultidrug resistance-associated protein 4transporter
DB00718Adefovir dipivoxilMultidrug resistance-associated protein 5transporter
DB00718Adefovir dipivoxilSolute carrier family 22 member 3transporter
DB00718Adefovir dipivoxilAdenylate kinase 2, mitochondrialenzyme
DB00718Adefovir dipivoxilAdenylate kinase 4, mitochondrialenzyme
DB00718Adefovir dipivoxilNucleoside diphosphate kinase Aenzyme
DB00718Adefovir dipivoxilNucleoside diphosphate kinase Benzyme
DB00724ImiquimodToll-like receptor 7target
DB00724ImiquimodToll-like receptor 8target
DB00724ImiquimodCytochrome P450 3A4enzyme
DB00726TrimipramineSodium-dependent serotonin transportertarget
DB00726TrimipramineSodium-dependent noradrenaline transportertarget
DB00726TrimipramineCytochrome P450 2D6enzyme
DB00726TrimipramineSodium-dependent dopamine transportertarget
DB00726Trimipramine5-hydroxytryptamine receptor 2Atarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Atarget
DB00726TrimipramineAlpha-1A adrenergic receptortarget
DB00726TrimipramineAlpha-1B adrenergic receptortarget
DB00726TrimipramineD(2) dopamine receptortarget
DB00726TrimipramineAlpha-2B adrenergic receptortarget
DB00726TrimipramineHistamine H1 receptortarget
DB00726TrimipramineCytochrome P450 2C19enzyme
DB00726TrimipramineMultidrug resistance protein 1transporter
DB00726TrimipramineCytochrome P450 2C9enzyme
DB00726Trimipramine5-hydroxytryptamine receptor 2Ctarget
DB00726Trimipramine5-hydroxytryptamine receptor 3Atarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Dtarget
DB00726TrimipramineAlpha-2A adrenergic receptortarget
DB00726TrimipramineD(1) dopamine receptortarget
DB00726TrimipramineBeta adrenergic receptortarget
DB00726TrimipramineMuscarinic acetylcholine receptortarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Ctarget
DB00730ThiabendazoleFumarate reductase flavoprotein subunittarget
DB00730ThiabendazoleCytochrome P450 1A2enzyme
DB00730ThiabendazoleCytochrome P450 1A1enzyme
DB00732Atracurium besylateNeuronal acetylcholine receptor subunit alpha-2target
DB00736EsomeprazolePotassium-transporting ATPase alpha chain 1target
DB00736EsomeprazoleCytochrome P450 2C19enzyme
DB00736EsomeprazoleCytochrome P450 3A4enzyme
DB00736EsomeprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00736EsomeprazoleMultidrug resistance protein 1transporter
DB00736EsomeprazoleSolute carrier family 22 member 8transporter
DB00739HetacillinPenicillin-binding protein 2atarget
DB00739HetacillinPenicillin-binding protein 1btarget
DB00739HetacillinPenicillin-binding protein 3target
DB00739HetacillinPenicillin-binding protein 1Atarget
DB00739HetacillinPenicillin-binding protein 2Btarget
DB00740RiluzoleSodium channel protein type 5 subunit alphatarget
DB00740RiluzoleCytochrome P450 1A2enzyme
DB00740RiluzoleCystine/glutamate transportertarget
DB00740RiluzoleATP-binding cassette sub-family G member 2transporter
DB00740RiluzoleCytochrome P450 1A1enzyme
DB00749EtodolacProstaglandin G/H synthase 1target
DB00749EtodolacProstaglandin G/H synthase 2target
DB00749EtodolacCytochrome P450 2C9enzyme
DB00749EtodolacUDP-glucuronosyltransferase 1-9enzyme
DB00749EtodolacRetinoic acid receptor RXR-alphatarget
DB00749EtodolacSerum albumincarrier
DB00749EtodolacSolute carrier family 22 member 6transporter
DB00749EtodolacUDP-glucuronosyltransferase 1-3enzyme
DB00749EtodolacUDP-glucuronosyltransferase 1-10enzyme
DB00749EtodolacUDP-glucuronosyltransferase 2B7enzyme
DB00751EpinastineHistamine H1 receptortarget
DB00751EpinastineHistamine H2 receptortarget
DB00751EpinastineAlpha-1A adrenergic receptortarget
DB00751EpinastineAlpha-2A adrenergic receptortarget
DB00751Epinastine5-hydroxytryptamine receptor 2Atarget
DB00751Epinastine5-hydroxytryptamine receptor 7target
DB00751EpinastineMultidrug resistance protein 1transporter
DB00751EpinastineCytochrome P450 2B6enzyme
DB00751EpinastineCytochrome P450 2D6enzyme
DB00751EpinastineCytochrome P450 3A4enzyme
DB00757Dolasetron5-hydroxytryptamine receptor 3Atarget
DB00757DolasetronCytochrome P450 3A4enzyme
DB00757DolasetronCytochrome P450 2D6enzyme
DB00757DolasetronCytochrome P450 2C9enzyme
DB00758ClopidogrelP2Y purinoceptor 12target
DB00758ClopidogrelCytochrome P450 3A4enzyme
DB00758ClopidogrelCytochrome P450 2B6enzyme
DB00758ClopidogrelCytochrome P450 3A5enzyme
DB00758ClopidogrelCytochrome P450 2C19enzyme
DB00758ClopidogrelCytochrome P450 2C9enzyme
DB00758ClopidogrelCytochrome P450 1A2enzyme
DB00758ClopidogrelCytochrome P450 2C8enzyme
DB00758ClopidogrelLiver carboxylesterase 1enzyme
DB00758ClopidogrelMultidrug resistance protein 1transporter
DB00758ClopidogrelSolute carrier family 22 member 1transporter
DB00758ClopidogrelSolute carrier family 22 member 2transporter
DB00760MeropenemD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00760MeropenemBeta-lactamase OXA-10enzyme
DB00766Clavulanic acidBacterial beta-lactamase enzymesenzyme
DB00766Clavulanic acidBacterial beta-lactamase enzymestarget
DB00766Clavulanic acidSodium/glucose cotransporter 1transporter
DB00767BenzquinamideMuscarinic acetylcholine receptor M4target
DB00767BenzquinamideMuscarinic acetylcholine receptor M1target
DB00767BenzquinamideMuscarinic acetylcholine receptor M5target
DB00767BenzquinamideMuscarinic acetylcholine receptor M2target
DB00767BenzquinamideMuscarinic acetylcholine receptor M3target
DB00767BenzquinamideHistamine H1 receptortarget
DB00768OlopatadineHistamine H1 receptortarget
DB00768OlopatadineProtein S100-A1target
DB00768OlopatadineProtein S100-A12target
DB00768OlopatadineProtein S100-Btarget
DB00768OlopatadineProtein S100-A13target
DB00768OlopatadineProtein S100-A2target
DB00768OlopatadineCytochrome P450 3A4enzyme
DB00768OlopatadineSerum albumincarrier
DB00768OlopatadineDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00768OlopatadineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00768OlopatadineMultidrug resistance protein 1transporter
DB00768OlopatadineHistamine H2 receptortarget
DB00768OlopatadineHistamine H3 receptortarget
DB00774HydroflumethiazideSolute carrier family 12 member 1target
DB00774HydroflumethiazideSodium/potassium-transporting ATPase subunit alpha-1target
DB00774HydroflumethiazideCarbonic anhydrase 4target
DB00774HydroflumethiazideCalcium-activated potassium channel subunit alpha-1target
DB00774HydroflumethiazideCarbonic anhydrase 2target
DB00774HydroflumethiazideCarbonic anhydrase 1target
DB00774HydroflumethiazideCarbonic anhydrase 9target
DB00774HydroflumethiazideCarbonic anhydrase 12target
DB00776OxcarbazepineSodium channel protein type 5 subunit alphatarget
DB00776OxcarbazepineCytochrome P450 2C19enzyme
DB00776OxcarbazepineCytochrome P450 3A4enzyme
DB00776OxcarbazepineCytochrome P450 3A5enzyme
DB00776OxcarbazepineSerum albumincarrier
DB00776OxcarbazepineUDP-glucuronosyltransferase 1-1enzyme
DB00776OxcarbazepineMultidrug resistance protein 1transporter
DB00777PropiomazineMuscarinic acetylcholine receptor M3target
DB00777PropiomazineAlpha-1B adrenergic receptortarget
DB00777PropiomazineD(1A) dopamine receptortarget
DB00777PropiomazineAlpha-1D adrenerg